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 Many risk factors for breast cancer differ between race/ethnic groups. Few studies 
have included Hispanic women: a genetically admixed population that differs from other 
ethnic groups for breast cancer incidence, survival, and tumor phenotype.   The objective 
of this study was to determine if genetic variation in ERα and TGF-β signaling genes 
(TGF-β1, TGF-βRI, RUNX1, RUNX2, RUNX3) is associated with breast cancer risk, and if 
these associations differ between Hispanic and non-Hispanic white women (NHW).  
 Data from The Breast Cancer Health Disparities (BCHD) study were used.  BCHD 
is a multi-site consortium including two case-control studies within the U.S. and one in 
Mexico.  A total of 3,524 cases (NHW=1,431; Hispanic=2,093) and 4,209 population-
based controls (NHW=1,599; Hispanic=2,610) had available DNA.  In-person interviews 
collected information on non-genetic risk factors.  Single nucleotide polymorphisms 
(SNPs) in TGF-β, RUNX and ERα genes were determined using an Illumina platform and 
PCR.  Associations with breast cancer risk were evaluated using multivariable logistic 
regression, adjusting for study site, age, and Native American genetic ancestry.  
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 Associations with breast cancer phenotypes (ER/PR status) were also evaluated 
and a genetic risk score (GRS) was calculated to determine the cumulative effect of 
selected SNPs.   
 Two SNPs were significantly associated with breast cancer risk: RUNX3 (rs906296 
ORCG/GG=1.15 95% CI 1.04-1.26) and TGF-β1 (rs4803455 ORCA/AA=0.89 95% CI 0.81-
0.98).  RUNX3 (rs906296) was specifically associated with risk in pre-menopausal women 
(p=0.002) and in those with moderate to high Native American ancestry.  There was a 
significant interaction between Native American ancestry and RUNX1 (rs7279383, 
p=0.04).  Four RUNX SNPs were associated with an increased risk of ER-/PR- (n=3) and 
ER-/PR+ (n=1) tumors.  A GRS including 6 SNPs (range=0-10 alleles) across ERα and 
TGF-β signaling genes was positively associated with overall risk (per allele OR=1.14 
95% CI 1.04-1.25), as well as ER+, but not ER- tumors.   
 These results suggest that genetic variation in these genes may explain the greater 
likelihood in Hispanic women for premenopausal, ER- breast cancer.  This is also the first 
population-based observational study to evaluate crosstalk between TGF-β and ERα 
signaling pathways.  The biological significance of these genes in breast cancer etiology is 
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 Breast cancer is the most frequently diagnosed cancer in women in the United 
States (U.S.) and Mexico in every major racial/ethnic group [1-4].  As a result of 
technological advances, the understanding of breast cancer has evolved to recognize that 
not all tumors are alike [5].  Epidemiological studies have attempted to evaluate the 
association of this tumor heterogeneity with lifestyle, ethnic, cultural, clinical, and 
biological factors in populations.  Most studies have explored these associations in 
predominately non-Hispanic white women (NHW).  Very few have included Hispanic 
women, a rapidly growing minority in the U.S., in which there are differences in risk of 
breast cancer and mortality, as well as risk factors associated with breast cancer in 
comparison to NHW women.  Factors that explain these disparities remain to be 
established. 
 More than 70% of breast cancers may be characterized as “estrogen-dependent”.  
The reproductive steroid hormone estrogen, which binds to estrogen receptors in the 
nucleus of the cell, is required for normal development as it stimulates cell proliferation 
in the breast epithelial tissue and activates target genes to produce specific growth-
promoting proteins [6-7].  Estrogen is implicated in breast carcinogenesis because of the 
influence it has on growth and hormones that stimulate cell division, as well as its 
presence in most tumors diagnosed [7].  As a result, biological factors that influence the 
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activation or inactivation of estrogen-related carcinogenesis, such as susceptibility genes 
in hormone pathways, are primary targets for research and therapy.  The extent to which 
genetic variation influences differences in breast cancer risk, between Hispanic and 
NHW, has not been established. 
 The primary objective of this dissertation was to evaluate differences between 
Hispanic and NHW women in the associations of selected genetic polymorphisms with 
breast cancer risk using data and DNA samples from The Breast Cancer Health 
Disparities (BCHD) study.  The BCHD study is a multi-site consortium including 3 
population-based case-control studies conducted within the U.S. and Mexico: the 4-
Corner’s Breast Cancer Study, the San Francisco Bay Area Breast Cancer Study, and the 
Mexico Breast Cancer Study [8].  Combined there are approximately 11,000 NHW and 
Hispanic/American Indian women diagnosed with a first primary breast cancer (in-situ/ 
invasive).  The goal of this consortium is to evaluate the biological basis of ethnic-related 
health disparities, using genetic factors in the  Convergence of Hormone, Inflammation 
and Energy Functioning (CHIEF) signaling pathway in combination with behavioral, 
social, and cultural factors [8].  The genes selected for study in this dissertation are 
limited to ones previously reported to influence the estrogen metabolism pathway and 
those that might explain differences in tumor phenotype: Estrogen Receptor-1 (ESR1 or 
ERα), Runt-related transcription factor  (RUNX) 1, 2, 3, Transforming growth factor-Beta 
1 (TGF-β1), and Transforming growth factor-Beta Receptor I (TGF-βRI).  Ultimately, 
data from this study could help illuminate genetic variation influencing ethnic disparities 





 Using data from a large, population-based case-control study, BCHD, which 
includes Hispanic and NHW women, the specific aims of this dissertation, are outlined 
below.  Previous literature indicates a dual function for the TGF-β signaling genes (TGF-
β1, TGF-βRI, RUNX1, RUNX2, and RUNX3) in breast carcinogenesis as promoters or 
suppressors depending on transcriptional influence of surrounding genes [9-10].  
Corresponding hypotheses are therefore stated as alternative hypotheses without 
directionality of association based on this evidence. 
 
(1) To determine if the risk of breast cancer is associated with individual single 
nucleotide polymorphism(s) (SNPs) in TGF-β signaling genes and 
ERα after adjusting for significant confounders. 
(2) To determine if the statistical association of the risk of breast cancer and 
common variants in TGF-β signaling genes and ERα differ by 
proportion of Native American ancestry and menopausal status. 
(3) To determine if genetic variants in TGF-β signaling genes and ERα differently 
affect the risk of breast cancer, as defined by Estrogen Receptor (ER) 
expression status, specifically ER+ and ER- tumors. 
(4) To determine if the association of ER+ and ER- tumors with genetic variants 
within TGF-β signaling genes and ERα differ by proportion of Native 
American ancestry and menopausal status. 
(5) To determine the statistical interactions between individual SNPs in TGF-β 
signaling genes and ERα and the association with risk of breast cancer.  
(6) To evaluate the cumulative effect of TGF-β signaling genes and ERα with risk 





H1: Women who have the variant genotypes for TGF-β signaling genes will have 
an association with breast cancer compared to those who do not have the variant 
genotype, after adjustment for significant confounders.  Women who have the 
variant genotypes for ERα gene will have a higher risk of breast cancer compared to 
those with the wild-type genotypes. 
 
H2: Women who have the variant genotypes for TGF-β signaling genes will have 
an association with ER- breast cancer compared to those who do not have the 
variant genotype, after adjustment for significant confounders.  Variant genotypes 
for ERα gene will have a higher risk of ER- tumors compared to those with the 
wild-type genotypes.   
 
H3: The risk of breast cancer for women with the TGF-β signaling and ERα 
variant (s) will be modified by menopausal status and ethnicity as measured by 
proportion of Native American ancestry after adjustment for significant 
confounders. 
 
H4: The risk of ER- breast cancer for women with the TGF-β signaling and ERα 
variant (s) will be modified by a factor of estrogen exposure: menopausal status, 
after adjustment for significant confounders.  The association will be modified by 






H5: The proposed crosstalk between TGF-β signaling pathway and ER-signaling 
pathway is presented in mouse models.  This will be demonstrated in this study 
population through statistical interactions among common genetic variants in TGF-
β signaling genes and common variants in ERα gene when modeling the risk of 
breast cancer. 
 
H6: There will be an additive effect observed when combining risk alleles across 
pathways.  The communication between signaling pathways is important when 
determining how genetic variation alters breast cancer risk.  The present study will 
demonstrate the crosstalk with the cumulative effect of risk alleles and the 





Racial/Ethnic Disparities in Breast Cancer Diagnosis and Outcomes 
 Approximately 23% of new cases of breast cancer (1.38 million) and 14% of the 
total cancer deaths (458,400) were ascertained in the U.S. in 2008 [3-4].  An estimated 
226,870 new cases of invasive breast cancer will be diagnosed during 2012, with 
considerable variation across ethnic groups [1-2].  Cancer of the breast ranks second, 
behind lung, as a cause of death from cancer in women, with an expected 39,510 dying 
from this disease during 2012 [1].  Based on rates from 2007-2009, a woman living in the 
U.S. has a 12.4%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer [2]. 
 The age-adjusted incidence of breast cancer varies among race/ethnic groups by 
nearly 2-fold in the U.S.  Data from the Surveillance Epidemiology and End Results 
(SEER) Program for the time period 2005-2009, indicate that NHW women have the 
highest incidence rate (127.3/100,000), followed by African American (121.2/100,000), 
Asian (94.5/100,000), Hispanic (92.7/100,000), and American Indian women 
(80.6/100,000) [2].  Cancer incidence rates for Hispanic women living in the U.S. have 
been available only since 1992.  Although the breast cancer incidence rate for Hispanic 
women has been decreasing at a slower rate than NHW since 1997, 0.9% versus 1.5%, 
respectively; it is still 27% lower than that of NHW women.  Conversely, evidence shows 
that breast cancer outcomes tend to be poorer among Hispanic women who are 20% more 
likely to die of this disease than NHW women diagnosed at a similar age and stage [11]. 
Because these population groups show disproportionate distributions in incidence and 
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mortality, epidemiological research has tried to explain these as ‘disparities’ in 
populations according to lifestyle, clinical, and biologically relevant characteristics [12].  
The National Cancer Institute defines a cancer disparity as ‘a difference in the incidence, 
prevalence, mortality, and burden of cancer and related adverse health conditions that 
exist among specific population groups in the U.S.’ [13]. 
 Reasons for the low incidence of breast cancer in Hispanic and Native American 
women are largely unknown.  Due to the lack of detailed surveillance data in Mexico at 
this time, it is difficult to compare breast cancer rates across ethnic groups in two 
different countries, although, data suggest that the incidence is lower among Mexico-born 
Hispanic women compared to NHW women in the U.S.  The BCHD study was designed 
to fill this knowledge gap by comparing Hispanic with NHW women living in the United 
States, as well as in Mexico, for breast cancer risk, taking European or Native American 
ancestry into account.  Most women in Mexico are Hispanic by self-identification and are 
similar to those living in the Southwestern U.S. with respect to European genetic 
ancestry.  Fejerman and colleagues found that the higher the proportion of European 
ancestry, the more positive the association was with risk of breast cancer in U.S. born 
Hispanic [14] and Mexico-born Hispanic [15] populations .  They do note, however, that 
it is important to consider unmeasured confounding variables that could influence this 
effect and conclude that if there is an environmental element driving this association it 
must be common to U.S. Hispanic and Mexican-Hispanic born women [14-15].   
 In Mexico, reliable data for incidence and prevalence at the national level is not 
available due to the lack of cancer registries.  Sources with available data, including 
National Institute for Statistics, Geography, and Information as well as the Ministry of 
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Health Database and the Mexican Social Security Institute, suggest that breast cancer is 
increasing steadily across the population, affecting all ages and socio-economic groups, 
with evidence of this increase exposed in hospital discharge rates associated with breast 
cancer, which increased by 80% for the time period 1986-2003 [16].  By 2006 breast 
cancer became the second leading cause of death among women aged 30-54 years in 
Mexico [16].  The significant burden of disease has challenged scientists to further 
research in basic science, epidemiology, clinical, and translational science to better 
understand breast cancer development and outcomes in diverse populations. 
Established Risk Factors for Breast Cancer-‘A Life Course Perspective’ 
 Fluctuation in breast cancer incidence and outcomes can partially be explained by 
the changes in the risk factor profile of a population.  Epidemiological studies have 
focused on determining the pattern or distribution of risk factors among various 
populations that may provide a biologically plausible basis for susceptibility, initiation 
and/or promotion of breast cancer.  The Institute of Medicine (IOM) 2011 report, ‘Breast 
Cancer and the Environment: A Life Course Approach’ [17] stressed the importance of a 
‘life course perspective’ as a tool for teasing out the significance of timing and interaction 
of exposures during a woman’s life when evaluating breast cancer risk factors, as the 
breast is characterized by continuous change and hormonal influence.  Individual 
behavioral choices, environmental exposures, and genes encompass a wide range of 
characteristics that influence the probability of developing breast cancer throughout 
critical periods of a woman’s life.  During these ‘periods’, ranging from in-utero through 
menopause, the breast transforms during gestation, menarche, pregnancy, breast-feeding, 
and menopause in response to varying levels of hormones, most commonly endogenous 
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or exogenous estrogen [17].  ‘Breast tissue ageing’, a term coined by Malcolm Pike, 
represents a mathematical model of the influence reproductive variables have on the risk 
of breast cancer, recognizing that the fluctuation in the rate of breast tissue aging is due to 
type of transformation the breasts undergo during critical periods [18].  An extension of 
Pike’s mathematical model suggests the rate of breast tissue ageing is correlated with 
vulnerability to breast tissue damage [19].  Following this concept, researchers, including 
the IOM, suggest that these critical periods could be ‘windows of susceptibility’ when the 
risk of breast cancer can be influenced depending on exposure to risk factors.   
Estrogen Hormone 
 Estrogen is a steroid hormone that serves as a chemical messenger necessary for 
the normal development of the breast, as well as for regulating menstruation, 
reproduction, and maintaining the heart and healthy bones.  The biosynthesis of estrogen 
occurs inside the cell in endocrine glands, specifically the ovaries and adrenal glands in 
women.  Estrogen also can be produced via peripheral tissues (e.g. adipose tissues) 
stimulated by circulating steroid precursors, and can be formed in the liver, adrenal 
glands, breast, bone, and brain in women, where aromatase (an enzyme responsible for 
the conversion of steroid precursors to estrogen) is expressed [7, 20].  The influence of 
estrogen has profound effects on breast development throughout life; and is implicated in 
breast carcinogenesis due to its role of inducing cell division in the breast, its effect 
during the growth cycles when breast growth and development occurs; its interaction and 
effect on other hormones that stimulate breast cell division, and its consistent presence in 
the growth of estrogen-responsive tumors [7, 21].   
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 The complexity of breast cancer etiology is not described exhaustively in this 
summary; rather it is evaluated with respect to established risk factors during a woman’s 
reproductive life span that influence the level of exposure to the steroid hormone 
estrogen.  Table 1 is a summary of the established risk factors for breast cancer by 
whether they cause an increase or decrease exposure to estrogen.  The positive, negative, 
or inconsistent association of each risk factor with breast cancer is stated.  NHW and 
Hispanic women can be characterized by different risk factor profiles according to 
epidemiological data and associations by these ethnic groups are presented.  The overall 
magnitude of association is not provided as some studies have shown that one ethnic 
group may have a stronger association with a specific risk factor compared to another.  




Table 1: Established Risk factors for Breast Cancer by Estrogen Exposure  
and the Association among Hispanic and non-Hispanic white (NHW) Women
a, b
 
Factor Description All  NHW  Hispanic  
Increases Exposure to Estrogen 
Age at Menarche Start of menarche (≤12 years) + + + 
Age at Menopause Natural menopause (≥55 years) + + + 
Alcohol  Consumption (>1 drink/day) + + + 
Hormonal Therapy Duration of estrogen use (≤ 2 years) + + + 
Oral Contraceptives Current users + + + 
Obesity Body mass index (≥30 kg/m²) + + - 
Decreases Exposure to Estrogen 
Parity 
Trend for increasing number of 
full-term births - - - 
Age at First Full-
term Birth 
Early age at first full-term birth 
(≤20 years) - - - 
Breast Feeding Duration of lactation - - +/- 
Physical Activity 
Moderate to vigorous intensity over 
long-term period  - - - 
a 
Symbol refers to association with risk of breast cancer: (+) positive or increase; (-) negative or 








Risk Factors That Increase Estrogen Exposure 
 Risk factors that increase exposure to estrogen can be either modifiable or non-
modifiable.  Risk factors that are non-modifiable include those that are part of the natural 
aging process and cannot be influenced by behavioral choices.  These include: increasing 
age, early age at menarche, and late age at menopause.  Cumulative exposure to 
endogenous and exogenous estrogen can affect the magnitude of lifetime risk of breast 
cancer.  For instance, early age at menarche and late age at menopause, extends exposure 
to estrogen [26].  Research has shown that for every year menopause is delayed there is 
an additional 3-5% increase in risk, with a 30% increase in risk for age at menarche at 
>55 years compared to <45 years of age.  Similarly, those who begin menarche at a later 
age (≥16 years) have a 15% decreased risk per year compared to those who begin at age 
12 [27-28].  The direction of association has been found to be the same for both Hispanic 
and NHW women.  Risk factors may also differ with respect to ER status and 
menopausal status, which are characterized by divergent levels of exposure to estrogen, 
and therefore may not have the same influence on risk.  The risk for ER- tumors has been 
found to be higher for premenopausal women and for Hispanic women compared to 
NHW women, although the cause is unclear [29-30]. 
 Modifiable risk factors that increase exposure to estrogen include: exposure to 
high levels of exogenous estrogen through use of post-menopausal hormone replacement 
therapy (HRT) or oral contraceptives (OC); obesity (body mass index (BMI)  ≥30 kg/m²); 
and high alcohol consumption (>1 drink per day).   
 HRT.  In a meta-analysis of nearly 4,000 cases conducted by the Collaborative 
Group on Hormonal Factors in Breast Cancer, post-menopausal HRT was found to 
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increase risk with duration of use.  The risk was 40% (relative risk (RR) of 1.07 per year) 
higher for women who had taken HRT for five years compared to those not taking HRT 
for all tumor phenotypes combined.  This estimate varied with dose of estrogen and 
progestin in HRT, and diminished each year after cessation [31].  The Multiethnic Cohort 
Study also found that HRT has the same effect on Hispanic (cases=257 of 11,792) and 
NHW (cases=419 of 13,659) women, although Hispanic women who were current users 
had a slightly higher risk (RR=1.36, 95% CI 5 1.20–1.54 versus RR= 1.26, 95% CI 5 
1.17–1.37, respectively).  Current HRT use was associated with ER+, but not ER- tumors 
[32].   
 OC use.  The Collaborative Group also reported a 25% excess risk for current OC 
users based on a combined exposure.  However, the effect diminished over time and after 
10 years of cessation there was no association with risk [33].  Some studies have shown 
that there is a stronger association with current use and ER- tumors than ER+ tumors in 
premenopausal women [34-35].   
 Obesity.  Obesity (BMI ≥30 kg/m²) increases exposure to estrogen when 
aromatase, found in adipose tissue, initiates the conversion of precursor steroids, mainly 
adrenal androgens, to estrogens [7].  The association of obesity with breast cancer differs 
by menopausal status: post-menopausal obese women have an increased risk while 
premenopausal obese women have a decreased risk of breast cancer [21, 25].  Some 
studies suggest this association may differ by ethnicity: in NHW obese women the risk is 
divergent by menopausal status, in contrast, for Hispanic obese women menopausal 
status does not affect the association of obesity and breast cancer [36].  The 4-Corners 
Breast Cancer Study reported that among premenopausal NHW women, obesity was 
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associated with a higher risk of ER- tumors (Odds Ratio (OR) = 2.47; 95% CI: 1.08-5.67) 
but was inversely associated with risk of ER- cancers among Hispanic women (OR = 
0.29; 95% CI: 0.13-0.66) [37] 
 Alcohol consumption.  While the etiology of alcohol and breast cancer is still 
under evaluation, the associated risk is hypothesized to be a result of an interaction 
between alcohol and estrogen metabolism or the metabolism of alcohol by-products, 
which cause DNA damage [38].  Alcohol is recognized to be associated with a moderate 
increase in breast cancer, and the range of intake appears to have a linear relationship 
with risk.  In 2006, Key and colleagues [22] conducted a meta-analysis of 98 studies, 
which showed that each additional 10 grams of alcohol/day was associated with a 10%  
increased risk (95% CI: 5–15%).  The National Institutes of Health - AARP Diet and 
Health Study (1995–2003) evaluated the alcohol and breast ER status association and 
found alcohol (5-30 grams/day compared to non-drinkers) was associated with ER+ but 
not ER- status [39]. 
Risk Factors That Decrease Estrogen Exposure 
 Risk factors that decrease the exposure to estrogen include:  parity, age at first 
full-term birth (FFTB), breastfeeding, and physical activity.   
 Parity.  Parity reduces the number of menstrual cycles and cumulative exposure 
to estrogens and induces the full differentiation of breast epithelium, making it more 
resistant to carcinogenic transformation.  After the first half of pregnancy and during 
lactation, estrogens do not affect breast growth and differentiation.  Epidemiological 
evidence suggests that women who have had a least one full-term birth have a 25% 
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reduced risk compared to nulliparous women, with protection increasing by as much as 
11% with the birth of each child [23, 40-41].   
 Age at FFTB.  Early age at FFTB is associated with a reduced risk of breast 
cancer and appears to be independent of the total number of births.  Women who have 
their FFTB before age 20 have half the risk of developing breast cancer compared to 
women with a FFTB at age 30 [42].  It has been reported that this  association appears to 
be associated with an increased risk of developing ER+ disease [41].   
 Lactation.  Breastfeeding for long duration (at least one year) is  reported to be 
associated with a decreased risk of breast cancer, as much as 25% in general as well as 
for both ER+ and ER- tumors [41].  The New Mexico Women’s Health Study assessed 
reproductive factors among Hispanic and NHW women and reported an inverse 
association of higher parity with breast cancer risk for NHW, but not Hispanic women (p 
<0.008).  Longer lactation was associated with reduced risk in premenopausal but not 
post-menopausal Hispanic women similar to the associations in NHW women [43].   
 Physical activity.  Physical activity decreases risk of breast cancer when measured 
at a consistent level of intensity over a long-term period [24].  The biological 
mechanisms may include reduced estrogen levels, decreased factors involved in 
inflammatory and immune responses, and maintenance of a healthy bodyweight.  Most 
studies indicate that at least 30 minutes of moderate to vigorous level intensity per day is 
associated with a decreased risk; and a dose-response relationship is observed with level 
of intensity.  However the magnitude of effect across studies ranges from a 20-80% risk 
reduction [24].  A systematic review of 19 cohort and 29 case-control studies reported 
through 2006 reported that the effect is stronger in post-menopausal women [24].  
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Interestingly, this effect has been found to be similar in post-menopausal women 
regardless of ethnicity.  Findings for pre-menopausal women indicated a reduction in risk 
for Hispanic women only [44]. 
Risk Factors Not Associated with Estrogen Exposure 
 Other factors not related directly to estrogen exposure that are important to 
consider are family history and socioeconomic status (SES).  Having a first degree family 
history of breast cancer is consistently associated with a 2-fold increase in risk compared 
to those with no family history, and risk increases for each additional relative affected 
[26].  The 4-Corner’s Breast Cancer Study reported that risk for an ER- tumor was higher 
for Hispanic women with a family history, whereas risk for an ER+ tumor was higher for 
NHW women [45]. 
 Several studies have shown that high SES is associated with increased risk of 
breast cancer across all ethnic groups, however the strength of the association is variable; 
it is stronger among NHW than Hispanic women at the highest SES level [46-48].  SES is 
a measure of individual or family attributes that contribute to a standard of living and 
common indicators are annual income, educational attainment, or occupational status.  
These factors are correlated with other risk factors such as parity, HRT, and alcohol use 
[47].  Low SES is reported to be associated with more aggressive ER- tumors in Hispanic 
but not in NHW women [49]. 
Use of Risk Factors in Statistical Analysis 
 The determination of risk factors and their contribution to breast cancer etiology 
is complicated.  The RR and OR estimate the strength and direction of the statistical 
association of a risk factor with breast cancer, but do not necessarily offer insight into 
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cause or mechanism or whether the impact is necessarily associated with a large 
proportion of cases [6].  However, if results are consistent across several studies with 
differing designs, and cannot be attributed to bias, confounding, or chance, then a risk 
factor may be recognized to be a potential etiologic factor [6].  These established risk 
factors can then be used as a means to evaluate other predictors (i.e. genes), and be used 
as confounders or effect modifiers of the independent variable (also known as the main 
predictor) and dependent variable (also known as the outcome) when testing for an 
association.  Most risk factors can be viewed as confounders, when they are associated 
with both main predictor and outcome, and not part of the causal pathway.  They will be 
accounted for by adjustment in statistical modeling [50].  An effect modifier is a variable 
that differentially (positively and negatively) modifies the association of a risk factor with 
an outcome.  The effect modification is detected when stratification reveals the effect 
estimates diverge across strata [50].  
 Most of the established risk factors discussed above were assessed as potential 
confounders in this dissertation (current age, age at menarche, age at menopause, alcohol 
consumption, HRT, OC use, obesity, parity, age at FFTB, physical activity, family 
history, and SES).  Some risk factors such as menopausal status, and ethnicity were also 
evaluated as potential effect modifiers.   
Breast Cancer Heterogeneity 
 When evaluating the biological features of breast cancer it is important to 
understand that it was once studied as a single disease and is now widely acknowledged 
as several distinct phenotypic subtypes that vary in etiology, gene expression, clinical 
features, and response to treatments, prognosis and outcome [5-6].  Most breast tumors 
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are associated with tumor markers that represent over-expression of specific reproductive 
hormone receptors and proteins, and their associated genes, that are involved in both 
initiation and promotion of carcinogenesis within the breast tissue [6].  However, some 
breast tumors do not express these markers and are believed to develop from a 
completely different biological mechanism.  The most widely studied tumor marker is 
ER, which is a product of the ERα gene.  The degree of tumor ERα expression (positivity) 
has been used for some time to classify breast tumors into subtypes believed to predict 
patient response to treatment, risk of recurrence and survival [6, 35, 51].  The 
Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor II (HER2), 
encoded by PGR and ERBB2 genes, respectively, is used increasingly in combination 
with ER status to classify tumors into subtypes.   
 The ability to establish tumor heterogeneity can be attributed to advances in 
molecular and cell biology and lab techniques involving DNA sequencing potential.  
Classification of breast tumors is part of the routine diagnostic tests and is commonly 
performed using two methods: immunohistochemistry (IHC) and gene expression 
profiles (GEP) [52-53].  IHC is performed in individual samples of formalin fixed, 
paraffin-embedded breast tumor tissue blocks (from core-needle biopsy or resections). 
The technique utilizes a Food and Drug Administration approved IHC kit that includes 
monoclonal antibodies that can bind to specific antigens on proteins in the cell, in this 
case those expressed by receptors such as ER/PR/HER2, to test for a proportion of cells 
stained positive as well as the intensity of staining [52-54].  In clinical practice, a patient 
with a proportion of cells ≥1% staining for ER, regardless of staining intensity, will 
usually benefit from endocrine therapy, and the American Society of Clinical Oncology 
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and College of American Pathologists (ASCO/CAP) has set this as the standard cut-off 
value for ER positivity [52].  According to ASCO/CAP, the cutoff value for PR positivity 
status is the same as ER, while HER2 positivity is defined as a score of 3+, which 
corresponds to ≥30% of cells positively stained [52, 55].  These classifications are most 
commonly reached through a semi-quantitative method in which the number of positively 
stained cells are estimated on a slide cut from the tumor block by a trained pathologist 
[53].  Four intrinsic breast tumor phenotypes have emerged according to ER/PR/HER2 
receptor status that corresponds to those established by gene expression (Figure 1).  They 
include: luminal A tumors (ER+ and/or PR+/HER2-), accounting for 65-70%, 
characterized by over-expression of ER, PR, and luminal-specific genes; luminal B 
tumors (ER+ and/or PR+/HER2+), accounting for 7-12%, and having an expression 
pattern similar to luminal A but with HER2 overexpressed; HER2-overexpressing tumors 
(ER-/PR-/HER2+), accounting for 6-10%, which do not express ER/PR, but are found to 
have high levels of HER2 expression; and triple negative, (ER-/PR-/HER2-) which 
account for approximately 6-10% of the distribution  [5, 56].  A full description of all 
breast tumor phenotypes is beyond the scope of this review as the focus is on ERα 
specifically. 
 While data have emerged describing incidence trends for breast cancer tumor 
phenotypes in different populations, the etiology associated with this heterogeneity is 
largely unknown and is the subject of growing epidemiologic research.  It is well 
established that family history is a strong predictor when determining risk, supporting the 
need to explore the contribution of genetic variation to breast cancer, and the influence 
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this variation may have over the genes that represent different tumor phenotypes and 
heterogeneity. 
Figure 1: Classification of Breast Cancer Subtypes by Hormone Receptor Status 
 
Adapted from Blows, F.M., et al., Subtyping of breast cancer by immunohistochemistry to 
investigate a relationship between subtype and short and long term survival: a 
collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 2010. 
7(5)[56]. 
Genetic Variation and Predisposition to Breast Cancer 
 The human genome contains over 20,000 genes that encode proteins.  A very 
small portion of the genome, approximately 1.5%, contains coding regions while the rest 
are non-coding [57].  All cancers involve the failure of genes to control cell growth and 
division.  Although a small proportion of breast cancers are strongly hereditary; it has 
been of interest to evaluate genetic variation in potential susceptibility genotypes and the 
association with breast cancer, as only a handful of genes to date explain the association 
[58].  There are different forms of genetic variation that are commonly described by the 



















High Penetrance Mutations 
 High penetrance mutations present a high risk but are very rare in populations.  
BRCA1/BRCA2 [59], and TP53 [60], are a few genes with these types of mutations.  They 
have been associated with relative risks that are 10 to 20-fold higher than risk for non-
carriers of these mutations; however they only account for approximately 5% of inherited 
breast cancers.   
Moderate Penetrance Variants 
 Moderate penetrance variants are uncommon with a minor allele frequency 
ranging from 0.005-0.01.  Variants found on some of the following genes that are 
involved in DNA repair mechanisms include: CHEK2 [61], ATM [62], and BRIP1 [63].  
The risk is 2 to 4-fold higher than risk for noncarriers of the variant but only account for 
about 3% of inherited breast cancers. 
Low-Penetrance Variants 
 Low-penetrance variants include the most common forms of genetic variation and 
are often SNPs.  These variants may increase risk <2-fold in some populations but have 
no effect in others [58, 64].  Large scale collaborative efforts such as International 
HapMap Project and Genome Wide Association Studies (GWAS) have identified 
approximately 12 susceptibility SNPs for breast cancer.  Some of these SNPs are located 
on FGFR2, TOX3, MAP3K1, and LSP1 genes [65].  GWAS have been conducted 
primarily in women of European background.  Some of these results have been replicated 
in other populations, including a subset of this study population to be examined in this 
dissertation (4-Corner’s Breast Cancer Study) [66-68].  Most variants are associated with 
ER+ tumors, although several population-based studies have identified a small number 
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associated with ER- tumors that appear to increase risk by only 3-14% [67].  Many are 
not considered to be causal variants but are thought to be in linkage disequilibrium with a 
neighboring functional variant [58].   
Population Substructure in Genetic Variation 
 When assessing genetic variation, it is important to consider the population 
substructure.  The phenomenon ‘population substructure’ is an effect seen in populations 
that could potentially differ genetically [69].  This substructure may be reflected in 
incidence of disease, proportions of cases and controls, or distribution of allele or 
genotype frequencies between groups and individuals.  Undetected population 
substructure can create a false positive association due to the bias of missed genetic 
heritage or ancestry [69].  One successful approach to controlling this issue is assessing 
genetic ancestry, also known as admixture, using a set of genetic markers.  The present 
study includes Hispanic women from the Southwest U.S. and Mexico who have Native 
American and European genetic heritages [8].  An estimate for the proportion of ancestry 
is used as a tool to control for potential confounding due to linkage disequilibrium within 
a genetically admixed population (See Methods-Genotyping-All Study Sites). 
Genes of Interest 
 In keeping with the goal of the BCHD consortium, this dissertation study has 
evaluated genes that are related to the CHIEF pathway.  The acronym ‘CHIEF’ was first 
described by Slattery and colleagues [70] using colorectal cancer (CRC) as an example.  
They describe the CHIEF pathway, including loci pertaining to inflammation, hormones 
and energy that are interrelated and have an effect on risk, to demonstrate the complexity 
of CRC etiology.  They further hypothesize that this pathway is also related to the 
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etiology of other cancers, specifically breast and prostate.  In breast cancer, hormone-
related loci are key determinates for risk and also have an effect on tumor promotion.  
Inflammatory loci are also involved in tumor growth when influenced by interaction with 
epithelial and vascular endothelial cells, which are partly regulated by genes in the TGF-β 
signaling pathway.  Energy-related factors include those related to insulin-signaling such 
as energy balance, physical activity, obesity, and diabetes.  Some of these factors, like 
obesity, are also involved in the inflammatory pathway.  In this dissertation study, genetic 
variation in the ERα and TGF-β signaling genes represents the interaction between the 
hormonal and inflammatory portions of the CHIEF pathway and are described below. 
ERα Signaling Pathway in Breast Cancer 
 The ESR1 (ERα) gene is part of the nuclear receptor subfamily 3 group A member 
1 (NR3A1) located on chromosome 6q24-q27, from positions 152,011,631-152,424,409; 
approximately 300 kb long and includes 8 exons or ‘protein-coding regions’ [71].  This 
gene encodes for the nuclear receptor ERα, a ligand-binding transcriptional factor that 
contains 5 structural functional domains (A-F) that are responsible for binding to steroid 
hormones and DNA, nuclear localization, and transcription activation [72].  
 Biological studies using mouse models have described two signaling mechanisms 
for ERα.  The classic ERα signaling pathway involves the ligand-binding domain (LBD), 
which is encoded within a region of about 300 amino acids, binding with estrogen that 
passively diffuses into the cell [7].  The binding causes a conformational change, called 
dimerization, in ERα, which then translocates into the cell nucleus.  The ERα-estrogen 
complex contains two zinc-fingers that allow it to bind to certain DNA sequences in the 
promoter region of the target genes known as estrogen response elements (ERE).  The 
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binding regulates gene transcription and is the primary mechanism by which estrogen 
either activates or represses gene expression, or simply turns it ‘on’ or ‘off’ [73-76].  The 
second related mechanism, “membrane-initiated signaling”, has been evaluated more 
recently [77], and involves activation of ERα on cell surfaces, signaling a cascade of 
events that regulate gene expression.   
 Through these inter-related mechanism(s), ERα mediates effects of estrogen on 
the expression of genes that regulate cellular development, reproduction, proliferation, 
and homeostasis.  Because the binding of estrogen to ERα plays an extensive role in 
many physiological processes it has been linked with the development of several cancers 
and diseases besides breast cancer.  These include cancers of the endometrium, ovaries, 
colon, and prostate and diseases such as cardiovascular, fibroids, endometriosis, 
osteoporosis, insulin resistance and obesity [72, 78]. 
 There have been two proposed biological mechanisms for estrogen-related 
carcinogenesis in the breast.  First, cell proliferation is stimulated in the mammary tissue 
when estrogen binds to ERα, causing an increase in target cell numbers, cell division, and 
DNA synthesis.  This increases the risk of replication errors that could disturb normal 
cellular function.  Second, the metabolism of estrogen directs the production of genotoxic 
by-products that could cause damage to DNA, resulting in point mutations [7]. 
 The expression of proteins transcribed by genes affected by the ERα-estrogen 
binding is complex and highly regulated, suggesting that they may serve different 
functions depending on the stage of tumor development or progression [78].   
 Heterogeneity of ERα in Population-based Studies.  ERα is overexpressed in 
approximately 75% of breast tumors and roughly corresponds to the “luminal” subtype 
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established by gene expression [6].  Endocrine therapy (i.e. tamoxifen and/or aromatase 
inhibitors) is often prescribed for ER+ luminal tumors in addition to surgery because they 
are considered “estrogen-dependent”.  ER- tumors are non-luminal and are associated 
with other tumor characteristics such as later stage, poorly differentiated grade, and larger 
tumor size, which result in a poor prognosis because they respond differently, if at all, to 
endocrine therapy.  Women with this tumor phenotype are usually prescribed various 
types of non-endocrine chemotherapy.  In addition, luminal subtypes are more likely than 
non-luminal to present at diagnosis as smaller, well-differentiated tumors at an earlier 
stage.  Established risk factors for breast cancer are mostly associated with ER+ tumors.  
Little is known about the etiology of ER- breast tumors or what treatment appears to be 
most beneficial.  Due to the fact that there is targeted therapy for ER+ tumors, women 
diagnosed with this subtype have a 90% 5-year survival rate compared to 50% in women 
diagnosed with ER- tumors, with most breast cancer-specific deaths occurring within the 
first 5 years following diagnosis [29, 35, 79-81].  With regard to ethnic disparity, while 
Hispanic women have a lower incidence rate of breast cancer than NHW women, they 
are at increased risk for development of tumors with less favorable clinical characteristics 
such as later stage, ER- status, and a poorly differentiated grade.  The reasons for these 
differences are not well established [82-86].  A large number of SNPs in the ERα gene 
have been evaluated in population-based studies and observed to have an association with 
breast cancer; however, very few studies have been able to assess Hispanic women. 
TGF-β Signaling Pathway in Breast Cancer 
 Genes in the TGF-B signaling pathway have been implicated in the development 
and progression of breast, colon, gastric, pancreatic, and ovarian cancer [87-88].  There is 
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increasing evidence that the TGF-β signaling pathway plays a dual role in cancer, acting 
as a tumor suppressor and promoter through a SMAD-mediated process [10].  To simplify 
the nomenclature, SMAD is used to describe homologs of both the Drosophila protein, 
mothers against decapentaplegic (MAD) and the Caenorhabditis elegans protein SMA 
(from gene sma for small body size) [89].  The SMAD family includes intracellular 
proteins that transduce signals given by TGF-β from the cell membrane to the nucleus 
providing instructions of protein production.  In the nucleus, the SMAD complexes bind 
to specific areas of DNA, and act as transcription factors where they control the activity 
of particular genes [89].  The following SMADs are associated with TGF-β signal 
transduction: receptor regulated (R-SMAD) SMAD2 and SMAD3; common mediator (co-
SMAD) SMAD4; and inhibitory (I-SMAD) SMAD6 and SMAD7 [89].  Their specific roles 
in the signaling pathway are described below.  
TGF-β1 and TGF-βRI.  TGF-β1 is part of the TGF-β family of multifunctional cytokines, 
and is located on chromosome 19q13.1 from positions 41,836,811 to 41,859,830; 
approximately 25 kb long, encoding 390 amino acids [90].  TGF-β1 is an abundant 
peptide expressed in many types of cells.  It functions in regulating biological processes 
such as cell proliferation, differentiation, adhesion, migration, and survival.  A general 
biological mechanism for TGF-β signaling has been described [91].  Upon activation, the 
TGF-β ligand is cleaved from TGF-β1, binding to TGF-βRII, a high affinity cell surface 
receptor.  It then recruits and phosphorylates TGF-βRI activating its kinase function.  
TGF-βRI is a cell surface receptor in the serine/threonine kinase family located on 
chromosome 9q22.33 from positions 101,867,411 to 101,916,473; approximately 49 kb 
long, containing 9 exons [92].  TGF-βRI initiates signal transduction into the intracellular 
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matrix with its protein kinase activity, phosphorylating R-SMAD2 and R-SMAD3.  These 
phosphorylated R-SMADs are then translocated to the nucleus, forming a complex with 
Co-SMAD4, and work to either activate or repress target genes regulating cell 
proliferation through interaction with other transcription factors.  SMAD6 and SMAD7 
inhibit TGF-β signaling by blocking TGF-βRI from phosphorylating R-SMAD2 or R-
SMAD3 [87, 91, 93].   
 In normal mammary cells, TGF-β1 has been found to have an anti-proliferative 
effect on epithelial and endothelial mammary cells by acting as a tumor suppressor by 
down-regulating cell growth, differentiation and apoptosis [87-88].  This is done by 
down-regulating components of the cell cycle such as proto-oncogene c-myc or cyclin-
dependent kinases (CDKs) and up-regulating CDK inhibitors [87-88, 93].  Some 
researchers have found evidence in mouse models that increased levels of TGF-β1 in 
serum strengthen tumor suppressor activity, reducing risk of breast cancer [94].  Immune 
cells, including B-Cell, T-Cell and macrophages, secrete TGF-β1, which negatively 
regulates their proliferation, differentiation and activation by other cytokines.  This 
makes TGF-β1 an effective immunosuppressor, and disruption of the signaling pathway 
is linked to autoimmunity, inflammation and cancer [95]. 
 In most tumor cells, genetic variation in key members of the pathway can cause 
resistance to the growth inhibitory effects of TGF-β signaling [96-97].  Exact 
mechanisms for resistance remain unknown, although researchers have hypothesized, 
through evidence in gastric, pancreatic, and colon cancer studies, that there may be 
decreased expression of receptors on the cell surface or increased expression I-SMAD6 or 
I-SMAD7 in the extracellular matrix, inhibiting the signaling function [87].  Some 
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researchers suggest that reduced expression or inactivation of TGF-β signaling could be 
caused by oncoproteins such as p53 [98] or decreased expression of other tumor 
suppressors that regulate the pathway such as RUNX3 [99].   
 There is also evidence that when TGF-β1 and TGF-βRI are overexpressed 
following tumor initiation, they further promote angiogenesis or the development of new 
blood vessels from pre-existing ones, a condition that is necessary for tumors to grow 
larger than 1-2 cm [87].  One possible explanation is that TGF-β induces the expression 
of vascular endothelial growth factor (VEGF), which then directly promotes 
angiogenesis, leading to tumor progression and metastasis [100].   
 In summary, TGF-β1 and TGF-βRI have been found to act at two different stages 
of carcinogenesis.  First, at cancer initiation, when they can act as tumor suppressors until 
a disruption causes resistance to its growth-inhibitory effects due to the loss or mutation 
of members of the pathway.  Second, during cancer progression, when there are tumor 
promoting effects, including enhanced motility, adhesion and angiogenesis in response to 
increased expression of TGF-β1 by the cancer cells themselves [87].  SNPs on these 
genes have not been implicated in risk of breast cancer in GWAS studies; however, an 
increasing number of epidemiological studies have suggested that genetic variants 
affecting TGF-β production and/or signaling may be related to the overall risk of breast 
cancer.  Several SNPs and/or mutations in TGF-β1 and TGF-βRI have been associated 
with increased breast cancer risk and ER+ tumors, although results from several studies 
involving multi-ethnic or small sample sizes have been inconsistent [96, 101-103]. 
RUNX1, RUNX 2, and RUNX3 Transcription Factors.  The RUNX family includes 3 
genes: RUNX1, RUNX2, and RUNX3.  They bind to DNA through the 128 amino acid 
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Runt domain (α-subunit), and share a common heterodimeric binding cofactor, called a 
core binding factor-beta (CBF-β).  The RUNX family members have been found to play 
an important tissue-specific role in determining the fate of cells during differentiation and 
growth and there is increasing evidence that the loss of function of these genes is 
involved in carcinogenesis [104-106].  Although widely expressed, the RUNX family 
members are regulators of tissue-specific expression and there is suggestion that one 
cannot compensate for the other if there is a loss of function during development, which 
is evident in the mouse knockout phenotypes (RUNX deficiency) [107].  Because of the 
regulatory role of RUNX proteins, there is physical interaction with R-SMADs and 
stimulation by the TGF- β signaling pathways, which mediate these cellular functions 
[108].  RUNX proteins are described as downstream effectors of TGF- β signaling and 
have the ability to stimulate growth regulation by making target cells sensitive to the 
effects of TGF- β family members.  In turn, TGF-β genes can activate RUNX genes at the 
transcription and post-transcriptional levels [9, 109].   
 RUNX1 is located on chromosome 21q22.3 from positions 36,160,097 to 
36,421,594, and includes 11 exons and 453 amino acids and spans 260 kb[110].  In 
normal cells, this gene is involved in regulation of hematopoiesis.  It is well-known for 
being the site of translocations in acute leukemia (AML and ALL), where they act as 
transcriptional repressors by hindering transcription of the wild-type allele and is often 
found amplified in these cancer cells [111-113].  RUNX1 protein has been found at high 
levels in normal luminal and basal cells of breast epithelium, whereas expression is low 
or deficient in breast tumors [114].  Interestingly, RUNX1 has been suggested to be a 
regulator of breast tissue development interacting with a family of transcription factors 
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called FOXO proteins [107, 115].  In-vitro studies indicate that there is an inverse 
relationship between FOXO and RUNX1, where the loss of RUNX1 expression, causing 
oxidative stress on cells, is compensated for and stabilized by FOXO.  The study reported 
that the FOXO expression is essential for breast cancers, specifically triple-negative 
subtypes with low RUNX1 expression and that the increased FOXO activity supports 
continued cell proliferation and tumor progression [107, 115]. 
 RUNX2 is located on chromosome 6p21 from positions 45,296,053 to 45,518,818, 
and produces instructions for transcription of a protein that builds and maintains the 
skeleton, specifically, osteoblast cells, suggesting that it is a regulator of ‘bone 
genes’[116].  This gene is the least studied of the three family members, although it has 
been suggested that growth factor families involved in tumor cell growth, such as FGF 
and IGF, may signal through RUNX2 and amplify its expression.  RUNX2 has been found 
to be amplified in osteosarcoma, however, more clinical studies need to be conducted to 
generalize this finding to other cancers [9].  The main interest in this gene is the 
implication that it is involved in bone metastasis.  The potential role of RUNX2 in bone 
metastasis was first observed when its target gene, collagenase-3, was expressed in breast 
cancer cell lines (MDA-MB-231), and whose cells are found to form osteolytic lesions in 
mice [117].  Breast cancer cells secrete parathyroid-hormone-related peptide (PTHrP), 
which encourages formation of osteoblasts during bone metastasis.  RUNX2 was reported 
to regulate PTHrP expression of metastatic breast cancer cells in the bone and the cell 
cycle of the cancer cells themselves [118-119].  It has also been demonstrated that 
RUNX2 alters factors, which can facilitate metastasis, including VEGF [120].  One recent 
study evaluated the percentage of RUNX2 immunoreactivity (positive protein expression) 
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within the nuclei of breast cancer cells and found it to be correlated with stage and 
histological grade of the tumor.  It was also associated with recurrence and overall 
survival in patients with ER-negative tumors, but not ER+, suggesting a potential 
indicator of prognosis for specific subtypes although further evidence is required to 
assess these complex interactions [121]. 
 RUNX3 is located on chromosome 1p36 from positions 25,226,002 to 25,291,612, 
approximately 66 kb long including 6 exons [122].  In normal cells RUNX3 regulates cell 
proliferation and cell death by apoptosis by interacting with DNA repair proteins, 
inhibiting angiogenesis, and functioning in cell adhesion and invasion [123].  
 RUNX3 expression is known to be down-regulated in several cancers, including 
gastric, bile duct, pancreatic, colorectal, and lung, strengthening its role as a tumor 
suppressor in normal cells [124].  It has been observed that RUNX3 is consistently under-
expressed in breast cancer cells compared to normal breast epithelial cells and is most 
likely a result of protein mislocalization and hypermethylation of the promoter region of 
RUNX3 [108, 125].  Fujii and colleagues reported silencing of RUNX3 in breast cancer 
cells lines via a method of epigenetic mechanism described as: enhancer of Zeste 
Homologue 2 (EZH2)—mediated histone methylation of H3 at the Lys27 (H3K27) 
residue, which results in repressed transcription.  In the same study, Fujii, et al. also 
found that EZH2 binds to the RUNX3 promoter, resulting in increased H3K27 
methylation and a subsequent decrease of RUNX3 expression [126].  In contrast, RUNX3 
overexpression is found to be correlated with reduced metastasis of breast cancer cells 
[125].  One of the most common epigenetic pathway events in cancer, hypermethylation 
of the CpGisland, suggests that RUNX3 inactivation is a significant risk factor for 
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carcinogenesis.  In a group of bladder cancer patients, researchers found that RUNX3 
inactivation not only occurs early in the process but also increases with age [127]. 
 To date, there does not appear to be any published population-based studies, 
which have evaluated SNPs on the RUNX genes and their association with breast cancer.  
The evidence to date for these genes is based on studies involving mouse models, gene 
expression, and copy number variants.  
Crosstalk between TGF-β and ERα Signaling Pathways 
 It is widely acknowledged that the ERα and TGF-β signaling pathways help to 
regulate mammary development, function, and carcinogenesis.  However, TGF-β family 
members and ERα have conflicting roles in cell proliferation and survival of breast 
epithelial cells.  ERα signaling supports proliferation and differentiation specifically by 
enhancing cyclin D1 and c-Myc, components of the cell cycle.  In contrast, TGF-β 
signaling pathway promotes apoptosis by reducing the expression of c-Myc and cyclin-
dependent kinases in epithelial cells [128].  The opposing regulatory effect on cell 
proliferation has motivated researchers to evaluate the relationship between the two 
signaling pathways. 
 Several studies have provided evidence that R-SMAD2, R-SMAD3 and Co-
SMAD4 come into direct physical contact with ERα [129-132].  Co-SMAD4 is found to 
be a mediator of crosstalk between TGF-β and ERα where it acts as a co-repressor of the 
transcription of ERα, inhibiting tumor growth.  Interestingly, Co-SMAD4 has been found 
to induce apoptosis in ER+ but not ER– cells [133].  R-SMAD3 has been found to be a 
co-activator of ERα changing the role of TGF-β.  In the absence of Co-SMAD4, TGF- β 
can regulate ERα transcription through a R-SMAD3-mediated process and enhance the 
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estrogen-ERα cell proliferation [131].  In fact, Araki and colleagues found that 65% of 
late stage breast cancers are characterized by activated R-SMAD3 and HDM2, a negative 
regulator of the tumor suppressor p53 [134].  Bierie and colleagues compared breast 
cancer expression signatures to TGF-β response signatures and found two correlations: 
first, the TGF-β response signature was associated with ER- tumors and poor prognosis; 
second, the absence of the TGF-β response signature was found to be higher in ER+ 
tumors and was associated with a poor prognosis [135]. 
 On the other hand, Ito and colleagues reported that the ligand activated estrogen-
ERα complex appears to cause degradation of R-SMAD2/3 complex, thereby reducing 
TGF-β signaling.  This degradation was not dependent on DNA binding or transcription 
of ERα and this non-genetic process was suggested to reduce migration and invasion 
caused by TGF-β; however, there are conflicting reports on the ability of ERα to 
effectively degrade R-SMAD2/3 complexes [130].  ERα activation has been reported to 
inhibit TGF-β transcription activity by up to 60% in reporter assays [129-130].  The 
hypothesized mechanism includes estrogen acting directly on the TGF-β signaling 
pathway to block the phosphorylation of R-SMAD 2/3 complex via ubiquitin-proteasome 
pathway [130]. 
 The RUNX transcription factors are also involved in regulation of cell growth and 
differentiation and have been shown to bind with SMADs, which in turn can affect ERα 
transcription.  RUNX1 has been called an ‘accessibility factor’ for ERα binding sites and 
may function to establish a cooperative chromatin structure in DNA used for binding to 
EREs and to control gene expression in ER+ cells specifically. 
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 Using mouse models, Huang and colleagues showed that RUNX3 may target ERα 
to function as a tumor suppressor by destabilizing the gene and inhibiting the expression 
[136].  They also found an inverse relationship between the two genes’ expression; the 
higher the RUNX3 expression the lower the ERα in ER+ cells and vice versa, while Lau 
and colleagues found the same effect in ERα – cells [125, 136].  This supports the tumor 
suppressor role in RUNX3 with ERα as a potential mediator of these effects. 
Summary and Rationale for Research 
 It is evident that breast carcinogenesis is highly complex and many factors can 
vary by ethnicity.  ERα has an imperative role in normal breast development as well 
tumor initiation and promotion.  Its status is a relevant prognostic and predictive factor 
after breast cancer diagnosis.  Genes in the TGF-β signaling pathway have numerous and 
often conflicting cellular effects, as either tumor promoters or suppressors, and as an 
either inhibitors or stimulators of angiogenesis.  Through animal models, these genes and 
ERα have been found to have an effect on expression of one another through a SMAD-
mediated process in the cell nucleus. 
 This evidence provides justification for studying genetic variation within these 
genes and the relationship between TGF-β and ERα signaling pathways as well as to 
evaluate whether the association differs in Hispanic and NHW women.  While high 
penetrance mutations only account for 5% of breast cancers overall, it is believed that the 
combined effect of low-penetrance variants may explain a large component of breast 
cancer risk [137-138].  It is therefore important to continue to explore variation within 





Study Population and Data Collection 
 The study population consists of 11,060 participants in a multi-site consortium 
including data harmonized across three population-based case-control studies conducted 
within the U.S. and Mexico: the 4-Corner’s Breast Cancer Study, the San Francisco Bay 
Area Breast Cancer Study, and the Mexico Breast Cancer Study.  The goal of this 
consortium is to evaluate the biological basis of ethnic-related health disparities between 
Hispanic and NHW women for breast cancer risk and survival using genetic factors in the 
CHIEF signaling pathway in combination with behavioral, social, and cultural factors.  It 
is hypothesized that these genetic factors may influence differences in breast cancer 
development and survival among these two ethnic groups [8].  A total of 40 selected 
SNPs, including those on TGF-β1, TGF-βR1, RUNX1, RUNX2 and RUNX3 were 
genotyped for the BCHD study.  An additional five SNPs on ERα were genotyped for a 
subset of the participants from the New Mexico site (n=1,954) of the 4-CBCS as well for 
this dissertation.  Taken together, these data were used to address the specific aims of this 
dissertation study.  Details of methodologies specific to each study have been previously 
described [139-141]; brief descriptions including objectives, eligibility, recruitment, 




4-Corner’s Breast Cancer Study 
 4-Corner’s Breast Cancer Study (4-CBCS) was conducted from 1999-2005.  The 
primary objective of this study was to evaluate the variation of risk factors associated 
with breast cancer between Hispanic and NHW women in the Southwest 4-Corners 
region of the U.S.  Eligibility criteria for breast cancer cases included:  self-identified 
Hispanic, American Indian, or NHW ethnicity; age 25 to 79 years; residency in Arizona 
(Cochise Coconino, Maricopa, Pima, Pinal, Santa Cruz, and Yuma counties), Colorado, 
New Mexico, or Utah; and diagnosis with a first primary breast cancer (in-situ or 
invasive) between October 1999 and May 2004.  Cases were ascertained and eligibility 
was confirmed through the respective state cancer registries; New Mexico and Utah 
registries are a part of the SEER Program, and Arizona and Colorado registries are a part 
of the Centers for Disease and Control (CDC).  At the time of selection, Hispanic 
ethnicity was identified using the computer program Generally Useful Ethnic Search 
System (GUESS) [142] and the Census Spanish Surname List [143].  NHW cases were 
matched on age to Hispanic cases and selected on a 1:1 ratio in Arizona and Colorado; a 
4:1 ratio for all cases in Utah and for cases under age 50 years in New Mexico; and a 1:1 
ratio for cases over age 50 years in New Mexico.  Controls were frequency-matched 
based on 5-year age distributions and ethnicity of the cases and were randomly selected 
from the target populations using commercial mailing lists (Arizona and Colorado) and 
driver’s license lists (New Mexico and Utah) for women under age 65, and from the 
Center for Medicare Services lists for women age 65 years and older.  Potential 




 A total of 5,163 women (cases: Hispanic=851, American Indian=22, 
NHW=1,683; controls: Hispanic=913, American Indian=23, NHW= 1,671) participated 
in the 4-CBCS.  Trained interviewers administered a computer-assisted questionnaire in 
English or Spanish including questions regarding socio-demographics, medical and 
reproductive histories, family history of breast cancer, diet (modified to include foods 
common to Southwestern part of U.S.), physical activity, smoking, alcohol, medications,, 
and weight history.  The referent year for most sections of the questionnaire was the year 
prior to diagnosis for cases and year prior to selection for controls.  Anthropometric 
measures (weight, height, waist/hip circumference) were also recorded.  For cases, the 
median time from diagnosis to date of interview was 671 days for Arizona; 540 days for 
Colorado; 599 days for New Mexico; and 267 days for Utah.  Blood was also collected 
from the majority (75%) of participants (cases=1,244 NHW, 606 Hispanic; 
controls=1,329 NHW, 728 Hispanic) and DNA was extracted for subsequent analysis 
[139]. 
San Francisco Bay Area Breast Cancer Study 
The San Francisco Breast Cancer Study (SFBCS) was conducted from 1995-
2004.  The primary objective of this study was to investigate the role of lifestyle factors, 
migration patterns and acculturation in Hispanic women, and ethnic differences in risk 
factors with breast cancer risk.  A primary focus was on vitamin D exposure and SNPs in 
the vitamin D receptor gene.  Eligibility criteria for breast cancer cases included: NHW, 
Hispanic, or African American ethnicity; age 35 to 79 years; living in the San Francisco 
Bay Area; and diagnosed with a first primary breast cancer (invasive) between April 1, 
1995 and April 30, 1998 for phase 1, May 1, 1998 and April 30, 1999 for phase 2a, May 
1, 1997 and April 30, 1998 for phase 2b, and May 1, 1999 and April 30, 2002 for phase 
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3.  Cases were ascertained and eligibility was confirmed through the California State 
Cancer Registry, a SEER registry.  Controls were randomly selected from the target 
population using random digit-dialing and frequency-matched to cases based on the 
expected 5-year age distributions and ethnicity.  Potential participants self-reported 
ethnicity in a telephone screening interview to determine eligibility.  A total of 3,823 
women (cases= NHW=596, Hispanic=1,119; controls= NHW=646, Hispanic=1,462) 
participated in an in-person interview that was conducted with trained interviewers who 
administered a questionnaire in English or Spanish and took anthropometric measures 
(weight, height, waist/hip circumferences).  Questions were similar to those used in the 4-
CBCS with additional questions on occupational history and sunlight exposure.  Blood 
specimens (or saliva sample, if blood collection was refused) were collected between 
1999-2002 (phase3) for 1,105 (93%) cases an 1,318 (92%) of controls, and DNA was 
extracted for subsequent analysis [140]. 
Mexico Breast Cancer Study 
 The Mexico Breast Cancer Study (MBCS) was conducted from 2004-2007.  The 
primary objective of this study was to investigate lifestyle, genetic, and socio-
demographic factors associated with the risk of breast cancer in Mexican women.  
Eligibility criteria for breast cancer cases included: 35 to 69 years of age; living in 
Mexico City, Monterrey, or Veracruz metropolitan areas at least 5 years prior to 
selection; and diagnosed with a first primary breast cancer (in-situ or invasive) between 
January 2004 and December 2007.  Cases were recruited from 12 participating hospitals 
in the three areas.  Controls were selected using a probabilistic multistage design based 
on the basic geo-statistical catchment areas of the 12 participating hospitals and were 
frequency-matched to cases based on the expected 5-year age distributions, to a 
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healthcare institute membership, and residency.  A total of 2,074 Mexican women 
(cases=1,000, controls=1,074) participated in an in-person interview that was conducted 
by trained interviewers.  Anthropometric measures (weight, height, waist/hip 
circumferences) and mammograms were collected.  For cases, the median time from 
diagnosis to date of interview was three days.  Questions were similar to 4-CBCS with 
additional questions on number and type of possessions owned (i.e. telephones, stoves, 
televisions, computers, etc) that was used to construct a socioeconomic index based on 
distribution of these variables in controls using principle components analysis.  Blood 
was collected for 850 (85%) cases and 1,031 (96%) controls and DNA was extracted for 
subsequent analysis [141]. 
 All studies were reviewed and approved by their respective Institutional Review 
Board for Human Subjects and all participants signed a written informed consent prior to 
participation. 
Harmonization of Data across Studies 
 Data from all three studies were harmonized at the University of Utah, the 
consortium’s coordinating site, using questionnaire data from each study.  Variables of 
interest based on study hypothesis involving the CHIEF pathway were identified and the 
distributions of data across studies were compared.  The distribution of the variables was 
highly correlated ensuring the validity of the harmonization [8].  Table 2 summarizes 







Table 2:  Descriptive summary of studies in the multi-collaborative case-control BCHD study (n=11,060) 
Study Description MBCS SFBCS 4-CBCS 
Study Objective 
 to investigate lifestyle, genetic, 
and socio-demographic factors 
with the risk of breast cancer in 
Mexican women 
 to investigate the role of lifestyle 
factors, migration patterns and 
acculturation in Hispanic women and 
ethnic differences in risk factors with 
breast cancer risk. 
 to evaluate the variation of risk factors 
associated with breast cancer among 
Hispanic and NHW women living in 
the Southwestern part of the United 
States 
Data collection period  2004-2007  1995-2004 (3 phases)  1999-2005 
Case Eligibility Criteria 
and Ascertainment 
 Hispanic ethnicity 
 resident of Mexico City, 
Monterrey, or Veracruz 
metropolitan areas at least 5 
years prior to selection 
 age 35-69 y 
 diagnosed with a first primary 
breast cancer (in-situ or invasive) 
between January 2004 and 
December 2007 
 recruited from 12 participating 
hospitals in the 3 areas 
 NHW, Hispanic, or African American 
ethnicity 
 resident of the San Francisco Bay 
Area 
 age 35-79 y 
 diagnosed with a first primary breast 
cancer (invasive) between 1995-2002 
 ascertained from SEER cancer 
registry 
 Hispanic, American Indian or NHW 
ethnicity 
 resident of Arizona (Cochise 
Coconino, Maricopa, Pima, Pinal, 
Santa Cruz, and Yuma counties), 
Colorado, New Mexico, or Utah 
 age 25-79 y 
 diagnosed with a first primary breast 
cancer (in-situ or invasive) between 
October 1999 and May 2004 
 ascertained from state cancer registries 
(SEER/CDC) 
Control Eligibility Criteria 
and Ascertainment 
 selected using a probabilistic 
multistage design based on the 
basic geo-statistic catchment 
area from the 12 participating 
hospitals 
 frequency-matched based on the 
expected 5-year age 
distributions, membership to a 
healthcare institute, and 
residency of the cases 
 randomly selected using random 
digit-dialing 
 frequency-matched to cases based on 
the 5-year age distributions and 
ethnicity 
 women <65 y were randomly selected 
using commercial mailing lists 
(Arizona and Colorado) and driver’s 
license lists (New Mexico and Utah) 
 women age ≥65 y were selected from 
Center for Medicare Services list 
 frequency-matched to cases based on 
5-year age distributions and ethnicity  
Participant Sample Size 
 cases=1,000  
 controls=1,074 
 total:2,074 Mexican women 
 cases=1,715 (H=1,119, NHW=596) 
 controls=2,108 (H=1,462, 
NHW=646) 
 total: 3,823 women 
 cases=2,556 (H=851, AI=22, 
NHW=1,683) 
 controls=2,607 (H=913, AI=23, 
NHW= 1,671) 
 total: 5,163 women 
DNA Sample Size 
(case/control) 
 850/1,031 
 91% of total population 
 1,105/1,318 
 63% of total population 
 collected between 1999-2002 
(phase3) 
 1,850/2,057 
 75% of total population 
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SNP Selection Criteria and Genotyping Methods 
Selection of SNPs 
With the exception of ERα, the genes of interest in this dissertation study were 
genotyped as part of the larger BCHD study.  In the BCHD study, a tagSNP approach was 
utilized to define variation across candidate genes and SNPs were selected to be included 
in the platform using the following five parameters: 
1. Linkage Disequilibrium (LD) blocks defined using a Caucasian LD map and an r2 
(pairwise LD measure representing correlation) ≥0.8 (when r
2
=1, two SNPs are in 
perfect LD;  
2. Minor allele frequency (MAF) >0.1;  
3. Range of -1500 base pairs (bps) from the initiation codon to +1500 bps from the 
termination codon;  
4. 1 SNP/LD bin; and 
5. Functional status (i.e. determined via in-vitro studies) 
ERα SNPs were selected based on a MAF>0.1 plus one or more of the following criteria:  
1. Previous literature indicating an association with breast cancer or any other cancer  
2. tagSNP 
3. LD block ≥0.8 with SNP under investigation or with a known functional variant 
In the current study, 45 SNPs among 6 genes were investigated:  
1. TGF-β1 (n=2): rs1800469, rs4803455;  
2. TGF-βR1 (n=5): rs6478974, rs1571590, rs1013186, rs11568785, rs10733710;  
3. RUNX1 (n=8): rs7279383, rs2268288, rs2252585, rs11701453, rs8127225, 
rs1474479, rs1883066, rs7279123;  
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4. RUNX2 (n=17): rs1321075, rs17209895, rs2677108, rs2819854, rs2790093, 
rs9463090, rs2396441, rs1316330, rs7750470, rs6930053, rs12208240, 
rs12209785, rs10948238, rs13201287, rs12333172, rs1200428, rs598953;  
5. RUNX3 (n=8): rs2236850, rs9438876, rs7517302, rs906296, rs7551188, 
rs6688058, rs11249206, rs447876; and  
6. ERα (n=5): rs2046210, rs6913578, rs851984, rs1801132, rs3798577. 
Genotyping – BCHD Study 
DNA was extracted from either whole blood (n=7,286) or saliva samples (n=637) 
from study participants.  Whole Genome Amplification (WGA) was carried out on the 
saliva-derived DNA samples prior to genotyping.  Genotyping included 1,466 SNPs in 
205 candidate genes and was conducted in the coordinating site lab at the University of 
Utah using a multiplexed bead array assay format based on GoldenGate chemistry 
(Illumina, San Diego, California).  A genotyping call rate of 99.93% was attained 
(99.65% for WGA samples).  There were 132 internal replicates that were blinded, 
representing 1.6% of the sample set.  The duplicate concordance rate was 99.996% as 
determined by 193,297 matching genotypes among sample pairs.   
 An additional 104 Ancestral Informative Markers (AIMs) were genotyped and 
used to characterize genetic admixture among participants [8].  AIMS were selected 
based on known differences in prevalence of alleles in Native American and European 
populations [144].  The computer program, STRUCTURE 2.0, was utilized to calculate 
the proportion of genetic admixture based on a two-population model that included 
European and Native American ancestry.  STRUCTURE allows the multilocus genetic 
data to define the population structure.  The proportion of an individual’s genome 
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(ancestry) originating from one of two original founding populations is estimated using a 
clustering algorithm [145]. 
Genotyping – ERα for 4-CBCS New Mexico Site 
 Preparation for assays began with measuring the concentration (ng/μL) of each 
DNA sample using the Nanodrop2000 instrument and software (Thermo Scientific, 
Wilmington, DE, USA).  The measured DNA concentration was used to determine the 
amount needed to dilute and standardize each sample to 4ng/μL for storage in the 
working plates. 
 ERα genotypes for 5 SNPs were determined using TaqMan assays (Applied 
Biosystems (ABI), Foster City, CA, USA) and evaluated on a 96-well single block ABI 
Step One Plus real-time polymerase chain reaction (PCR) machine.  Each 20ul reaction 
sample contained 5uL genomic DNA (20ng), primers, probes, and TaqMan Universal 
Master Mix (containing AmpErase UNG, AmpliTaq Gold enzyme, dNTPs, and reaction 
buffer).  Polymerase Chain Reaction (PCR) was carried out under the following 
conditions: 50°C for 2 minutes to activate UNG, 95°C for 10 min to active Gold enzyme, 
followed by 40 cycles of 92°C for 15 seconds and 60°C for 1 minute, and then through a 
final extension phase at 72°C for 7 minutes.  A Veriti Thermal Cycler was used to run two 
96-well plates simultaneously; however the ABI PCR machine reported the endpoint 
reading and produced results because of the specific feature called sequence detection, 
which gives fluorescent endpoint readings of the TaqMan-DNA reactions.  Results were 
merged to the harmonized BCHD dataset via study ID for the New Mexico site analysis. 
Description of Independent, Dependent Variables and Potential Confounders 
 The TGF-β1, TGF-βR1, RUNX1, RUNX2, RUNX3, and ERα SNPs were evaluated 
based on their genotypes.  As an example, using alleles that make up the genotypes, C 
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represents the wild-type allele, and T represents the variant/minor allele so that each 
genotype was categorized: CC=0, CT=1, TT=2.  Homozygous wild types were used as 
the referent group.  Heterozygous and homozygous minor allele genotypes were analyzed 
for association of breast cancer risk.  Women were excluded from analysis if missing data 
on any one particular SNP. 
 Diagnosis of breast cancer was the dependent or outcome variable.  Cases were 
included in analysis if the baseline diagnosis was a first primary breast cancer, either in-
situ (stage 0) or invasive (stages 1-4).  Women were excluded from analysis if their 
baseline diagnosis was not a first primary breast cancer. 
 Potential confounders and the specified categories were selected based on a priori 
knowledge when there was evidence that a factor was a significant confounder of the 
main effect variable (i.e. SNPs) being modeled.  Covariates that were assessed included:   
 age (years, <40-referent, 40-49, 50-59, 60-69, 70+); 
 study site (4-CBCS-referent, MBCS, SFBCS); 
 self-reported ethnicity (NHW-referent, Hispanic/American Indian); 
 first-degree family history of breast cancer (no-referent, yes); 
 history of HRT (no-referent, yes); 
 history of OC use (no-referent, yes); 
 menopausal status (pre-/peri- vs. post-); 
 age at menarche (years, <12-referent, 12, 13, 14+); 
 parity (nulliparous-referent, 1-2, 3-4, 5+); 
 age at FFTB (years, <20-referent, 20-24, 25-29, 30+); 
 education (< high school-referent, high school/GED, post-high school); 
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 long-term alcohol consumption (grams per day, none-referent, low (<5), 
moderate (5-9), high (10+)); 
 physical activity (total hours of vigorous intensity activity/week, continuous);  
 BMI during referent year (World Health Organization cut-points for normal-
referent (18.5-24.9 kg/m²), overweight (25-29.9 kg/m²), and obese (30+ kg/m²)); 
 cigarette smoking (never-referent, former or current status); and 
 genetic admixture, % Native American ancestry (≤28%-referent, 0.29-0.70%, 71-
100%) 
 BMI calculated from a participant’s weight and height using the formula weight 
in kilograms divided by height in meters squared (kg/m²).  BMI is assessed as described 
by the well-known World Health Organization international cut-points for normal, 
overweight, and obese.  Alcohol intake (grams per day) over the lifetime was available 
for all but 600 cases and controls from California.  For these individuals, alcohol 
consumption during the referent year was used.  Physical activity was measured as total 
hours of vigorous intensity per week.  Menopausal status was determined based on 
responses to questions on menstrual history and hormone therapy use.  Women who 
reported having periods during the referent year were defined as pre-menopausal. Women 
who reported using hormone therapy were defined as post-menopausal if they reported 
natural menopause (did not report have a period within the past 12 months) and were 
≥95
th
 percentile of age for race/ethnicity within each study site of those.  This age for 
natural menopause was 58 years for NHW and 56 years for Hispanics from the 4-CBCS, 
54 years for MBCS, and 55 years for NHW and 56 years for Hispanics from the SFBCS.  
Each covariate was assessed for its individual association with breast cancer risk, using a 
conservative significance level of (Wald p=≤0.20) to determine whether to further 
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evaluate it as a confounder in multivariable modeling.  Participants were classified by 
level of percent Native American ancestry in genetic admixture groups based on 
evaluation of AIMs (See Genotyping).  Cut‐points were made based on the distribution of 
genetic ancestry in the control population so that each ancestral group had sufficient 
power when assessing associations. 
Statistical Analysis   
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). 
Descriptive Statistics 
 Descriptive statistics for all potential confounders, as well as the distribution of 
genotypes for selected SNPs for RUNX1 (n=8), RUNX2 (n=16), RUNX3 (n=8), TGF-β1 
(n=2), TGFβ-R1 (n=5) and ERα (n=5) genes, were calculated and reported by ethnicity 
and case-control status within each ethnic group.  Significant differences between groups 
were determined using t-tests for continuous variables and chi-square (X
2
) for categorical 
variables.  Significant differences between study centers were also evaluated.  Mantel 
Haenszel X
2
 p-values for between and within group comparisons, were reported.   
Testing for Hardy Weinberg Equilibrium 
 Genotype distributions were also evaluated for agreement with Hardy Weinberg 
Equilibrium (HWE) by the Pearson Χ² test among controls, which is used to compare the 
observed versus the expected frequency of genotypes [146].  HWE is an approximation 
of genotype frequencies in a population.  The fundamental concept for HWE is that allele 
frequencies do not change from generation to generation, and assumes independent 
segregation of alleles at a locus.  When HWE is satisfied, the following assumptions are 
made in a population:  random mating, no mutations, and no selection, migration, or drift.  
The null hypothesis (H0) is that HWE holds in a population, the alternate hypothesis (HA) 
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is that it does not.  In order to correct for multiple hypothesis testing, HWE was adjusted 
for the False Discovery Rate as originally described by Benjamini and Hochberg (1995) 
[147]. 
Assessment of Potential Confounders and Model Building 
 The best approach taken for statistical model building is one that minimizes 
confounding through evaluation of selected covariates and finds the most parsimonious 
model that best fits the data [148].  For the present analysis, a purposeful selection 
algorithm was utilized for multivariable model building as proposed originally by 
Hosmer and Lemeshow [50].  Each covariate was tested in a univariable logistic 
regression model; testing the individual association with risk of breast cancer.  Genotypes 
for each SNP were initially assessed as a co-dominant (Let C=major allele and T=minor 
allele, (0 (CC) vs. 1(CT); and 0 (CC) vs.2 (TT)) mode of inheritance, adjusting for age 
and study site.  Unconditional logistic regression modeling was used because the controls 
were frequency-matched, not fully matched, with the cases.  OR and corresponding 95% 
confidence intervals (95% CI) are reported, along with Wald p-values.  A covariate with 
a Wald p-value ≤0.2 was considered a candidate for inclusion when constructing the 
multivariable models.  The multivariable logistic regression model was based on the 
following equation: 
      {      }   0    1 1     2 2     3 3       k k (1) 
Let       = log (probability of being a case over probability of being a control); 
X=covariate(s) of interest. 
 When constructing multivariable models, full models were compared to a reduced 
model (age and study site adjusted OR for the particular SNP) to evaluate the presence of 
confounding.    
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 Those corresponding to a >10% change in the effect estimate (OR) for the SNP, at 
a significance level of α=0.05, were retained in the final multivariable logistic regression 
models after further calculating the log likelihood ratio of models with and without the 
significant covariates [50].  The following is an example of a full model with all potential 
covariates of interest: 
           (2) 
      {      }          𝐸𝑅𝛼                                      
                                                                  
                           𝑅                                      
                                                      
                                                                 
                   
 Statistical models of the associations for the SNPs were also evaluated based on 
mode of inheritance as follows: (Let C=major allele and T=minor allele) additive model 
(0 (CC) + 1 (CT) + 2 (TT), continuous); dominant model (0 (CC) vs. 1 (CT) + 2 (TT) 
(referent)); or recessive model (0 (CC) + 1(CT) (referent) vs. 2 (TT)), when sufficient 
power could be gained by collapsing genotypes and a trend towards a different mode of 
inheritance is observed for OR for significant models using a co-dominant mode of 
inheritance. 
Effect Modifiers and Interaction 
 Multiplicative interaction models were used to determine the statistical 
interactions between the 45 SNPs of interest with the hypothesized effect modifiers 




Using menopausal status as an example, the interaction model can be described as: 
           (3) 
       {      }                                                 
                            
 The significance of the interaction term was tested using the Χ² p-value for 
interaction (p< 0.05).  The interaction term was further evaluated using the difference in 
maximum likelihood estimates for logistic regression models, with and without the 
constructed interaction term, using a Χ² test with 2 degree of freedom (2-df, co-dominant 
model) or 1 degree of freedom (1-df, additive, dominant, or recessive models).  
Evaluation of odds ratios between the strata was conducted and p values for 
heterogeneity were calculated for differences in association between strata groups by 
comparing the difference in maximum likelihood estimates for a logistic regression 
model as described above.  Trend p-values were conducted based on the Χ² p-value of the 
SNP assessed as a continuous variable within each stratum.  SNP-SNP interactions, 
including those with a potentially meaningful association with breast cancer (p<0.15), 
were conducted and evaluated in the same manner.  A multiplicative interaction effect on 
the logit scale was assumed for these two-way interactions. 
Multinomial Logistic Regression 
Utilizing data from cases and controls, multinomial logistic regression was 
conducted to evaluate the association between genotypes and risk of developing breast 
tumor phenotypes defined by ER/PR status (+/-).  This statistical technique is an 
extension of logistic regression where the dependent variable has >2 categories, also 
known as a polytomous response.  For the BCHD study this method was based on a 
nominal dependent variable with five unordered categories: control (referent); cases 
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(ER+/PR+, ER+/PR-, ER-/PR+, and ER-/PR-).  For the New Mexico subpopulation this 
method was based on a nominal dependent variable with three unordered categories: 
control (referent); case with ER+ tumor; and case with ER- tumor.  Using the maximum 
likelihood estimation, the probability of being a case with an ER+ or ER- tumor was 
compared to the probability of being a control, creating several binary logistic regression 
models [50, 149].  Additionally, the hypothesized effect modifiers, menopausal status and 
genetic admixture, were assessed via stratification, although sample size and power was 
reduced.  A p-value for heterogeneity was calculated using an interaction term for each 
model.  Trend p-values were conducted based on the Χ² p-value of the SNP assessed as a 
continuous variable within each stratum.  Equation 4 depicts the separate binary logistic 
regression models that results from using the multinomial model fit. 
 
      {    𝐸𝑅                }=                             (4) 
      {    𝐸𝑅                }=                              
Genetic Risk Score-Cumulative effect of risk alleles 
 While these SNPs may have a relatively weak individual effect on breast 
carcinogenesis, there may be a stronger cumulative effect.  The hypothesize for the 
present study is that these SNPs work with one another for proper function of the gene 
and therefore the cumulative effect may have an association with breast cancer.   
 SNPs that were significantly (p<0.05) or marginally significantly (p<0.15) 
associated with breast cancer (per-allele/trend effect) were used to create a genetic risk 
score (GRS).  These SNPs were then divided into two groups: those that increased or 




simply counting the number of risk alleles for each SNP (0, 1, or 2) and summing across 
SNPs [150].  GRS was created for the TGF-β signaling pathway genes (RUNX1, RUNX2, 
RUNX3, TGF-β1, TGF-βRI); and across TGF-β signaling pathway genes and ERα.  When 
not evaluated as a continuous variable, GRS categorization was based on the distribution 
of the variable among controls and differs for each of the two GRS.  Multivariable 
logistic regression analyses were conducted and OR and 95% CI, adjusting for age, study, 
and genetic admixture, were estimated for each GRS category.  Trend p-values were also 
conducted evaluating GRS as a continuous variable. 
Multiple Comparisons 
 The p-values, for both main effects and interactions, based on 1-df Wald Χ² test 
statistic, were adjusted for multiple comparisons taking into account tagSNPs within each 
gene using the step-down Bonferroni-correction method [151].  This method is based on 
the effective number of independent SNPs as determined using the SNP spectral 
decomposition method proposed by Nyholt [152], and modified by Li and Ji [153] using 
the eigenvalues of a correlation matrix of the SNPs for each gene.  This method of 
correcting for multiple comparisons is conservative, especially when evaluating 
correlated variables such as SNPs within a gene.  However, it is less conservative than 
the conventional Bonferroni correction because you have more opportunities to reject the 
null hypotheses, which results in an increase in statistical power [153].   
Power Analysis 
 Calculating the power of a case-control genetic association study is necessary to 
determine if there is a sufficient sample size to detect a hypothesized effect, or know the 
smallest detectable effect, between groups.  Power is the probability of successfully 
detecting an effect, or difference, between groups.  It is calculated from the false-
 
52 
negative, or type II, error rate (Beta, B) as 1-B.  Eighty percent is the most common 
sought after power.  This means that there is an 80% or greater chance of finding a 
statistically significant difference, if one is present, or of rejecting the null hypothesis, 
when it should be, thus avoiding a type II error rate [146].  Statistical power depends 
upon:  sample size and the specified magnitude of effect (i.e. odds ratio/relative risk), 
genotype frequencies, and desired level of statistical significance (alpha, α=0.05 (the 
false positive, type I, error rate)).  There are several assumptions made when calculating 
power, including disease prevalence in the general population compared to population 
under investigation, penetrance of alleles (corresponding to mode of inheritance), high 
linkage disequilibrium (LD or D΄) with disease loci (D΄=0.8), and proportion of variance 
explained by the loci under investigation [146, 154].   
Power was calculated utilizing software called The Genetic Power Calculator 
(available at: http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) for the analysis of 
discreet traits in case-control studies; in the present study, the presence or absence of 
breast cancer [154].  The following parameters were fixed based on the studies’ 
participation and blood collection: number of cases, and ratio of controls to cases.  The 
estimate for prevalence of breast cancer was based on the SEER age-adjusted prevalence 
of breast cancer for all races [2].  Table 3 shows the variables used for known or fixed 
parameters used in all power analyses for the entire study population.  The software was 
utilized to estimate power assuming varying frequencies for MAF (determined from 
genotyping), and genotype relative risk (assuming an additive model: risk increases 2-
fold when there are 2 minor alleles) for the entire study population, as well as for the 
New Mexico site.  The power is reported for a 1-df (A vs. a) and a general 2-df test (AA 
vs. Aa vs. aa).    
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Table 3: Fixed case-control parameters for the BCHD study and the New Mexico 
site of the 4-CBCS. 
 
 BCHD Study Population  







Number of cases 3,524 2,093 1,431 694 
Control : case ratio 1.194 1.247 1.118 1.03 
SEER Prevalence of breast 
cancer 
0.0108 0.0108 0.0108 0.0108 
D prime (D΄) 0.80 0.80 0.80 0.80 
Defined Type I error rate (α) 0.05 0.05 0.05 0.05 
Defined Power 0.80 0.80 0.80 0.80 
a Number of cases for New Mexico are a subset of the number of cases for the BCHD study 
population.   
 
Because 40 selected SNPs were evaluated from TGF-β1, TGF-βR1, RUNX1, 
RUNX2, and RUNX3 genes in this population, power was estimated using the minimum, 
median, and maximum MAF of the SNPs taken together.  In addition, a ‘threshold’ for a 
specified relative risk was determined for varying MAF and ethnic-specific subgroups.  
Power analysis was conducted for the three studies combined and stratified by ethnicity 
(See Table 3).  There were five SNPs from ERα and power was evaluated based on the 4-
CBCS New Mexico site participants with available DNA samples (n=1,458). 
Results of Power Analysis 
 Figure 2a shows the power curve for the whole study population based upon 
varying MAF of TGF-β signaling SNPs of interest when RR=1.05-1.50, measured in 0.5 
increments.  Assuming a 1-df model, there was 80% power to detect the following: 
RR=1.10 when MAF=0.49; R=1.12 when MAF=0.26; RR=1.17 when MAF=1.14; and 






 DF=degree of freedom; MAF= Minor allele frequency. 
 MAF for each SNP can differ by subgroups, which is evident for a few SNPs 
when stratified by ethnicity.  As an example, both Hispanic and NHW women had the 
lowest MAF for TGF-βR1 rs11568785; however NHW was higher than for Hispanic 
women: 8% versus 4%, respectively.  Figure 3a shows the power curve for Hispanic 
women.  For 80% power, assuming a 1-df model, the present study was able to detect a 
RR=1.15 when MAF=0.49; R=1.17 when MAF=0.28; RR=1.20 when MAF=0.16; and 
RR=1.40 when MAF=0.04.  The NHW subgroup has a smaller sample size; therefore the 
detectable RRs are slightly higher than for the Hispanic subgroup for similar MAF.  The 
present study was able to detect a RR=1.19 when MAF=0.50; R=1.22 when MAF=0.25; 
RR=1.25 when MAF=0.17; and RR=1.35 when MAF=0.08 (Figure 4a).  Results are 
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Figure 2a:  
1 DF Power Analysis Curve-TGF-β Signaling SNPs 











 The power curve for the overall New Mexico sample using MAF for ERα SNPs is 
shown in Figure 5a.  For 80% power, assuming a 1df model, the present study had the 
ability to detect a RR=1.30 when MAF=0.44 or 0.40; RR=1.33 when MAF=0.29; and 
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Figure 3a: Hispanic 
1 DF Power Analysis Curve-TGF-β Signaling SNPs 
n=4,703 (Cases=2,093; Controls=2,610) 
MAF=0.04 (Min)
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Figure 4a:  non-Hispanic White 
1 DF Power Analysis Curve-TGF-β Signaling SNPs 








 There were approximately twice as many NHW women compared to Hispanic 
women in this New Mexico subsample (927 vs. 482).  For Hispanic women, regardless of 
MAF, there was not sufficient power (80%) to detect a RR of 1.05-1.50; with only 70% 
power to detect RR=1.50 (Figure 6a).  In contrast, for NHW women there was 80% to 
detect a RR=1.38 when MAF=0.44 or 0.40; RR=1.40 when MAF=0.29; and RR=1.50 
when MAF=0.17 (Figure 7a).  Results are similar when evaluating power using a 2-df 
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Figure 6a: Hispanic  
1 DF Power Analysis Curve-ERα Signaling SNPs 
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Descriptive Characteristics - BCHD 
 The present study included a total of 7,733 participants (cases=3,524; 
NHW=1,431, Hispanic=2,093; controls=4,209; NHW=1,599, Hispanic=2,610) (Table 4) 
that had available DNA (69.9%).  Statistically significant differences were observed by 
ethnic group regardless of case-control status for all descriptive variables, with the 
exception of age at menarche (p-values in Table 4).  Approximately 60% of all 
participants were over 50 years of age; with a higher proportion of pre-menopausal 
women among Hispanic than NHW women for both cases (41% vs. 34%) and controls 
(41% vs. 32%) (p<0.0001).   
 Among NHW women, >99% of participants were characterized by the lowest NA 
ancestry strata (≤0.28), while 65% of Hispanic women had a moderate (0.28-0.70) 
proportion of NA ancestry.    Among, Hispanic compared to NHW women tended to be 
more obese (≥30 kg/m²) (43% vs. 26%), be less educated (<high school) (57% vs. 5%), 
report higher parity (5+) (21% vs. 9%), and to report no history of smoking (71% vs. 
58%) (data not shown, p-values in Table 4).  Hispanic cases were more frequently 
diagnosed with ER- tumors compared to NHW cases (26% vs. 20%) (Table 4).  NHW 
compared to Hispanic cases reported a higher alcohol intake (≥10 g/day) (13% vs. 3%), 




 Among statistically significant differences within Hispanic women, cases 
compared to controls had a higher proportion of 1
st
 degree family history of breast cancer 
(12% vs. 8%); age at menarche, ≤12 years of age (49% vs. 45%); and history of HRT 
(32% vs. 29%).  Conversely, Hispanic compared to NHW cases had a lower proportion of 
participants with number of full-term births (parity 3+) (52% vs. 63%); age at first full-
term birth <20 years of age (24% vs. 32%); obesity, BMI 30or greater kg/m
2 
(39.7% vs. 
45.5%); and less than a high school education (53% vs. 60%).  Hispanic controls were 
more likely to have >70% ancestry than cases (24% vs. 21%) (Table 4).  Among 
statistically significant differences within NHW women, cases compared to controls 
tended to have a first degree family history of breast cancer (23% vs. 16%) and report 
OCU (71% vs. 66%).  NHW controls tended to be >70 years of age (19% vs. 14%); and 
reported more full-term births (3+) (44% vs. 38%) compared to NHW cases (Table 4). 
 These potential confounders were further tested for differences by study sites.  
The 4-CBCS contributed 82.9% of NHW and 27.9% of Hispanic women in the BCDS, 
while the SBCS contributed 17.1% of NHW and 33.5% of Hispanic women.  The MBCS 
contributed 39% of Hispanic women.  The goal of this additional testing was to evaluate 
to what extent the differences in characteristics between case-control status were 
influenced by study site.  There were no differences between study sites for age at first 
full-term birth, OCU and physical activity.  However, statistically significant differences 
between study sites were observed for other covariates under evaluation.  For example, 
there was a statistically significant greater proportion of cases compared with controls 
who reported a parity ≥5 within the studies:  MBCS (20% and 29%); SFBCS (13% and 







Table 4.  Descriptive covariates stratified by ethnicity and case-control status, Breast Cancer Health Disparities Study (n=7,733) 
 non-Hispanic White (n= 3,030) Hispanic/American Indian (n= 4,703)  
  Cases (n=1431)  Controls (n= 1599)  Cases (n= 2093)  Controls (n=2610)   
Covariate, categorical N (%)  N (%) p
a





Age (years)              
 <40 87 6.1  117 7.3 
0.04 
198 9.5  313 12.0 
0.22 <.0001 
 40-49 401 28.0  409 25.6 708 33.8  834 31.9 
 50-59 403 28.2  410 25.6 614 29.3  758 29.0 
 60-69 340 23.8  356 22.3 425 20.3  530 20.3 
 70+ 200 13.9  307 19.2 148 7.1  175 6.7 
Study              





0.94 <.0001  MBCS - - 
 - - 816 39.0 994 38.1 
 SFBCS 254 17.8  264 16.5 698 33.4 880 33.7 
Family history, 1
st
 degree               






 No 1071 77.4  1289 84.5 1799 88.1 2326 91.8 
Menopausal status              






 Post-menopausal 919 65.9  1075 68.5 1186 58.8 1499 59.3 
Age at menarche (years)              
 <12 282 20.1  288 18.3 
0.12 
496 24.0  555 21.6 
0.002 0.99 
 12 389 27.7  435 27.6 523 25.3  608 23.6 
 13 381 27.1  418 26.5 466 22.6  590 22.9 
 14+ 353 25.1  435 27.6 581 28.1  820 31.9 
Parity              





<.0001 <.0001  1-2 622 44.0  638 40.3 774 37.2 790 30.5 






 non-Hispanic White (n= 3,030) Hispanic/American Indian (n= 4,703)  
  Cases (n=1431)  Controls (n= 1599)  Cases (n= 2093)  Controls (n=2610)   
Covariate, categorical N (%)  N (%) p
a





 ≥5 102 7.2  167 10.6 353 17.0  626 24.1 
Age at first full-term birth (years)       
 
    
 Nulliparous 249 17.6  248 15.7 
0.91 
225 10.9 181 7.0 
0.005 .0005 
 <20 170 12.0  199 12.6 503 24.4 825 31.9 
 20-24 499 35.3  609 38.5 716 34.7 922 35.7 
 25-29 314 22.2  342 21.6 356 17.3  451 17.5 
 30+ 180 12.8  184 11.6 262 12.7  204 7.9 




            
 <25 651 46.1  699 44.4 0.30 482 23.4  453 17.6 
<.0001 <.0001  25-29.9 411 29.1  465 29.5  762 37.0  951 36.9 
 30+ 350 24.8  412 26.1  818 39.7  1172 45.5 
History of hormone replacement therapy            






 Never 354 30.8  401 30.8 1282 67.6 1708 70.7 
History of oral contraceptive use            






 Never 405 28.9  539 34.2 892 43.2 1167 45.2 
Alcohol intake (g/day)
 
              






 Low (<5g/day) 292 25.3  315 24.3 148 8.1 175 7.8 
 Moderate (5-<10g/day) 135 11.7  130 10.0 96 5.3 80 3.6 
 High (≥10g/day) 155 13.4  161 12.4 47 2.6 65 2.9 
Smoking status              





0.38 <.0001  Former 368 31.7  360 27.3 313 17.2 347 15.5 






 non-Hispanic White (n= 3,030) Hispanic/American Indian (n= 4,703)  
  Cases (n=1431)  Controls (n= 1599)  Cases (n= 2093)  Controls (n=2610)   
Covariate, categorical N (%)  N (%) p
a





Education              





<.0001 <.0001  High school grad/GED 284 20.1  338 21.3 377 18.3 419 16.4 
 Post High school 1059 74.9  1168 73.7 594 28.9 597 23.4 
%  Native American ancestry              





.0012 <.0001  0.28-0.70 7 0.5  7 0.44 1373 65.6 1697 65.0 
 >0.70 4 0.3  1 0.1 444 21.2 633 24.3 
Estrogen/Progesterone Receptor (ER/PR) Status            






 ER+/PR- 116 11.7  - - 117 12.1 - - 
 ER-/PR+ 17 1.7  - - 28 2.9 - - 
 ER-/PR- 181 18.2  - - 225 23.2 - - 
Covariate, continuous Mean SD  Mean SD p
c





Age 55.6 11.2  56.7 12.3 0.05 52.7 10.6  52.3 10.8 0.26 <.0001 
Study, Total MET hrs/week              
 4-CBCS 1.35 2.9  1.44 3.1 0.47 1.18 2.9  1.00 2.4 0.22 .0008 
 MBCS - -  - - - 1.45 4.1  1.48 5.9 0.89 - 
 SFBCS 1.94 3.10  2.21 4.0 0.39 1.09 2.7  0.97 3.1 0.44 <.0001 
Note: Column percentages (%) may not add up to 100% due to rounding. Column totals (n) may not add up to total for each column due to missing observations: education 
(n=121), family history (n=247), menopausal status (n=227),  age at menarche (n=113)parity (n=62),  age at first full-term birth (n-=94), HRT use (n=971), OCU (n=112), alcohol 
(n=1,213), smoking status (n=1,194), BMI (n=107), vigorous physical activity (n=56). 
a Case-control status comparisons within each ethnic group, Mantel-Haenszel chi-square p values reported 
b Ethnic group comparisons regardless of case-control status, Mantel-Haenszel chi-square p values reported 
c Case-control status comparisons within each ethnic group (and studies for physical activity), p values from t- tests reported 




Descriptive Characteristics for 4-CBCS – New Mexico Site 
 A total of 927 NHW (cases=452, controls=475) and 482 Hispanic women 
(cases=242, controls=240) with available DNA (72.1%) were included in analyses 
evaluating SNPs from the ERα gene, based on data from the New Mexico site only.  
Descriptive characteristics of the New Mexico subset of the BCHD study population 
stratified by ethnicity and case-control status are shown in Table 5.  Similar to the larger 
study population, a larger proportion (63%) of participants were over 50 years of age; 
with a slightly higher proportion of post-menopausal women for NHW compared to 
Hispanic (67% vs. 63%) women.  In addition to being slightly older, NHW women, 
compared to Hispanic women, tended to report more family history of breast cancer (22% 
vs. 16%), lower parity (nulliparous) (18% vs. 10%), less obesity (≥30 kg/m²) (21% vs. 
31%), history of HRT (69% vs. 57%), history of OCU (69% vs. 58%), no long-term 
alcohol consumption (46% vs. 64%), history of cigarette smoking (48% vs. 38%), post-
high school education (76% vs. 50%), ≤0.28 NA ancestry (99% vs. 20%), and a higher 
mean vigorous MET hours per week of physical activity (1.45 vs. 1.09) (data not shown, 
p-values in Table 5).  There were only 13 participants total that had >70% NA ancestry; 
therefore the strata were collapsed into two categories (≤28%, 29-70%).  The presence of 
a family history of breast cancer was significantly higher for both NHW cases (27% vs. 
18%) and Hispanic cases (21% vs. 10%) compared to controls (Table 5).  There was no 
difference for ER/PR status by ethnicity (p=0.13), which was observed in the larger 







Table 5.  Descriptive covariates stratified by ethnicity and case-control status,  
New Mexico sub-population of 4-Corners Breast Cancer Study (n=1,409) 
 non-Hispanic White (n=927) Hispanic/American Indian (n=482)  
  Cases (n=452)  Controls (n=475)  Cases (n=242)  Controls (n=240)   
Covariate, categorical N (%)  N (%) p
a





Age (years)              
 <40 19 4.2  20 4.2 
0.86 
21 8.7  23 9.6 
0.92 <.0001 
 40-49 134 29.7  138 29.1 85 35.1  79 32.9 
 50-59 109 24.1  129 27.2 67 27.7  66 27.5 
 60-69 121 26.8  113 23.8 50 20.7  60 25.0 
 70+ 69 15.3  75 15.8 19 7.9  12 5.0 
Family history, 1
st
 degree               
 Yes 115 26.5  81 17.8 
0.002 
48 21.4  22 9.8 
.0007 0.005 
 No 319 73.5  373 82.2 176 78.6  203 90.2 
Menopausal status              
 Pre-/ peri-menopausal 151 33.4  151 31.8 
0.60 
91 37.6  85 35.6 
0.64 0.13 
 Post-menopausal 301 66.6  324 68.2 151 62.4  154 64.4 
Age at menarche (years)              
 <12 88 19.6  77 16.3 
0.17 
54 22.3  52 21.8 
0.66 0.10 
 12 106 23.7  115 24.4 68 28.1  58 24.3 
 13 139 31.0  141 29.9 52 21.5  63 26.4 
 14+ 115 25.7  139 29.5 68 28.1  66 27.6 
Parity              
 Nulliparous 89 19.7  74 15.6 
0.006 
22 9.1  27 11.3 
0.75 <.0001 
 1-2 223 49.3  215 45.4 99 40.9  93 38.8 
 3-4 121 26.8  154 32.5 90 37.2  90 37.5 
 ≥5 19 4.2  31 6.5 31 12.8  30 12.5 






 non-Hispanic White (n=927) Hispanic/American Indian (n=482)  
  Cases (n=452)  Controls (n=475)  Cases (n=242)  Controls (n=240)   
Covariate, categorical N (%)  N (%) p
a





Age at first full-term birth (years)            
 Nulliparous 89 19.7  74 15.6 
0.97 
22 9.1  27 11.3 
0.08 0.18 
 <20 54 12.0  66 13.9 50 20.7  60 25.0 
 20-24 150 33.2  188 39.7 106 43.8  98 40.8 
 25-29 98 21.7  92 19.4 42 17.4  44 18.3 
 30+ 61 13.5  54 11.4 22 9.1  11 4.6 




            
 <25 214 47.7  229 48.4 
0.95 
82 34.2  73 30.7 
0.42 <.0001  25-29.9 143 31.9  142 30.0 87 36.3  89 37.4 
 30+ 92 20.5  102 21.6 71 29.6  76 31.9 
History of hormone replacement therapy            
 Ever 248 69.5  263 69.2 
0.94 
96 53.0  113 61.8 
0.09 <.0001 
 Never 109 30.5  117 30.8 85 47.0  70 38.2 
History of oral contraceptive use            
 Ever 310 68.7  325 68.9 
0.97 
137 56.9  139 58.2 
0.77 <.0001 
 Never 141 31.3  147 31.1 104 43.1  100 41.8 
Alcohol intake (g/day)
 
              
 None 195 43.1  233 49.3 
0.10 
159 66.3  145 61.4 
0.19 <.0001 
 Low (<5g/day) 128 28.3  123 26.0 42 17.5  44 18.6 
 Moderate (5-<10g/day) 66 14.6  58 12.3 18 7.5  18 7.6 
 High (≥10g/day) 63 13.9  59 12.5 21 8.8  29 12.3 
Smoking status              
 Never 226 50.0  257 54.3 
0.24 
154 63.9  143 59.8 
0.21 0.006  Former 151 33.4  144 30.4 58 24.1  57 23.9 






 non-Hispanic White (n=927) Hispanic/American Indian (n=482)  
  Cases (n=452)  Controls (n=475)  Cases (n=242)  Controls (n=240)   
Covariate, categorical N (%)  N (%) p
a





Education              
 <High school 21 4.7  17 3.6 
0.63 
54 22.4  39 16.2 
0.34 <.0001  High school grad/GED 83 18.3  105 22.2 68 28.2  81 33.8 
 Post High school 348 77.0  352 74.3 119 49.4  120 50.0 
%  Native American ancestry            
 ≤ 0.28 441 98.9  463 99.6 
0.15 
50 21.1  43 17.9 
0.49 <.0001  0.28-0.70 3 0.6  2 0.4 181 76.4  192 80.0 
 >0.70 2 0.5  0 0.0 6 2.5  5 2.1 
Estrogen/Progesterone Receptor (ER/PR) Status           
 ER+/PR+ 200 68.7  - - 
- 
91 61.1  - - 
- 0.13 
 ER+/PR- 33 11.3  - - 18 12.1  - - 
 ER-/PR+ 3 1.0  - - 6 4.0  - - 
 ER-/PR- 55 18.9  - - 34 22.8  - - 
Covariate, continuous Mean SD  Mean SD p
c





Age 56.5 11.1  56.5 11.2 0.97 53.1 10.7  52.8 10.7 0.81 <.0001 
Total MET hrs/week 1.40 3.3  1.51 3.4 0.61 0.90 1.89  1.30 3.3 0.11 0.03 
Note: Column percentages (%) may not add up to 100% due to rounding. Column totals (n) may not add up to total for each column due to missing observations:  
education (n=2), family history (n=72), menopausal status (n=1),  age at menarche (n=8), parity (n=1), age at first full-term birth (n=1), HRT lifetime (n=308),  
OCU lifetime (n=6), alcohol (n=8), smoking status (n=4), BMI (n=9), genetic admixture (n=21), or ER/PR status (n=254; cases only included, n=440). 
a Case-control status comparisons within each ethnic group, Mantel-Haenszel chi-square p values reported 
b Ethnic group comparisons regardless of case-control status, Mantel-Haenszel chi-square p values reported 
c Case-control status comparisons within each ethnic group (and studies for physical activity), p values from t- tests reported 






Descriptive data for SNPs in the TGF-β signaling pathway and ERα 
 A description of selected SNPs from TGF-β signaling pathway and ERα 
including: the SNP(s) relative to the chromosome (region, location, and position), major 
and minor alleles, MAF by ethnicity, HWE by ethnicity and proportion missing are 
shown in Table 6.  The MAF and HWE are calculated based on the frequencies of alleles 
and genotypes in the control population.  In the BCHD population, the MAF for the 
majority of SNPs was ≥ 0.10 in both NHW and Hispanic populations.  NHW women had 
two SNPs with a MAF=0.08 (RUNX2 (rs12208240) and TGF-βR1 (rs11568785)).  
Hispanic women had one SNP with a MAF=0.04 (TGF-βR1 (rs11568785)) and one SNP 
with a MAF=0.07 (RUNX1 (rs1883066)).  The HWE assumption (p >0.05) was met for 
all SNPs analyzed in this dissertation.  The proportion missing for each SNP is virtually 
zero, but it is important to note that the dataset was restricted to those with data for each 
SNP so that the sample size may differ for each analysis but differs by no more than 4 
participants.  The genotype distributions (homozygous wild-type, heterozygote, and 
homozygous variant) of the 45 SNPs evaluated are shown in Table 7 stratified by 
ethnicity and case-control status (See Appendix).  Statistically significant differences 
were observed between ethnic groups for SNPs (3 genotypes), regardless of case-control 
status, for all but four SNPs (RUNX2 (rs10948238 and rs7750470); RUNX3 (rs4478762 
and rs6688058)).  For the majority of SNPs, the proportions of homozygous variants 
were higher among NHW compared to Hispanic women, with the exception of 11 SNPs: 
RUNX1 (rs2252585 and rs8127225); RUNX2 (rs1200428, rs12208240, rs12209785, 
rs13201287, rs1321075, rs2677108, rs598953); TGF-β1 (rs1800469); and TGF-βR1 






Table 6.  Chromosome, allele, MAF and HWE for selected SNPs for genes in TGF-β signaling pathway, Breast Cancer 







Missing Region Location Position Major  Minor  NHW H/NA NHW H/NA 
RUNX1 
rs7279383 INTRON 21q22.3 36224963 C  G  0.19 0.11 0.89 0.74 0.0002 
rs2268288 INTRON 21q22.3 36232671 T  C  0.20 0.12 1.00 0.84 0.0000 
rs2252585 INTRON 21q22.3 36241929 T  C  0.27 0.43 0.96 0.42 0.0000 
rs11701453 INTERGENIC 21q22.3 36338916 G  C  0.20 0.15 0.96 0.81 0.0000 
rs8127225 INTERGENIC 21q22.3 36364765 T  C  0.13 0.27 0.96 0.75 0.0014 
rs1474479 INTERGENIC 21q22.3 36405666 G  A  0.38 0.17 0.78 0.40 0.0000 
rs1883066 INTERGENIC 21q22.3 36412156 G  C  0.12 0.07 0.96 0.91 0.0002 
rs7279123 INTERGENIC 21q22.3 36415087 C  T  0.26 0.18 0.96 0.69 0.0033 
RUNX2 
rs17209895 INTRON 6p21 45402445 T  C  0.27 0.14 0.96 0.08 0.0000 
rs2677108 INTRON 6p21 45403774 T  C  0.41 0.54 0.97 0.72 0.0005 
rs2819854 INTRON 6p21 45404528 T  C  0.51 0.47 0.96 0.43 0.0005 
rs2790093 INTRON 6p21 45437484 A  G  0.33 0.31 0.86 0.68 0.0000 
rs9463090 INTRON 6p21 45453345 G  A  0.21 0.18 0.86 0.82 0.0010 
rs2396441 INTRON 6p21 45467765 C  T  0.50 0.49 0.86 0.11 0.0002 
rs1316330 INTRON 6p21 45469626 G  T  0.25 0.16 0.66 0.72 0.0005 
rs7750470 INTRON 6p21 45473256 T  C  0.19 0.20 0.97 0.84 0.0000 
rs6930053 INTRON 6p21 45488758 C  T  0.41 0.30 0.89 0.99 0.0000 
rs12208240 INTRON 6p21 45501937 G  A  0.08 0.12 0.96 0.95 0.0000 
rs12209785 INTRON 6p21 45506122 A  G  0.25 0.28 0.59 0.52 0.0005 
rs10948238 INTRON 6p21 45511541 C  T  0.39 0.39 0.68 0.32 0.0007 
rs13201287 INTRON 6p21 45511945 G  A  0.25 0.30 0.62 0.64 0.0000 
rs12333172 INTRON 6p21 45512215 C  T  0.20 0.16 1.00 0.52 0.0000 












Missing Region Location Position Major  Minor  NHW H/NA NHW H/NA 
rs598953 INTERGENIC 6p21 45520030 T  A  0.37 0.43 0.93 0.71 0.0000 
RUNX3 
rs2236850 INTRON 1p36 25240341 T  C  0.44 0.40 0.96 0.59 0.0017 
rs9438876 INTRON 1p36 25241116 A  G  0.54 0.42 0.62 0.80 0.0000 
rs7517302 INTRON 1p36 25254317 T  C  0.43 0.37 0.96 0.88 0.0007 
rs906296 INTRON 1p36 25264658 C  G  0.23 0.18 0.96 0.39 0.0007 
rs7551188 INTRON 1p36 25273200 C  T  0.54 0.47 0.98 0.21 0.0012 
rs6688058 INTRON 1p36 25274998 G  A  0.13 0.14 0.96 0.61 0.0000 
rs11249206 INTRON 1p36 25277982 T  C  0.51 0.35 0.96 0.81 0.0159 
rs4478762 INTRON 1p36 25281015 G  A  0.11 0.12 0.62 0.82 0.0005 
TGF-β1 
rs1800469 INTERGENIC 19q13.1 41860296 C  T  0.32 0.46 0.62 0.82 0.0124 
rs4803455 INTRON 19q13.1 41851509 C  A  0.49 0.35 0.96 0.63 0.0589 
TGF-βRI 
rs6478974 INTRON 9q22 101874403 T  A  0.47 0.35 0.89 0.94 0.0002 
rs1571590 INTRON 9q22 101883808 A  G  0.20 0.10 0.97 0.47 0.0002 
rs1013186 INTRON 9q22 101884337 G  A  0.20 0.11 0.97 0.60 0.0000 
rs11568785 INTRON 9q22 101905834 A  G  0.08 0.04 0.96 0.67 0.0000 
rs10733710 INTRON 9q22 101907424 G  A  0.23 0.35 0.97 0.12 0.0002 
ERα 
rs2046210 INTERGENIC 6q25.1 151948366 G A 0.36 0.28 0.85 0.85 0.02 
rs6913578 INTERGENIC 6q24 151949556 A C 0.33 0.25 0.95 0.85 0.01 
rs851984 5’-UTR 6q25.1 152023191 G A 0.38 0.39 0.95 0.95 0.007 
rs1801132 EXON 4 6q24 152265522 C G 0.22 0.26 0.85 0.95 0.006 
rs3798577 3'-UTR 6q24 152462823 T C 0.45 0.40 0.85 0.95 0.003 
1Minor Allele Frequency (MAF) is based on control population  
2 Hardy-Weinberg Equilibrium (HWE)  is based on the control population and is FDR adjusted 
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 Overall, regardless of ethnicity, genotype distributions differed between cases and 
controls for RUNX3 (rs906296, p=0.005, homozygous wild-type, CC, 64% vs. 61%); and 
TGF-βR1 (rs10733710, p=0.01, homozygous variant, AA, .8.5% vs. 10%) and 
(rs6478974, p=0.01, homozygous variant, AA, 18% vs. 16%)).   
 Among NHW women, genotype distributions differed between cases and controls 
for only 2 SNPs: RUNX2 (rs10948238, p=0.04, homozygous variant, TT, 18% vs. 14%) 
and TGF-βR1 (rs10733710, p=0.03, homozygous variant, AA, 3.9% vs. 5%).  Between 
cases and controls in Hispanic women there was a difference in genotype distributions for 
two SNPs: RUNX2 (rs6930053, p=0.05, homozygous variant, TT, 11% vs. 8.9%) and 
RUNX3 (rs906296, p=0.007, homozygous wild-type, CC, 63% vs. 67%). 
 In the New Mexico sub-population, genotype distributions differed by ethnicity in 
all but one of the ERα SNPs (rs851984, p=0.53), as shown in Table 8 (See Appendix).  
There were a higher proportion of homozygous variants among NHW cases and controls, 
for ERα SNPs: rs3798577, rs2046210, and rs6913578.  Hispanic cases and controls had a 
higher proportion of homozygous variants for ERα (rs1801132).  Genotype distributions 
did not differ between cases and controls within NHW or Hispanic women for ERα 
SNPs. 
Univariable Analysis 
 Univariable OR(s), 95% CI(s), and p-values are reported for all descriptive 
characteristics for the BCHD study population and were further stratified by self-reported 
ethnicity in Table 9.  Significant covariates, defined with p-values ≤ 0.20, associated with 
breast cancer in the overall study population were considered in multivariable modeling 
and included: age, family history, age at menarche, parity, age at first full-term birth, 
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BMI, history of HRT and OCU, long-term alcohol consumption, smoking status, 
education, and genetic admixture.  Study site was also included in multivariable modeling 
as the distributions of significant covariates have been found to vary in each study 
population.  Univariable OR(s) were comparable for majority of covariates stratified by 
Hispanic and NHW ethnicities, except for age (70+), [ORH=1.34; 95% CI 1.01-1.77 vs. 
ORNHW= 0.88; 95%CI: 0.63-1.22]; BMI (30+ kg/m
2
), [ORH=0.66; 95% CI 0.56-0.77 vs. 
ORNHW= 0.91; 95%CI: 0.76-1.09]; history of HRT, [ORH=1.15; 95% CI 1.01-1.31 vs. 
ORNHW= 1.00; 95%CI: 0.84-1.19]; and education (< high school) [ORH=0.71; 95% CI 
0.62-0.82 vs. ORNHW= 0.99; 95%CI: 0.71-1.38].  Table 10 reports the Univariable OR(s), 
95% CI(s), and p-values for descriptive characteristics for the New Mexico sub-
population and further stratified by self-reported ethnicity.  Overall, only family history 
and education showed significant association with breast cancer risk, however, the 
following covariates are implicated as risk factors in previous literature and were 
considered in multivariable modeling: age, age at menarche, parity, age at first full-term 
birth, BMI, history of HRT and OCU, alcohol, smoking status, and genetic admixture.  
Associations stratified by Hispanic and NHW in this sub-population proved to be more 
divergent compared to the overall BCHD population, in particular for age (70+), 
[ORH=1.73; 95% CI 0.68-4.41 vs. ORNHW= 0.97; 95%CI: 0.48-1.97]; parity (5+) 
[ORH=1.27; 95% CI 0.60-2.69 vs. ORNHW= 0.51; 95%CI: 0.27-0.98]; age at first full-term 
birth (30+) [ORH=2.45; 95% CI 0.98-6.14 vs. ORNHW= 0.94; 95%CI: 0.58-1.52]; history 
of HRT [ORH=0.70; 95% CI 0.46-1.06 vs. ORNHW= 1.01; 95%CI: 0.74-1.39]; alcohol 
consumption (high ≥10 g/day) [ORH=0.66; 95% CI 0.36-1.21 vs. ORNHW= 1.28; 95%CI: 
0.85-1.91]; and smoking status (current) [ORH=0.69; 95% CI 0.41-1.18 vs. ORNHW= 1.18; 
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95%CI: 0.82-1.71].  Genetic admixture was not associated with breast cancer in this 
subpopulation (Table 10). 
Table 9.  Univariable Odds Ratios (OR) and 95% Confidence Intervals (CI) for 
Descriptive Characteristics:  The Breast Cancer Health Disparities Study by Self-
reported Ethnicity 
  Total NHW (n=3,030) Hispanic (n=4,703) 
Covariate, categorical OR 95% CI p OR 95% CI OR 95% CI 
Age (years)        
 <40 1.00 REF  1.00 REF 1.00 REF 
 40-49 1.35 1.14-1.59 .00006 1.32 0.97-1.80 1.34 1.09-1.65 
 50-59 1.31 1.11-1.56 0.002 1.32 0.97-1.80 1.28 1.04-1.58 
 60-69 1.30 1.09-1.56 0.004 1.28 0.94-1.76 1.27 1.02-1.58 
 70+ 1.09 0.89-1.34 0.41 0.88 0.63-1.22 1.34 1.01-1.77 
Study        
 4-CBCS 1.00 REF  1.00 REF 1.00 REF 
 MBCS 0.97 0.87-1.08 0.57 -- -- 1.04 0.91-1.20 
 SFBCS 0.98 0.88-1.09 0.73 1.09 0.90-1.32 1.01 0.87-1.17 
Family history, 1
st
 degree         
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 1.57 1.38-1.80 <.0001 1.58 1.31-1.91 1.52 1.25-1.84 
Menopausal status        
 Pre-/ peri-menopausal 1.00 REF  1.00 REF 1.00 REF 
 Post-menopausal 0.95 0.87-1.05 0.31 0.89 0.76-1.04 0.98 0.87-1.10 
Age at menarche (years)        
 <12 1.00 REF  1.00 REF 1.00 REF 
 12 0.95 0.83-1.08 0.42 0.91 0.74-1.13 0.96 0.81-1.14 
 13 0.91 0.80-1.04 0.17 0.93 0.75-1.15 0.88 0.74-1.05 
 14+ 0.81 0.71-0.92 0.001 0.83 0.67-1.03 0.79 0.68-0.93 
Parity        
 Nulliparous 1.00 REF  1.00 REF 1.00 REF 
 1-2 0.89 0.76-1.03 0.11 0.97 0.79-1.20 0.79 0.63-0.98 
 3-4 0.69 0.60-0.81 <.0001 0.83 0.67-1.03 0.59 0.47-0.73 
 5+ 0.52 0.44-0.62 <.0001 0.61 0.45-0.82 0.45 0.36-0.57 
Age at first full-term birth (years)       
 Nulliparous 1.00 REF  1.00 REF 1.00 REF 
 <20 0.60 0.51-0.70 <.0001 0.85 0.65-1.11 0.49 0.39-0.61 
 20-24 0.72 0.62-0.84 <.0001 0.82 0.66-1.01 0.63 0.50-0.78 
 25-29 0.77 0.65-0.90 0.002 0.91 0.72-1.16 0.64 0.50-0.81 
 30+ 1.03 0.85-1.25 0.75 0.97 0.74-1.28 1.03 0.79-1.35 




      
 <25 1.00 REF  1.00 REF 1.00 REF 
 25-29.9 0.84 0.75-0.94 0.003 0.95 0.80-1.13 0.75 0.64-0.88 
 30+ 0.75 0.67-0.84 <.0001 0.91 0.76-1.09 0.66 0.56-0.77 
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  Total NHW (n=3,030) Hispanic (n=4,703) 
Covariate, categorical OR 95% CI p OR 95% CI OR 95% CI 
History of hormone replacement therapy      
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 1.13 1.03-1.24 0.01 1.00 0.84-1.19 1.15 1.01-1.31 
 
       
History of oral contraceptive use       
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 1.17 1.06-1.28 0.001 1.28 1.10-1.50 1.09 0.97-1.22 
Alcohol intake (g/day)
 
        
 None 1.00 REF  1.00 REF 1.00 REF 
 Low (<5g/day) 1.12 0.97-1.29 0.12 1.12 0.92-1.36 1.06 0.85-1.34 
 Moderate (5-<10g/day) 1.37 1.13-1.66 0.002 1.25 0.96-1.63 1.51 1.11-2.05 
 High (≥10g/day) 1.11 0.91-1.36 0.30 1.16 0.91-1.49 0.91 0.62-1.33 
Smoking status        
 Never 1.00 REF  1.00 REF 1.00 REF 
 Former 1.20 1.07-1.36 0.003 1.25 1.05-1.50 1.14 0.96-1.35 
 Current 1.05 0.90-1.22 0.52 1.07 0.84-1.38 1.04 0.86-1.25 
Education        
 <High school 0.77 0.69-0.85 <.0001 0.99 0.71-1.38 0.71 0.62-0.82 
 High school grad/GED 0.93 0.82-1.06 0.27 0.93 0.78-1.11 0.90 0.76-1.08 
 Post high school 1.00 REF  1.00 REF 1.00 REF 
%  Native American ancestry       
 ≤ 0.28 1.00 REF  - - - - 
 0.28-0.70 0.89 0.81-0.98 0.02 - - - - 
 >0.70 0.78 0.68-0.90 .0004 - - - - 
Continuous Variable        
Total MET hrs/week 1.00 0.99-1.01 0.87 0.99 0.97-1.01 1.01 0.99-1.02 
Missing observations: education (n=121), family history (n=247), menopausal status (n=227),  age at menarche 
(n=113)parity (n=62),  age at first full-term birth (n-=94), HRT use (n=971), OCU (n=112), alcohol (n=1,213), 





Table 10.  Univariable Odds Ratios (OR) and 95% Confidence Intervals (CI) for 
Descriptive Characteristics:  New Mexico Sub-population by Self-reported Ethnicity 
  Total (n=1,409) NHW (n=927) Hispanic (n=482) 
Covariate, categorical OR 95% CI p OR 95% CI OR 95% CI 
Age (years)        
 <40 1.00 REF  1.00 REF 1.00 REF 
 40-49 1.09 0.68-1.74 0.73 1.02 0.52-2.00 1.18 0.61-2.29 
 50-59 0.97 0.60-1.56 0.90 0.89 0.45-1.75 1.11 0.56-2.20 
 60-69 1.06 0.66-1.72 0.80 1.13 0.57-2.22 0.91 0.45-1.84 
 70+ 1.09 0.65-1.83 0.75 0.97 0.48-1.97 1.73 0.68-4.41 
Family history, 1
st
 degree        
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 1.84 1.40-2.42 <.0001 1.66 1.20-2.29 2.51 1.46-4.33 
Menopausal status        
 Pre-/ peri-menopausal 1.00 REF  1.00 REF 1.00 REF 
 Post-menopausal 0.92 0.74-1.15 0.47 0.93 0.71-1.22 0.92 0.63-1.33 
Age at menarche (years)        
 <12 1.00 REF  1.00 REF 1.00 REF 
 12 0.91 0.67-1.26 0.58 0.81 0.54-1.21 1.13 0.67-1.89 
 13 0.85 0.62-1.16 0.31 0.86 0.59-1.27 0.80 0.47-1.35 
 14+ 0.81 0.59-1.11 0.19 0.72 0.49-1.07 0.99 0.59-1.65 
Parity        
 Nulliparous 1.00 REF  1.00 REF 1.00 REF 
 1-2 0.95 0.70-1.30 0.75 0.86 0.60-1.24 1.31 0.70-2.45 
 3-4 0.79 0.57-1.09 0.15 0.65 0.44-0.96 1.23 0.65-2.31 
 5+ 0.75 0.47-1.18 0.21 0.51 0.27-0.98 1.27 0.60-2.69 
Age at first full-term birth (years)      
 Nulliparous 1.00 REF  1.00 REF 1.00 REF 
 <20 0.75 0.52-1.09 0.13 0.68 0.42-1.09 1.02 0.52-2.01 
 20-24 0.81 0.59-1.12 0.21 0.66 0.46-0.97 1.33 0.71-2.48 
 25-29 0.94 0.66-1.34 0.72 0.89 0.58-1.35 1.17 0.58-2.37 
 30+ 1.16 0.76-1.77 0.49 0.94 0.58-1.52 2.45 0.98-6.14 




      
 <25 1.00 REF  1.00 REF 1.00 REF 
 25-29.9 1.02 0.80-1.30 0.90 1.08 0.80-1.45 0.87 0.57-1.34 
 30+ 0.93 0.72-1.22 0.62 0.97 0.69-1.35 0.83 0.53-1.31 
History of hormone replacement therapy      
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 0.88 0.69-1.13 0.32 1.01 0.74-1.39 0.70 0.46-1.06 
History of oral contraceptive use       
 No 1.00 REF  1.00 REF 1.00 REF 
 Yes 0.97 0.78-1.21 0.79 0.99 0.75-1.31 0.95 0.66-1.36 
Alcohol intake(g/day)
 
        
 None 1.00 REF  1.00 REF 1.00 REF 
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  Total (n=1,409) NHW (n=927) Hispanic (n=482) 
Covariate, categorical OR 95% CI p OR 95% CI OR 95% CI 
 Low (<5g/day) 1.09 0.84-1.41 0.53 1.24 0.91-1.70 0.87 0.54-1.41 
 Moderate (5-<10g/day) 1.18 0.84-1.66 0.34 1.36 0.91-2.03 0.91 0.46-1.82 
 High (≥10g/day) 1.02 0.73-1.42 0.91 1.28 0.85-1.91 0.66 0.36-1.21 
Smoking status        
 Never 1.00 REF  1.00 REF 1.00 REF 
 Former 1.10 0.86-1.39 0.46 1.19 0.89-1.59 0.95 0.61-1.45 
 Current 0.99 0.73-1.33 0.93 1.18 0.82-1.71 0.69 0.41-1.18 
Education        
 <High school 1.35 0.94-1.96 0.03 1.25 0.65-2.41 1.40 0.86-2.26 
 High school grad/GED 0.82 0.64-1.05 0.02 0.80 0.58-1.11 0.85 0.56-1.28 
 Post high school 1.00 REF  1.00 REF 1.00 REF 
%  Native American ancestry      
 ≤ 0.28 1.00 REF  - - - - 
 0.29-0.70 0.98 0.77-1.24 0.85 - - - - 
Continuous Variable        
Total MET hrs/week 0.98 0.94-1.01 0.20 0.99 0.95-1.03 0.93 0.87-1.02 
Missing observations: education (n=2), family history (n=72), menopausal status (n=1),  age at menarche (n=8), parity (n=1), age at 




The TGF-β signaling (n=40) and ERα (n=5) SNPs were initially assessed as 
codominant models (data not shown).  After evaluation of univariate OR (s), 95% CI (s) 
and p-values, the following were assessed as recessive models: RUNX1 (rs2252585, 
rs2268288, rs1474479); RUNX2 (rs12333172, rs12209785, rs10948238, rs13201287); 
RUNX3 (rs4478762, rs6688058, rs7517302); TGF-βR1 (rs6478974, rs10733710, 
rs11568785) and ERα (rs1801132, rs3798577); or as dominant models: RUNX1 
(rs7279383, rs8127225, rs1883066); RUNX3 (rs906296); TGF-β1 (rs4803455) and ERα 
(rs2046210), while the remaining SNPs were kept in codominant models of inheritance.  
Six SNPs [RUNX2 (10948238), RUNX3 (rs906296), TGF-βR1 (rs6478974, 
rs10733710), and ERα (rs1801132, rs3798577)] were found to be independently 
associated with breast cancer risk (p≤0.05, data not shown).   
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When model building, a covariate was considered significant in multivariable 
analyses if it altered the age and study adjusted OR by ≥10%.  Due to missing 
observations for each covariate multivariate model was restricted to women who had all 
data for all covariates so there was comparability for the same sample number.  
Confounding was not observed at this level so the characteristics [family history, age at 
menarche, parity, age at first full-term birth, BMI, history of HRT and OCU, long-term 
alcohol consumption, smoking status, or education] were not retained in the final models 
as covariates in analyses presented.  Age and study (BCHD multi-site study only) were 
included as the base model and in subsequent analyses because characteristics related to 
the risk breast cancer differ among the two.  Genetic admixture was also included as a 
covariate to account for differences in allele/genotype distribution between strata of NA 
ancestry. 
Overall Association with Breast Cancer 
 After adjustment for age, study (TGF-β signaling SNPs only), and genetic 
admixture, nine SNPs [RUNX1 (rs7279383 and rs8127225); RUNX2 (rs10948238 and 
rs13201287); RUNX3 (rs906296); TGF-β1 (rs4803455); TGF-βR1 (rs6478974), and ERα 
(rs1801132 and rs3798577)] were found to be significantly associated with overall breast 
cancer risk (Table 11a). Results for all SNPs are found in Table 11b (See Appendix). 
 A significant increase risk of breast cancer was observed with the dominant 
models of RUNX3 (rs906296, CG/GG vs. CC, OR=1.15; 95% CI 1.04-1.26; padj=0.03) 
and RUNX1 (rs8127225, TC/CC vs. TT, OR=1.11; 95% CI 1.01-1.22; padj=0.23) and 
recessive models of RUNX2 (rs10948238, TT vs. TT/TC, OR=1.15; 95% CI 1.01-1.30; 
padj=0.42) and ERα [(rs1801132, GG vs. CC/CG, OR=1.72; 95% CI 1.10-2.69; padj=0.08) 
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and (rs3798577, TT vs. TT/TC, OR=1.36; 95% CI 1.04-1.76; padj=0.08)].  There was an 
inverse association with dominant model of RUNX1 (rs7279383, CG/GG vs. CC, 
OR=0.89; 95% CI 0.80-0.99; padj=0.23) and TGF-β1 (rs4803455, CC/AA vs. CC, 
OR=0.89; 95% CI 0.81-0.98; padj=0.04).  In recessive models, the AA genotypes of 
RUNX2 (rs13201287, OR=1.18; 95% CI 1.00-1.39; p=0.05), TGF-βR1 (rs6478974, 
OR=1.13; 95% CI 1.00-1.28; p=0.05) and RUNX3 (rs4478762, OR=1.45; 95% CI 0.97-
1.27; p=0.07) were also positively associated with an increase in risk, although the 
associations were borderline significant before adjustment for multiple comparisons.  
After multiple comparisons adjustment only two SNPs [RUNX3 (rs906296) and TGF-β1 




Table 11a: TGF-β signaling genes and ERα: overall associations with breast cancer 
risk, The Breast Cancer Health Disparities Study (Abbreviated table) 
    Controls Cases      
    N (%) N (%) OR
a




      
 
 




CG/GG 1110 26.4 876 24.9 0.89 (0.80, 0.99) 
RUNX1 (rs8127225) 
      
 
 




TC/CC 1612 38.4 1407 39.9 1.11 (1.01, 1.22) 
RUNX2 (rs10948238) 
      
 
 




TT 604 14.4 571 16.2 1.15 (1.01, 1.30) 
RUNX2 (rs13201287) 
      
 
 




AA 310 7.4 298 8.5 1.18 (1.00, 1.39) 
RUNX3 (rs906296) 
      
 
 




CG/GG 1505 35.8 1379 39.2 1.15 (1.04, 1.26) 
RUNX3 (rs4478762) 
      
 
 




AA 45 1.1 54 1.5 1.45 (0.97, 1.27) 
TGF-β1 (rs4803455) 
      
 
 




CA/AA 2561 64.7 2032 63.0 0.89 (0.81, 0.98) 
TGF-βR1 (rs6478974) 
      
 
 




AA 677 16.1 639 18.1 1.13 (1.00, 1.28) 
ERα (rs1801132)  
 
    
 
 
CC/CG 672 95.3 630  92.2 1.00 
  
0.018 (0.08) 
 GG 33  4.7 53  7.8 1.72 (1.10, 2.69) 
ERα (rs3798577)  
 
    
 
 




CC 128 18.2 157 23.0 1.36 (1.04, 1.76) 
a  TGF-β signaling SNPs (n=7733)  adjusted for age, study site, and genetic admixture;  ERα SNPs adjusted for age and 
genetic admixture (n=1388) 




Interaction with Menopausal Status 
 
 Several genes (RUNX1, RUNX3, and ERα) have SNPs that were associated with 
risk within menopausal strata (Table 12a).  Although there were no significant 
interactions there were associations where risk was divergent among pre- and post-
menopausal women.  Among post-menopausal women, RUNX1 (rs2268288, ORCC=1.47; 
95% CI 1.03-2.09), RUNX3 (rs4478762, ORAA=1.71; 95% CI 1.04-2.82) and ERα 
(rs1801132, ORGG=2.14; 95% CI 1.18-3.87) were modestly associated with an increase in 
risk while pre-menopausal risk was attenuated (OR=0.88-1.33, respectively). The 
following SNPs were significant for an increase in pre-menopausal risk: RUNX1 
(rs8127225, ORTC/CC=1.24; 95% CI 1.06-1.44) and RUNX3 (rs906296, ORAA=1.33; 95% 
CI 1.14-1.55); but not in post-menopausal risk (OR=1.04-1.05, respectively).   
 After adjustment for multiple comparisons within menopause strata, there was 
one SNP with a p-trend that remained significant in pre-menopausal [RUNX3 (rs906296)] 
and post-menopausal [ERα (rs1801132)] breast cancer.  Associations for all SNPs 







Table 12a. The association of TGF-β signaling and ERα genes and breast cancer stratified by menopausal status  
(Abbreviated table) 
  
Pre/Peri Menopause Post Menopause 
   
Controls Cases 
   
Controls Cases 
  
    N (%) N (%) OR
a
 (95% CI) N (%) N (%) OR
a




               
 
TT/TC 1480 97.3 1273 97.5 1.00 
  









   
1.00 
      
0.26 
   
RUNX1 (rs8127225) 
               
 
TT 919 60.6 747 57.2 1.00 
  









   
0.06 
      
1.00 
   
RUNX3 (rs906296) 
               
 
CC 1009 66.3 774 59.3 1.00 
  









   
0.002 
      
1.00 
   
RUNX3 (rs4478762) 
               
 
GG/GA 1504 98.9 1293 99.0 1.00 
  








   
0.95 
      
0.26 
   
ERα (rs1801132)
 
               
 
CC/CG 220 94.0 219 92.0 1.00 
  









   
0.65 
      
0.045 
   aOdds Ratios adjusted for age, study, and genetic admixture for RUNX genes (n=7,506); adjusted for age and genetic admixture for ERα (n=1387) 
bInteraction p-value (gene*menopause); Bonferroni-Holm p-value for multiple comparisons shown in parenthesis 
c Wald p-value within strata adjusted for multiple comparisons (MC) (Bonferroni-Holm step-down method), bold text indicates significance after MC adjustment
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Interaction with Proportion Native American Ancestry 
 Associations were stratified by genetic admixture, based on the distribution of 
genetic ancestry in the control population: low (0-28%), moderate (29-70%), and high 
(71-100%) proportion NA ancestry (Table 13a).  There was a significant interaction with 
genetic admixture and RUNX1 (rs7279383, padj=0.04) after adjustment for multiple 
comparisons.  In the dominant model of rs7279383 (CG/GG vs. CC) results were 
divergent between strata; individuals in the 71-100% admixture strata had a significant 
increase in risk (ORCG/GG =1.75 95% CI 1.17-2.63) while those in the 0-28% and 29-70% 
had a reduced risk [(ORCG/GG =0.87 95% CI 0.76-1.00) and (ORCG/GG =0.82 95% CI 0.69-
0.97), respectively].  There were no other significant interactions, although a few SNPs 
were associated in genetic admixture strata.  Individuals in the 29-70% strata had a 
significantly higher risk with RUNX1 (rs8127225, ORTC/CC=1.19); RUNX2 (rs6930053, 
ORTT=1.29); and TGF-β1 (rs1800469, ORTT=1.29); while there was a null or inverse 
association within 0-28% and 29-70% strata for these genotypes.  The AA genotype of 
RUNX3 (rs4478762) risk was >2 fold for the 0-28% strata, while the 29-70% and 71-
100% were not positively associated.  Risk was similar between low and high admixture 
strata for RUNX2 [(rs10948238, ORTT=1.27 and 1.34) and (rs13201287, ORAA=1.39 and 
1.36)]; although it was null for the 29-71% admixture group.  Risk was similar for 
RUNX3 (rs906296) for 29-71% and 71-100% admixture groups (ORCG/GG=1.23 and 
1.24), while it was towards the null for 0-28% (ORCG/GG=1.05).  When adjusting for 
multiple comparisons by admixture strata, two SNPs remained positively associated with 
moderate admixture and one with high admixture. Table 13b shows associations for all 






Table 13a.  The association of TGF-β signaling genes and breast cancer stratified by proportion Native American ancestry 
(Abbreviated table) 
Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a






             
 














   
0.14 
   
0.05 
   RUNX1 (rs8127225) 
             
 














   
0.12 
   
1.00 
   RUNX2 (rs6930053) 
             
 








CT 808/944 0.87 (0.75, 1.00) 596/731 1.06 (0.91, 1.23) 158/224 0.98 (0.75, 1.27) 
 
 






   
0.57 
   
1.00 
   RUNX2 (rs10948238) 
             
 














   
1.00 
   
1.00 
   RUNX2 (rs13201287) 
             
 














   
1.00 
   
1.00 
   RUNX3 (rs906296) 
             
 















Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a










   
0.04 
   
0.61 
   RUNX3 (rs4478762) 
             
 














   
1.00 
   
1.00 
   TGF-β1 (rs1800469) 
             
 








CT 692/759 1.01 (0.88, 1.17) 692/854 1.11 (0.94, 1.31) 206/299 0.95 (0.69, 1.30) 
 
 






   
0.04 
   
0.94 
   TGF-β1 (rs4803455) 
             
 














   
0.06 
   
0.94 
   
a  Odds Ratios adjusted for age and study 
b  Interaction p-value (SNP*admixture); Bonferroni-Holm p-value for multiple comparisons shown in parenthesis; bold text indicates significance after MC adjustment 
c
 Wald (or trend) p-value within strata adjusted for multiple comparisons (MC) by admixture strata (Bonferroni-Holm step-down method), bold text indicates significance (p≤0.05) 





 Table 14 shows ERα SNPs and breast cancer by genetic admixture strata (≤28%, 
29-70%).  No ERα SNPs were found to significantly interact with genetic admixture.  
However, within the ≤28% NA ancestry strata, there was a trend for ERα (rs3798577, 
ORCC=1.43 95% CI 1.06-1.52, p=0.02), while the risk in 29-70% NA ancestry strata was 
attenuated and not significant (ORCC=1.11 95% CI 0.65-1.91).  However, this trend did 
not remain significant after adjustment for multiple comparisons.  Although not 
significant, findings were comparable between strata for ERα (rs1801132, rs2046210 and 
rs6913578) and divergent for ERα [rs851984, ≤28% (ORAA=1.34 95% CI 0.65-1.91); 29-







Table 14.  The Association ERα SNPs and breast cancer stratified by proportion Native American ancestry 









   
 
    N (%)  
N (%) OR
a








               
 
 
CC/CG 458 93.3 
 




186 93.5 1.00 
  0.92 
(1.00) 
 
GG 33 6.7 
 
20 3.9 1.74 (0.98-3.08) 20 10.4 
 




   
0.06 (0.22) 






             
 
 
TT/TC 368 74.9 
 




167 83.9 1.00 
  0.41 
(1.00) 
 
CC 123 25.1 
 
96 19.0 1.43 (1.05-1.93) 34 17.7 
 













             
 
 
GG 183 37.3 
 




110 55.3 1.00 
  0.93 
(1.00) 
 
GA/AA 308 62.7 
 
294 58.1 1.24 (0.96-1.60) 94 49.0 
 













             
 
 
GG 180 36.7 
 




70 35.1 1.00 
  0.40 
(1.00) 
 
GA 231 47.0 
 
237 46.8 1.09 (0.83-1.43) 91 47.4 
 
93 46.4 0.95 (0.61-1.48) 
 
AA 80 16.3 
 
67 13.2 1.33 (0.90-1.94) 30 15.6 
 













             
 
 
AA 205 41.8 
 




117 58.8 1.00 
  0.90 
(1.00) 
 
AC 223 45.4 
 
218 43.1 1.16 (0.89-1.52) 75 39.1 
 
71 35.7 1.20 (0.78-1.83) 
 
CC 63 12.8 
 
59 11.7 1.22 (0.81-1.82) 14 7.3 
 











a Odds Ratios and 95% CIs are adjusted for age  
b Interaction p-value (SNP*genetic admixture);  Bonferroni-Holm p-value adjusted for multiple comparisons shown in parentheses 
c Trend (additive) or Wald (dominant/recessive) p-value within strata adjusted for multiple comparisons (Bonferroni-Holm step-down method) shown in parentheses
 
86 
Association with Breast Cancer, Defined by ER/PR expression Status 
Using controls (n=3,215) as the referent group, TGF-β signaling SNPs were assessed for 
the association with risk of breast cancer defined ER/PR phenotypes (cases, n=1,963) 
(Table 15a).  When evaluating the Wald p-value for overall models, there were five SNPs 
[RUNX1 (rs7279123, p=0.01), RUNX2 (rs9463090, p=0.01), RUNX2 (rs12333172, 
p=0.01), RUNX3 (rs2236850, p=0.03; rs7517302, p=0.005) and TGF-βR1 (rs10733710, 
p=0.05)] significant at the 0.05 level; however, only one was significant after multiple 
comparisons (RUNX3, rs7517302).  Several SNPs were associated with breast cancer 
within specific ER/PR tumor phenotype strata.  Variants in RUNX1 (1 SNP), RUNX3 (2 
SNPs), and TGF-βR1 (1 SNP) were associated with ER+/PR+ tumors (OR between 0.78 
and 1.90); in RUNX1 (2 SNPs) and TGF-βR1 (2 SNPs) were associated with ER+/PR- 
tumors (OR between 0.44 and 3.55); in RUNX3 (2 SNPs) were associated with ER-/PR+ 
tumors (OR between 2.52 and 2.88); and in RUNX1 (1 SNP), RUNX2 (5 SNPs), and 
RUNX3 (2 SNPs) were associated with ER-/PR- tumors (OR between 0.71-2.31). 
 The Wald-p for the overall dominant or recessive models remained significant for 
one SNP (RUNX3 (rs7517302), padj=0.04.  The p-trend for 5 SNPs within ER/PR tumor 
phenotype strata [ER+/PR+ (n=0); ER+/PR- (RUNX1, rs7279123); ER-/PR+ (RUNX3, 
rs2236850); ER-/PR- (RUNX2, rs9463090, rs12333172; RUNX3, rs7517302)] remained 
significant at 0.05 level after adjustment for multiple comparisons (Table 15a).  Results 








Table 15a.  The Association of TGF-β signaling genes and breast cancer defined by ER/PR status (Abbreviated table) 
    Controls
a
 ER+/PR+ ER+/PR- ER-/PR+ ER-/PR- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p
c 
RUNX1 (rs7279383) 
                 
 










CG/GG 965 351 0.87 (0.75, 1.00) 66 0.92 (0.69, 1.24) 13 0.99 (0.51, 1.91) 100 0.77 (0.60, 0.98) 
 RUNX1 (rs8127225) 
                 
 










TC/CC 1078 458 1.14 (0.99, 1.31) 96 1.40 (1.06, 1.85) 17 1.08 (0.58, 2.02) 144 1.04 (0.83, 1.30) 
 RUNX1 (rs7279123) 
                 
 










CT 1083 466 1.12 (0.97, 1.29) 65 0.72 (0.53, 0.97) 14 0.83 (0.44, 1.57) 135 0.98 (0.78, 1.22) 
 
 
TT 184 79 1.10 (0.83, 1.46) 7 0.44 (0.21, 0.96) 0 0.00 (0.00, 0.00) 20 0.88 (0.55, 1.43) 
 RUNX2 (rs1321075) 
                 
 










CA 1102 456 1.11 (0.97, 1.28) 80 1.00 (0.75, 1.34) 19 1.33 (0.71, 2.51) 127 0.90 (0.72, 1.14) 
 
 
AA 195 81 1.17 (0.89, 1.55) 14 1.00 (0.56, 1.80) 3 1.18 (0.34, 4.09) 39 1.56 (1.06, 2.29) 
 RUNX2 (rs9463090) 
                 
 










GA 1016 410 1.02 (0.88, 1.17) 70 0.93 (0.70, 1.25) 17 1.34 (0.72, 2.50) 130 1.10 (0.87, 1.38) 
 
 
AA 144 49 0.83 (0.59, 1.16) 8 0.72 (0.35, 1.50) 3 1.81 (0.54, 6.10) 38 2.31 (1.57, 3.39) 
 RUNX2 (rs6930053) 
                 
 










CT 1516 598 1.01 (0.88, 1.16) 118 1.16 (0.87, 1.54) 20 0.99 (0.52, 1.89) 181 0.85 (0.68, 1.06) 
 
 
TT 419 187 1.13 (0.92, 1.38) 29 1.03 (0.66, 1.59) 7 1.28 (0.53, 3.11) 42 0.71 (0.50, 1.02) 
 RUNX2 (rs12209785) 
                 
 










GG 190 82 1.10 (0.84, 1.44) 13 0.92 (0.52, 1.65) 3 1.20 (0.37, 3.93) 34 1.49 (1.01, 2.18) 
 RUNX2 (rs10948238) 






    Controls
a
 ER+/PR+ ER+/PR- ER-/PR+ ER-/PR- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p
c 
 










TT 470 205 1.11 (0.93, 1.33) 33 0.97 (0.66, 1.41) 9 1.47 (0.70, 3.09) 78 1.39 (1.07, 1.82) 
 RUNX2 (rs12333172) 
                 
 










TT 106 40 0.92 (0.63, 1.33) 11 1.44 (0.76, 2.73) 2 1.36 (0.32, 5.72) 28 2.12 (1.37, 3.27) 
 RUNX3 (rs2236850) 
                 
 










TC/CC 2135 877 1.09 (0.95, 1.26) 156 1.01 (0.76, 1.35) 33 1.51 (0.76, 3.00) 299 1.43 (1.13, 1.80) 
 RUNX3 (rs9438876) 
                 
 










AG 1527 634 1.10 (0.94, 1.28) 120 1.08 (0.79, 1.49) 19 1.37 (0.60, 3.15) 192 1.09 (0.84, 1.41) 
 
 
GG 817 319 1.01 (0.85, 1.22) 50 0.83 (0.57, 1.23) 18 2.52 (1.08, 5.87) 113 1.21 (0.91, 1.62) 
 RUNX3 (rs7517302) 
                 
 










TC 1541 604 1.01 (0.88, 1.17) 100 0.80 (0.59, 1.07) 22 1.68 (0.79, 3.58) 210 1.36 (1.07, 1.74) 
 
 
CC 548 242 1.14 (0.95, 1.38) 41 0.93 (0.63, 1.37) 13 2.80 (1.22, 6.46) 82 1.51 (1.11, 2.04) 
 RUNX3 (rs906296) 
                 
 










CG/GG 1203 530 1.18 (1.03, 1.34) 98 1.22 (0.93, 1.61) 18 1.16 (0.63, 2.12) 159 1.09 (0.88, 1.35) 
 RUNX3 (rs4478762) 
                 
 










AA 35 26 1.90 (1.14, 3.18) 1 0.39 (0.05, 2.88) 0 0.00 (0.00, 0.00) 6 1.35 (0.56, 3.23) 
 TGF-βR1 (rs11568785) 
                 
 










GG 16 7 1.08 (0.44, 2.63) 4 3.55 (1.17, 10.8) 1 5.70 (0.73, 44.6) 1 0.55 (0.07, 4.21) 
 TGF-βR1 (rs10733710) 
                 
 










AA 276 84 0.78 (0.60, 1.00) 11 0.53 (0.28, 0.99) 4 0.92 (0.32, 2.61) 25 0.67 (0.44, 1.03) 
 
a ER/PR data were compared with 3,214 controls from sites where cases have ER/PR data Mexico data is excluded because they do not have data for ER/PR status (n=1,810) 
b Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture; Bonferroni-Holms p-value adjustment for multiple comparisons shown in 
parentheses.  Note: OR in bold text indicates significance remained for wald-p (dominant/recessive) or p-trend (additive) after adjustment for multiple comparisons 
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 Table 16 reports the association of ERα SNPs and breast cancer defined by ER+/- 
tumor phenotype (sample size limits evaluation by ER/PR status combined) adjusting for 
age and genetic admixture.  Participants with available data on ER status and genetic 
admixture were used in analysis [n=1,135 (controls=705, referent; cases=430)].  Risk was 
similar for ER+ and ER- tumors for rs3798577 (ORCC=1.35 95% CI 0.98-1.36 and 
ORCC=1.41 95% CI 0.84-2.36, respectively.  Risk was moderately higher among ER- 
tumors for rs1801132 (ORGG=2.04) and rs851984 (ORAA=1.54) compared to ER+ tumors 
(OR=1.56 and 1.04, respectively).  Risk was slightly higher among ER+ tumors for 
rs2046210 (ORCC=1.23) and rs6913578 (ORCC=1.30) compared to ER- tumors (OR=1.10 
and 1.02, respectively).  None of these associations were significant for the overall model 








Table 16: The Association of ERα SNPs and breast cancer defined by ER status
 a 
    Controls ER+ ER-  
SNP  Genotype N (%) N (%) OR
b 





            
 
 
CC/CG 672 95.3 313 93.2 1.00 
  









    
0.11 (0.40) 





            
 
 
TT/TC 577 81.8 259 77.1 1.00 
  









   
0.07 (0.32) 





            
 
 
GG 322 45.7 135 40.2 1.00 
  









    
0.13 (0.40) 





            
 
 
GG 272 38.6 124 36.9 1.00 
  




GA 330 46.8 164 48.8 1.10 (0.83-1.46) 45 47.9 1.19 (0.73-1.94)  
 





    
0.70 (0.70) 





            
 
 
AA 346 49.1 145 43.2 1.00 
  




AC 289 41.0 152 45.2 1.23 (0.93-1.63) 40 42.6 1.08 (0.69-1.71)  
 




    
0.12 (0.40) 




a ER data is available for 1135 subjects (430 cases (ER+=336; ER-=94) and is compared to 705 controls) 
b OR (odds ratios) and 95% confidence interval (CI) adjusted for age and genetic admixture 
c Wald-p for over all model; Bonferroni-Holm multiple comparison adjustments shown in parentheses 




Association with Breast Cancer, Defined by ER Expression Status:  
Stratified by Menopause 
 TGF-β signaling SNPs were also evaluated for their association with breast 
cancer, defined by ER status, stratified by menopausal status (sample size limits 
evaluation by ER/PR status combined, as well as associations with ERα SNPs).  Table 
17a shows SNPs associated with ER+/ER- breast cancer that differ by menopausal status 
after adjustment for multiple comparisons.  Among pre-menopausal women, the 
association was suggestive for an increase in risk of ER+ breast cancer with RUNX3 
(rs906296, ORCG/GG=1.33, p=0.06), while an inverse association was observed with 
RUNX2 (rs598953, ORAA=0.61, p=0.07).  These associations were divergent from the 
risk of ER- tumors, however not significant.  A suggestive inverse association was 
observed for both ER+ and ER- tumors with TGF-βR1 (rs10733710, ORAA=0.58 and 
0.45, respectively).  The findings for these particular SNPs were not similar in post-
menopausal women. 
 Among post-menopausal women, there were two SNPs significantly suggestively 
associated with an increase in risk of ER+ breast cancer:  RUNX3 (rs4478762), with a >2-
fold increase in risk (ORAA=2.08, p=0.13), which was not observed for ER- tumors.  In 
contrast, TGF-β1 (rs4803455) was associated with a reduced risk of ER+ tumors 
(ORAA=0.82, p=0.13); the trend was similar for ER- tumor, although not significant.   
 With regards to risk of ER- tumors, one association suggestive of a reduced risk 
was observed with RUNX1 (rs7279383, ORGG=0.76, p=0.16), while risk for ER+ tumors 
with was null (ORGG=1.01).  RUNX2 (rs12333172) was associated with a suggestive 
increase in risk of ER- tumors (ORAA=1.97, p=0.13), while RUNX1 (rs2268288) and 
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RUNX2 (rs12333172) were significantly associated with a modest increase in risk for ER- 
tumors (ORCC=2.47, p=0.04 and ORTT=2.25, p=0.04, respectfully), which was not 
observed for ER+ tumors.  There were no significant interactions between SNPs and 
menopausal status for ER+ or ER- breast cancer; i.e. the outcome did not differ within 
menopausal status and SNP categories.  Associations for all SNPs and breast cancer 
defined by ER, stratified by menopausal status, can be found in Table 17b (See 
Appendix).  
Association with Breast Cancer, Defined by ER Expression Status:  
Stratified by Proportion Native American Ancestry 
 Table 18a shows SNPs associated with ER+/ER- breast cancer that differ by 
proportion Native American ancestry (low, moderate/high) after adjustment for multiple 
comparisons. (Note: moderate to high ancestry were grouped together to increase power).   
Among low proportion (0-28%) of Native American ancestry, RUNX2 (rs9463090 and 
rs10948238) was associated with an increase in risk of ER- tumors (ORAA=2.03 and 
ORTT=1.68, respectfully).  There were a larger number of significant associations for 
those with moderate to high (29-100%) Native American ancestry:  RUNX1 (rs8127225) 
and RUNX3 (rs906296) were both positively associated with ER+ tumors; while RUNX3 
(rs2236850) was associated with ER- tumors. Regardless of ER status, TGF-βRI 
(rs10733710) had an inverse association with breast cancer risk, although it was stronger 
for ER- vs. ER+ tumors (ORAA=0.48 vs. ORAA=0.64).  Associations for all SNPs and 
breast cancer defined by ER, stratified by proportion Native American ancestry, can be 







Table 17a.  TGF-β signaling SNPs and breast cancer defined by ER status, stratified by menopausal status (Abbreviated table) 






a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX1 (rs7279383) 
                 
 










CG 864 130 0.88 (0.69, 1.13) 51 0.86 (0.61, 1.23) 242 0.87 (0.72, 1.03) 45 0.65 (0.46, 0.92) 
 
 







   
1.00 
   
1.00 
   
0.16 
   RUNX1 (rs2268288) 
                 
 
















   
1.00 
   
1.00 
   
0.04 
   RUNX2 (rs9463090) 
                 
 










GA 978 152 0.89 (0.71, 1.12) 66 1.05 (0.76, 1.47) 309 1.08 (0.91, 1.28) 73 1.19 (0.88, 1.62) 
 
 






   
0.34 
   
1.00 
   
0.13 
   RUNX2 (rs12333172) 
                 
 
















   
0.90 
   
1.00 
   
0.04 
   RUNX2 (rs598953) 
                 
 










TA 1489 233 0.85 (0.68, 1.07) 97 1.02 (0.73, 1.42) 456 0.99 (0.84, 1.18) 118 1.09 (0.81, 1.47) 
 
 






   
1.00 
   
1.00 
   
1.00 
   












a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX3 (rs906296) 
                 
 
















   
1.00 
   
0.76 
   
0.78 
   RUNX3 (rs4478762) 
                 
 
















   
1.00 
   
0.13 
   
0.78 
   TGF-β1 (rs4803455) 
                 
 










CA 1414 200 0.98 (0.75, 1.27) 74 0.85 (0.58, 1.23) 406 0.83 (0.69, 1.00) 92 0.86 (0.62, 1.21) 
 
 






   
0.92 
   
0.13 
   
0.27 
   TGF-βRI  (rs10733710) 
                 
 
















   
0.10 
   
0.61 
   
1.00 
   
a ER/PR data were compared with 3,214 controls from sites where cases have ER/PR data Mexico data is excluded because they do not have data for ER/PR status (n=1,810) 
b Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture; OR in bold text indicates significance remained for p-trend (per-allele) or 
Wald-p after adjustment for multiple comparisons 







Table 18a.  TGF-β signaling and breast cancer defined by ER status, stratified by Native American ancestry (Abbreviated table) 
   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX1 (rs8127225) 
                 
 
















   
1.00 
   
0.008 
   
1.00 
   RUNX2 (rs9463090) 
                 
 










GA 1016 304 1.01 (0.85, 1.19) 89 1.29 (0.97, 1.72) 176 1.00 (0.81, 1.24) 58 0.94 (0.68, 1.32) 
 
 






   
0.03 
   
0.77 
   
0.73 
   RUNX2 (rs10948238) 
                 
 
















   
0.03 
   
0.77 
   
1.00 
   RUNX3 (rs2236850) 
                 
 










TC 1526 451 1.03 (0.86, 1.24) 126 1.31 (0.95, 1.81) 281 1.13 (0.90, 1.41) 105 1.47 (1.03, 2.09) 
 
 






   
0.55 
   
0.49 
   
0.03 
   RUNX3 (rs906296) 
                 
 
















   
1.00 
   
0.04 
   
1.00 
   
                    
                    






   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
TGF-βR1 (rs10733710) 
                
 
















   
1.00 
   
0.04 
   
0.05 
   
a ER data were compared with 3,214 controls from sites where cases have ER data Mexico data is excluded because they do not have data for ER status (n=1,810) 
b Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture; OR in bold text indicates significance (p≤0.05) or suggestive of an association 
(p≤0.15) for p-trend (per-allele) or Wald-p after adjustment for multiple comparisons 




SNP-SNP Interaction and Association with Breast Cancer 
SNP-SNP interactions were evaluated between SNPs with a potentially meaningful 
overall association (p<0.15) with breast cancer.  A combination of two SNPs 
(dominant/recessive mode) resulted in a 4 category variable, the referent as the 
combination of the referent groups for both SNPs being evaluated.  Table 19 shows 
results for interactions between RUNX1 (rs7279383, rs2268288, rs8127225, 
rs7279123)*TGF-β1 (rs4803455); and RUNX1*TGF-βRI (rs6478974).  There were no 
significant p-values for the interaction term in the model for each pair of SNPs.  There 
were few significant associations evaluating the combined risk.  (Note: minor alleles are 
denoted with bolded text).  There was an inverse association for rs7279383*rs4803455 
(OR=0.79 95% CI 0.68-0.92); where either one/two copies (CG/GG-CA/AA) of the 
minor allele lowered risk.  Others associated with an inverse association include: 
rs7279383*rs6478974 (CG/GG-TT/TA, OR=0.87 95% CI 0.79-0.98); 
rs2268288*rs4803455 (TT/TC-CA/AA, OR=0.89 95% CI 0.81-0.99); and 
rs7279123*4803455 (CT/TT-CA/AA, OR=0.81 95% CI 0.71-0.93).  A modest increase 
in risk was observed when four minor alleles are present for rs2268288*rs4803455 (CC-
AA, OR=1.83 95% CI 1.02-3.27), while there was a slight increase for 
rs8127225*rs4803455 [(TT-AA, OR=1.14 95% CI 1.03-1.26 and TC/CC-TT/TA, 
OR=1.20 95% CI 1.03-1.39)], which appear to be driven by the TGF-β1 minor alleles.  
All other combinations of RUNX1*TGF-β1 and RUNX1*TGF-βRI SNPs were not 




Table 19.  Interactions between RUNX1, TGF-β, TGF-βRI genes and breast cancer 

































CA/AA 523/707 0.79 (0.68-0.92) 





















AA 183/197 1.06 (0.86-1.32) 





















CA/AA 73/74 1.08 (0.77-1.51) 





















AA 29/19 1.83 (1.02-3.27) 





















CA/AA 763/913 1.00 (0.87-1.15) 





















AA 222/241 1.17 (0.97-1.43) 





















CA/AA 748/1006 0.81 (0.71-0.93) 
















TT/TA 1029/1291 0.94 (0.85-1.04) 
  
 
CT/TT   AA 243/275 1.02 (0.85-1.23)     
a
Minor alleles (bolded text): rs4803455=A;  rs6478974=A; rs7279383=G; rs2268288=C; rs8127225=C; rs7279123=T
 
bOR and 95% CI adjusted for age, study, and genetic admixture 
cWald-p for model; d Interaction p-value for interaction term in model (SNP*SNP) 
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 Results for interactions between RUNX2 (rs12209785, rs10948238, 
rs13201287)*TGF-β1 (rs4803455); and RUNX2*TGF-βRI (rs6478974) are found in 
Table 20.  There were no significant interaction terms.  There were significant 
associations among RUNX2*TGF-β1 genotypes; the combination of 4 minor alleles was 
associated with an increase in risk for rs12209785* rs6478974 (GG-AA, OR=1.61 95% 
CI 1.08-2.40); rs10948238* rs6478974 (TT-AA, OR=1.42 95% CI 1.08-1.87); and 
rs13201287* rs6478974 (AA-AA, OR=1.48 95% CI 1.01-2.17), while there were no 
significant associations among the combinations RUNX2*TGF-β1 genotypes. 
 In contrast to the other RUNX and RUNX2 genes, there were two interactions for 
RUNX3*TGF-βRI found (Table 21).  For rs7517302*rs6748974 (p=0.003), risk was 
similar for two categories, each with a differing homozygous minor allele group: TT/TC-
AA and CC-TT/TA (OR=1.20-1.23).  For rs906296*rs6748974 (p=0.02), risk was also 
increased among two categories, CC-AA and CG/GG-TT/TA (OR=1.20-1.26).  While 
the other SNP-SNP interactions were not significant, an association was observed for 
when there is one homozygous minor allele group for rs4478762*rs6478974, GG/GA-





Table 20.  Interactions between RUNX2, TGF-β, TGF-βRI genes and breast cancer 

































CA/AA 143/171 0.97 (0.77-1.23) 





















AA 57/43 1.61 (1.08-2.40) 





















CA/AA 331/381 1.00 (0.84-1.19) 





















AA 120/101 1.42 (1.08-1.87) 





















CA/AA 167/190 1.02 (0.82-1.28) 





















AA 59/49 1.48 (1.01-2.17) 
  aMinor alleles (bolded text): rs4803455=A;  rs6478974=A; rs12209785=G; rs10948238=T; rs13201287=A
 
bOR and 95% CI adjusted for age, study, and genetic admixture 




Table 21.  Interactions between RUNX3, TGF-β, TGF-βRI genes and breast cancer 

































CA/AA 372/408 1.03 (0.87-1.21) 





















AA 101/136 0.92 (0.71-1.20) 





















CA/AA 807/937 1.01 (0.88-1.16) 





















AA 233/260 1.15 (0.95-1.39) 





















CA/AA 32/31 1.22 (0.74-2.02) 





















AA 5/7 0.86 (0.27-2.70) 
  aMinor alleles: rs4803455=A;  rs6478974=A; rs7517302=C; rs906296=G; rs4478762=A 
bOR and 95% CI adjusted for age, study, and genetic admixture 




 There were no significant interaction terms when evaluating ERα (rs1801132 and 
rs3798577)*TGF-β genes (genes/SNPs evaluated in previous interactions) (Table 22b, 
See Appendix).  Most of the significant associations among combined genotypes were 
observed when homozygous variants for rs1801132 and rs3798577 were combined with 
the homozygous wild-type for other SNPs.  These effects were expected, because when 
evaluated alone, these variant genotypes have similar magnitudes to the ones observed.  
 There were, however, notable differences among few combined genotypes (Table 
22a).  (Note: bold text indicates minor allele).  Two significant associations had a >3-4-
fold increase in risk for ERα*TGF-β1 [rs1801132*rs4803455, GG-CC, OR=3.12) and 
ERα*TGF-βRI (rs1801132*rs6478974, GG-AA, OR=4.01)].  An increase in risk, 
although not as large, was also seen for ERα*TGF-βRI (rs3798577*rs6478974, CC-
TT/TA, OR=1.45 95% CI 1.08-1.95).  There was >2-fold increase in risk with the 
combination of homozygous variants for ERα*RUNX1 [rs1801132*rs7279383, GG-
CG/GG, OR=2.42) and ERα*RUNX2 (rs3798577*rs12209785, CC-GG, OR=2.13).  An 
increase in risk was also observed for ERα*RUNX3 [(rs1801132*rs7517302, GG-CC, 




Table 22a.  SNP-SNP interactions between ERα and TGF-β signaling genes (Abbreviated 
table) 

































CA/AA 31/26 1.19 (0.68-2.08) 





















AA 11/3 4.01 (1.11-14.47) 





















AA 31/29 1.22 (0.72-2.07) 





















CG/GG 21/9 2.42 (1.10-5.36) 





















GG 13/7 2.13 (0.84-5.40) 





















CC 12/4 3.37 (1.08-10.53) 





















CG/GG 64/49 1.58 (1.05-2.37) 
  aMinor alleles: rs1801132=G; rs3798577=C; rs4803455=A;  rs6478974=A; rs12209785=G; rs7517302=C; 
rs906296=G; rs7279383=G 
bOR and 95% CI adjusted for age and genetic admixture 
cWald-p for model; d Interaction p-value for interaction term in model (SNP*SNP)  
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Cumulative Effect of Risk Alleles and Association with Breast Cancer 
 A GRS was created for those significant (p<0.05) or marginally significant 
(p<0.15) SNPs was split into those that were associated with increased risk and reduced 
risk of breast cancer.  The number of risk alleles (0, 1 or 2) was summed across SNPs.  
Table 23 shows GRS-1, creating by summing risk alleles for TGF-B signaling SNPs 
associated with reduced risk (n=4).  GRS-1 range was 0-7 and the per-allele effect was 
significantly associated with a reduced risk (OR=0.92 95%CI 0.88-0.96).  When evaluated as a 
categorical variable, compared to those individuals with ≤1 risk allele, those with ≥5 risk alleles 
had the largest inverse association (OR=0.65 95% CI 0.49-0.87). 
Table 23.  Genetic Risk Score 1: TGF-β signaling SNPs associated with reduced risk 
Gene SNP Risk allele
a





RUNX1 rs7279383 G 0.91 (0.83-1.00) 0.05 
RUNX1 rs7279123 T 0.94 (0.87-1.02) 0.13 
TGF-β1 rs4803455 A 0.95 (0.89-1.02) 0.15 
TGF-βR1 rs10733710 A 0.94 (0.88-1.01) 0.08 
a Allele associated with breast cancer when compared to wild-type allele (referent) 
b OR (95% CI) is SNP entered as continuous; adjusted for age, study, genetic admixture 
c Wald-p for SNP entered as continuous, per-allele effect  
Genetic Risk Score (GRS)-1 
  GRS-1
d 




Categories* ≤1 1114/1287 1.00 (Referent) 
 
 
2 1048/1235 0.96 (0.86-1.08) 0.51 
 
3 669/904 0.83 (0.73-0.95) 0.005 
 
4 296/384 0.86 (0.72-1.02) 0.08 
  ≥5 81/138 0.65 (0.49-0.87) 0.003 
Trend 
g 
0-7  Alleles 3208/3948 0.92 (0.88-0.96) 0.0003 
d Number of  risk allele categories are based on control population 
e OR (95% CI) adjusted for age, study, genetic admixture 
f Wald-p for each GRS-1 category; g Wald-p for GRS-1 entered as continuous, per-allele effect 
 
 Details regarding the SNPs summed to create GRS-2 are shown in Table 24.  
There was one SNP from RUNX1, RUNX2, RUNX3 and TGF-βR1 used to create GRS-2, 
all associated with increased risk.  GRS-2 range was 0-7 risk alleles and the per-allele 
effect was significantly associated with a slight increase in risk (OR=1.08 95% CI 1.04-
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1.12).  Compared to those individuals with ≤1 risk allele, those with 2 or 3 risk alleles had the 
similar risk (OR=1.17 and 1.19, respectively).  Individuals with 4 or ≥5 risk alleles also had 
similar risk, which was larger in magnitude than the other categories (OR=1.34). 
 
Table 24:  Genetic Risk Score 2: TGF-β signaling SNPs associated with increased risk 
Gene SNP Risk allele
a





RUNX1 rs8127225 C 1.08 (1.00-1.17) 0.05 
RUNX2 rs10948238 T 1.05 (0.99-1.13) 0.11 
RUNX3 rs906296 G 1.11 (1.03-1.20) 0.009 
TGF-βR1 rs6478974 A 1.07 (1.00-1.14) 0.04 
a Allele associated with breast cancer when compared to wild-type allele (referent) 
b OR (95% CI) is SNP entered as continuous; adjusted for age, study, genetic admixture 
c Wald-p for SNP entered as continuous, per-allele effect 
Genetic Risk Score (GRS)-2 
  GRS-2
d 




Categories* ≤1 738/1027 1.00 (Referent) 
 
 
2 1069/1269 1.17 (1.03-1.33) 0.014 
 
3 940/1102 1.19 (1.05-1.35) 0.008 
 
4 560/580 1.34 (1.15-1.55) 0.0002 
 
≥5 211/218 1.34 (1.08-1.66) 0.007 
Trend 0-7  Alleles 3518/4196 1.08 (1.04-1.12) <0.0001 
d Number of  risk allele categories are based on control population 
e OR (95% CI) adjusted for age, study, genetic admixture 
f Wald-p for each GRS-2 category; g Wald-p for GRS-2 entered as continuous, per-allele effect 
 
 Lastly, GRS-3 was created to evaluate the cumulative effect between pathways 
using the four SNPs from GRS-2 and summing with number risk alleles from ERα 
(rs1801132 and rs6913578) (Table 25).  GRS-3 range was 0-10 risk alleles and the per-
allele effect was also significantly associated with a slightly higher risk (OR=1.14 95% 
CI 1.04-1.25). Compared to those individuals with ≤3 risk alleles, those with 5 or 6 had 
the highest risk (OR=1.67 and 1.52, respectively).  Those with ≥7 risk alleles only had a 




Table 25:  Genetic Risk Score 3: ERα and TGF-B signaling SNPs associated with 
increased risk 
Gene SNP Risk allele
a





RUNX1 rs8127225 C 1.08 (1.00-1.17) 0.05 
RUNX2 rs10948238 T 1.05 (0.99-1.13) 0.11 
RUNX3 rs906296 G 1.11 (1.03-1.20) 0.009 
TGF-BR1 rs6478974 A 1.07 (1.00-1.14) 0.04 
ERα rs1801132 G 1.18 (0.99-1.40) 0.07 
ERα rs6913578 C 1.14 (0.97-1.34) 0.11 
a Allele associated with breast cancer when compared to wild-type allele (referent) 
b OR (95% CI) is SNP entered as continuous; adjusted for age, study, genetic admixture 
c Wald-p for SNP entered as continuous, per-allele effect 
Genetic Risk Score (GRS)-3 
  GRS-2
d 




Categories* ≤3 314/360 1.00 (Referent) 
 
 
4 162/190 0.99 (0.76-1.28) 0.93 
 
5 120/83 1.67 (1.21-2.29) 0.002 
 
6 66/50 1.52 (1.02-2.26) 0.04 
 
≥7 21/22 1.11 (0.60-2.06) 0.74 
Trend 0-10  Alleles 683/705 1.14 (1.04-1.25) 0.007 
d Number of  risk allele categories are based on control population 
e OR (95% CI) adjusted for age and genetic admixture 
f Wald-p for each GRS-3 category; g Wald-p for GRS-3 entered as continuous, per-allele effect 
 
 GRS-3 was further evaluated to test for associations with breast cancer defined by 
ER status (Table 26).  Risk was similar for ER+ and ER- tumors with the exception of 
those individuals with 6 risk alleles: there was a significantly higher risk for ER+ breast 
cancer (OR=1.61) but not ER- (OR=1.17).  For those with ≥7 risk alleles there was a 
higher risk for ER- breast cancer (OR=1.44), but not ER+ (OR=1.13); however, these 
estimates did not reach statistical significance. 











≤3 360 159 1.00 (Referent) 45 1.00 (Referent) 
4 190 77 0.92 (0.67-1.27) 20 0.83 (0.47-1.45) 
5 83 53 1.45 (0.98-2.15) 18 1.68 (0.92-3.06) 
6 50 36 1.61 (1.01-2.57) 7 1.17 (0.50-2.76) 
≥7 22 11 1.13 (0.54-2.40) 4 1.44 (0.47-4.39) 
0-10(trend)
c 
705 336 1.11 (1.02-1.21) 94 1.07 (0.93-1.24) 
a Number of  risk allele categories are based on control population 




The primary aim for this dissertation study was to evaluate genetic variation in TGF-β 
signaling genes (TGF-β1, TGF-βRI, RUNX1, RUNX2, and RUNX3) (n=7,733), ERα gene 
(n=1,409) and breast cancer risk among Hispanic and NHW women who participated in 
one of three population-based case-control studies: 4-CBCS, MBCS, or SFBCS.  
Ancestry informative markers were also evaluated to make a distinction between 
proportion of European and Native American ancestry (genetic admixture strata), which 
serves as an indicator of ethnicity.  Due to the hypothesized cross-talk within and across 
the TGF-β signaling pathway and ERα, there was particular interest to evaluate the 
association with breast cancer defined by ER status. 
Overall Associations with Breast Cancer 
Summary Results 
 After adjustment for age, study, and genetic admixture, nine SNPs [RUNX1 
(rs7279383 and rs8127225); RUNX2 (rs10948238 and rs13201287); RUNX3 (rs906296); 
TGF-β1 (rs4803455); TGF-βR1 (rs6478974), and ERα (rs1801132 and rs3798577)] were 
associated with overall breast cancer risk.  However; only two SNPs remained 
significantly associated after adjustment for multiple comparisons, one with a slight 
inverse association, TGF-β1 (rs4803455), while the other slightly increased risk, RUNX3 





 Genes from the TGF-β super-family play important roles in regulating cellular 
processes such as proliferation, differentiation, adhesion, migration, and survival [155].  
This pathway has been found to be the most commonly altered cellular signaling pathway 
in cancer, , and may suppress or promote tumors depending on the inactivity of core 
components, making it an attractive candidate when studying cancer etiology [93, 155].  
Several epidemiological case-control studies have investigated associations between 
select SNPs in TGF-β1, TGF-βR1 and breast cancer risk [96, 101-102, 156-167].  Data 
are inconsistent and most studies are underpowered and include NHW or Asian women 
only.  There have been several meta-analyses conducted for TGF-β1 and TGF-βR1 SNPs. 
 The most common TGF-βR1 SNP evaluated is *6A or rs1466445, which results 
from the deletion of three alanines within a nine-alanine (*9A) stretch in exon 1 [168].  
This variant has been associated with decreased expression of TGF-βRI [169].  TGF-
βR1*6A was found to increase breast cancer risk (per-allele OR=1.15) in a 
comprehensive meta-analysis conducted in 2012 including 17 case-control studies [170], 
including NHW, Asian or Indian populations and lacked inclusion of Hispanic women.  
The Nurses’ Health Study was the largest with ~1,200 cases, predominately NHW [101].  
Zhang and colleagues estimated that, given the high carrier rate (general population 
frequency ~14% heterozygote ; 0.5% homozygous variant), the population attributable 
risk (PAR) was 4.9% (2.7%-7.2%) for all breast cancers [164].  Although this variant was 
not genotyped for the present study, 5 tagSNPs were evaluated.  TGF-βR1 (rs6478974) 
was associated with a slight increase in risk (ORAA=1.13 95% CI 1.00-1.28, p=0.05), 
although significance did not remain after adjustment for multiple comparisons.  Two 
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studies have found that TGF-βR1 (rs11568785) is in strong LD with TGF-βR1*6A and 
suggest that it may mediate the functionality of TGF-βR1*6A [169, 171].  In the present 
study TGF-βR1 (rs11568785) was associated with a modest increase in risk (OR=1.41 
95% CI (0.74-2.69).  Although it was not statistically significant, theoretically it could be 
associated with a non-synonymous SNP (*A).  However, it is beyond the means of this 
study to test for LD between the two SNPs. 
 The most widely reported TGF-β1 SNPs are rs1982073 (T869C), located on exon 
1, which results in a leucine to proline substitution at codon 10(Leu10Pro), and 
rs1800469 (C-509T) in the promoter region [10].  The variant allele of rs1982073 (C) has 
been found to be associated with increased serum and plasma concentrations of TGF-β1.  
It has been hypothesized that women carrying this allele may be at a lower risk of breast 
cancer [159, 172-173].  However, two recent meta-analyses suggest that the per-allele 
effect of TGF-β1 (rs1982073) is associated with a ~5-8% increased risk of breast cancer 
in NHW women [88, 103].  Wei and colleagues [174] also conducted a meta-analysis on 
TGF-β1 (rs1982073) and reported a null association (OR=1.02 95% CI 0.94-1.07); 
however they did not include one large study with data from ~13,000 cases in the Breast 
Cancer Association Consortium (BCAC) that found a significant association with this 
SNP and breast cancer (per allele OR=1.08 95% CI 1.04-1.31) [156].  Le Marchand, et al. 
[157] was the only study to report an estimate for Hispanic women in the Multiethnic 
Cohort study, including post-menopausal women only.  Compared to Hispanic women 
with the TT genotype, women with CC-genotype had reduced risk (OR=0.81 95% CI 
0.52-1.27). However, the number of women was small (cases=67, controls=179) and the 
analysis was underpowered. 
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Three meta-analyses were conducted for TGF-β1 (rs1800469) and breast cancer risk in 
2010 [103, 175-176], although there were differences in studies used for a pooled 
estimate, results were similar.  Niu, et al. [176] included 9 study populations [101, 159-
162, 177], Qi, et al. [103] included 8 of the 9 [101, 159-162, 177], and Woo, et al. [175] 
included 7 of 9 [101, 159-160, 162].  Woo, et al. did not include two studies [161, 177], 
which contributed ~10,700 women to the other two pooled estimates.  It is important to 
note here that only one of the NHW populations included in this meta-analysis was from 
the US [101], while others studies represented NHW populations in Finland, Germany, 
Poland, and United Kingdom [103, 175-176].  Evaluating the recessive model (TT vs. 
CC/CT), the TGF-β1 (rs1800469) was found to have no effect in all three meta-analyses 
[(ORCC=1.00 (95% CI 0.89-1.15) [176]; (ORCC=1.00 (95% CI 0.88-1.14) [103]; and 
(ORCC=0.92 (95% CI 0.83-1.03) [175].  Data from the present study suggest there is a 
moderate LD (r
2
=0.67) between TGF-β1 (rs1800469) and TGF-β1 (rs4803455) in both 
Hispanic and NHW women.  After adjustments for multiple comparisons, a significant 
inverse association of breast cancer was observed for TGF-β1 (rs4803455) (ORCA/AA 
=0.89) and a non-significant positive association for TGF-β1 (rs1800469) (ORTT =1.08).  
When evaluated by Native American ancestry, there was a positive association for TGF-
β1 (rs1800469) among women with 29-71% ancestry (ORTT=1.29), while the association 
was inverse for TGF-β1 (rs4803455) (ORCA/AA=0.86), which did not remain significant 
after adjustment for multiple comparisons.  In contrast to findings from this study, 
Scollen and colleagues found that TGF-β1 (rs4803455) increased risk in a co-dominant 




 TGF-β1 (rs1982073 and rs1800469) have also been linked to a higher expression 
of TGF-β1 in breast tumors [102, 159].  The Asian population of the Shanghai Breast 
Cancer study [160] was included in the three meta-analyses and reported that rs1982073 
and rs1800469 were in high LD.  They evaluated the association of breast cancer defined 
by stage of diagnosis.  Compared to the homozygous wild-types, carries of homozygous 
wild-types were inversely associated with early stage (0/I) of disease and there was a 
non-significant increase for later stage (II-IV) for both SNPs.   
 All three RUNX genes have been shown to be important in colorectal cancer 
[178].  Little is known about the role of genetic variation in these genes in breast cancer 
etiology, although research is warranted given their role in the signaling pathway 
mediated by TGF-β1.  In the present admixed population, before multiple comparison 
evaluation, one SNP was associated with reduced risk: RUNX1 (rs7279383); while four 
SNPs were significantly associated with increased risk: RUNX1 (rs8127225), RUNX2 
(rs10948238 and rs13201287), and RUNX3 (rs906296).  These findings appear to be the 
first for an association between genetic variation in the RUNX genes and breast cancer 
risk, providing additional support for the TGF-β signaling pathway and breast cancer 
etiology. 
 The gene ERα regulates the biological function of the steroid hormone estrogen 
and is an important predictive and prognostic factor in breast cancer [7].  Most published 
association studies have evaluated the most common SNPs of ERα: PvuII (397T > C, 
rs2234693) and the XbaI (351A > G, rs9340799) restriction fragment length 
polymorphisms, both located in intron 1 and found to be in LD [179].  There are mixed 
results for these two SNPs reported from several studies [180-187].  In a meta-analysis of 
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11 case–control studies (cases=8,255; controls=13,164) there was a slight non-significant 
decrease in risk observed for PvuII (rs2234693) with the TT vs. CC genotype (OR=0.92 
95% CI 0.86-0.99).  In a meta-analysis of 10 case-control studies (cases=8,645; 
controls=12,805) there was a null association (OR=0.99 95% CI 0.90-1.08) for GG vs. 
AA genotype of XbaI (rs9340799) [188].  In one of the studies included in this 
dissertation, 4-CBCS, Slattery and colleagues evaluated XbaI (rs9340799) and did not 
find an association with breast cancer in Hispanic or NHW women overall [187].  
 The present study evaluated five ERα SNPs; two of which (rs1801132 and 
rs3798577) were found to be associated with a modest increase in breast cancer before 
adjustment for multiple comparisons.  ERα (rs1801132) is a well-studied, synonymous 
SNP in codon 325 of exon 4 (hormone binding domain), and has been evaluated in 
several previous population-based studies [180, 182-183, 185, 189-193].  Li and 
colleagues [188] conducted a meta-analysis including seven of these studies [180, 182-
183, 185, 190, 192-193] (cases=5,649, controls=6,856) and reported a non-significant 
reduced risk for the dominant model (ORCG/GG=0.92 95% CI 0.95-0.99), however they 
were not able to pool estimates for a recessive model.  Since this meta-analysis, Anghel 
and colleagues [189] did not find an association with rs1801132 and overall risk, 
however there was a significant association for age at diagnosis (diagnosis >50 years, 
p=0.02).  There was a non-significant increased risk for rs1801132 in a recent study in a 
Chinese population (ORCG/GG=1.12 95% CI 0.90–1.40), however it was not significant 
[191].  The present study found a non-significant increase in the dominant model 
(ORCG/GG=1.13 95% CI 0.91-1.39); although when evaluating the recessive model there 
was a higher and more significant association (ORGG=1.72 95% CI 1.10-2.69), which is 
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in contrast to the meta-analysis.  This dissertation study also found a significant increase 
in risk for ERα (rs3798577, ORCC=1.36), which is located in the 3'-untranslated region 
(3’-UTR; a region of messenger RNA (mRNA)) of ERα.  Although its functionality is not 
well established, this region seems to alter the ERα expression [189].  A meta-analysis, 
conducted by Li and colleagues [188], pooled data from three studies [180, 182-183] and 
no association was observed (estimate not given). Lastly, two studies have reported an 
increase in risk:  a small study (n=192) conducted in Romania [189] reported a >2-fold 
increase in risk (per-allele); and a study conducted in the United Kingdom with ~3,900 
women (per-allele OR=1.11) [194].   
 The present study did not find a significant association with breast cancer for ERα 
rs2046210, rs851984, or rs6913578.  In contrast, these SNPs were reported to be 
associated with breast cancer in previous studies that included NHW, Japanese and/or 
Chinese populations.  ERα (rs2046210) is located on 6q25.1 (1,440 base pairs upstream 
of the coding region of ERα).  Zheng, et al. found a significant increase in risk in a 
GWAS of Chinese women (ORAA=1.59 95% CI 1.40–1.81) as well as European women 
from the Nashville Breast Health Study (ORAA=1.35 95% CI 1.06–1.71) [195].  Cai and 
colleagues pooled data from fourteen studies (cases=17,188, controls=14,660) and 
replicated the results of Zheng [196] in women of Chinese (ORAA=1.64), Japanese 
(ORAA=1.37) and European ancestry (ORAA=1.18); although there was no association in 
African American women.  Han et al. reported a significant increased association for the 
dominant model (GA/AA vs. GG, OR=1.47 95% CI 1.27–1.69).  This study also supports 
an increase in risk with the dominant model (ORGA/AA=1.22 95% CI 0.98-1.43), although 
of borderline significance.  ERα (rs6913578) is 1,440 bp downstream of rs2046210.  Cai 
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and colleagues suggested that ERα (rs6913578) may be a functional variant as they found 
that the minor allele (C) of rs6913578 significantly altered DNA-protein complex (II) 
intensity in both Human Embryonic Kidney 293 cells (HEK293) and Michigan Cancer 
Foundation-7 cells (MCF-7, breast cancer cell line).  They also report rs6913578 to be in 
high LD with rs2046210 in Chinese (r
2
=0.91) and European-ancestry (r
2
=0.83), and 
found an increased risk in both populations, ORCC=1.54 and 1.31, respectively [196].  
Again, data from the present study appear to support an increase in risk (ORCC=1.26 95% 
CI 0.88-1.81), although not statistically significant.  
 Lastly, ERα (rs851984), located near the promoter region [183], was evaluated in 
the present study and found to have a slight, non-significant positive association 
(ORAA=1.16 95% CI 0.84-1.59).  In contrast, MARIE-GENICA (a pooled analysis of 
postmenopausal women (cases=3,149, controls=5,489) from two population-based 
studies in Germany found a significant per-allele effect (ORA=1.13 95% CI (1.03-1.25) 
[197]. 
Biological Mechanism 
Breast Cancer Initiation 
 It is widely acknowledged that components of TGF-β signaling pathway, ERα and 
their target genes play a role in breast development and can either support or inhibit the 
growth of tumor cells.  Understanding the complex functioning of these genes and the 
relationship with breast cancer is a significant issue for a further evaluation of predictive 
risk factors. 
 In most tumor cells, genetic variation in key members of the pathway can cause 
resistance to the growth inhibitory effects of TGF-β signaling [96-97].  Exact 
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mechanisms for resistance remains unknown, although researchers have hypothesized, 
through evidence in gastric, pancreatic, and colon cancer studies, that there may be 
decreased expression of its receptors (TGF-βRI and TGF-βRII) on the cell surface or 
increased expression of inhibitory SMADs (I-SMAD6 or I-SMAD-7) in the extracellular 
matrix, inhibiting the signaling function [87].  Some researchers suggest that reduced 
expression or inactivation of TGF-β signaling could be caused by oncoproteins such as 
p53 [98] or decreased expression of other tumor suppressors that regulate the pathway 
such as RUNX3 [99].   
 The RUNX genes are established down-stream effectors of TGF-β signaling.  
RUNX3 is best known for its role as a tumor suppressor in the gastrointestinal tract.  
More recently, research has found it to be a tumor suppressor in breast cancer, as RUNX3 
mRNA is consistently under expressed in tumor cells compared to normal cells [136].  
This could be a result of protein mislocalization, which could potentially cause a 
disturbance in the mechanism that controls nuclear transport of RUNX3 resulting in the 
atypical localization of RUNX3in the cytoplasm.  Epigenetic changes, most commonly, 
hypermethylation of the CpG island in the promoter region of RUNX3 can cause 
silencing or functional inactivation of the tumor suppressor function [124-125].   
 RUNX1 is established as a tumor suppressor in hematopoietic malignancies.  It 
has been reported to be expressed in luminal and basal epithelial cells in normal breast 
tissue, but to be deficient in breast tumor tissue [107, 114].  Although its role in breast 
tissue is understudied, research suggests RUNX1 may be deregulated in breast 
carcinogenesis.  Janes and colleagues report that RUNX1 and a family of transcription 
factors, called FOXO, have an antagonistic relationship.  Specifically, when cells are 
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RUNX1-deficient, they are under oxidative stress and FOXO expression increases to 
stabilize and support cell proliferation [107].  
 In contrast to components of the TGF-β, ERα supports cell proliferation.  When 
estrogen binds to nuclear ERα, the estrogen-ERα complex then binds to sequences known 
as estrogen response elements (ERE) and effects transcriptional activity [78].  The role 
ERα plays in breast carcinogenesis is well studied and two biological mechanisms have 
been described [7].  First, binding of estrogen to the ERα stimulates mammary cell 
proliferation, increasing in cell division and DNA replication leading to spontaneous 
errors or mutations.  As an example in ER+ cells, estrogen down-regulates E-cadherin, a 
mediator of cell-cell interactions that plays an important role in tumor suppression in the 
breast.  Lowered E-cadherin expression in both normal and tumor epithelial cells in the 
breast is caused via a decrease in promoter activity and subsequent mRNA levels [198]. 
 The second mechanism involves metabolism of endogenous estrogen producing 
genotoxic by-products that could directly harm DNA [199].  As an example, ring 
hydroxylation at the C-2 and C-4 positions of endogenous estrogens forms catechol 
estrogens and then reactive quinone metabolites that have been increasingly associated 
with estrogen-induced breast cancer that cause oxidative damage to DNA [200].  This is 
further supported by an epidemiologic study that reported postmenopausal women with 
low-activity genotype for catechol-O-methyltransferase (COMT, gene responsible for 
inactivating catechol estrogens) are at increased risk of breast cancer compared to those 
with the highly active genotype [201]. 
 There are also hormone-independent tumors (ERα negative) that can develop, 
whose mechanism is not understood.  Suggested mechanisms include loss of ligand-
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binding and responsiveness of estrogen via genetic mutations in ERα.  Variants at the 
mRNA level with alternative splicing can yield deletion of exon 3, 5, or 7 causing 
repression of ERα protein.  Amino acids in the AF-1 domain of ERα are phosphorylated 
by activation of a signaling cascade downstream of receptor tyrosine kinases. The 
phosphorylated ERα is then able to regulate the transcription of target genes via protein-
protein interaction with other transcription factors or corregulators [202].  In addition, 
DNA methylation of ERα may control its expression and therefore play an important role 
in the hormone-independent breast cancer [203].  Ultimately, the result of these 
mechanisms disturbs the normal functions of the cell cycle, apoptosis and DNA repair, 
leading to breast cancer development and promotion.   
Breast Cancer Promotion 
 There is also evidence that these genes can influence breast cancer progression.  
When TGF-β1and TGF-βRI are overexpressed following tumor initiation, they promote 
metastasis [87].  In order for a tumor to metastasize, tumor cells must have the ability to 
migrate in and out of blood vessels and invade surrounding tissues.  This has also been 
called the epithelial to mesenchymal differentiation of tumors and TGF-B protein is able 
to induce this transition in cultures of breast epithelial cells [204].  This concept of ‘re-
programming’ the TGF-B protein has been suggested to be in response to a disturbance 
by epigenetic mechanisms or genetic alterations, such as the activation of Ras, a 
subfamily of GTPase proteins that transmit signals within cells [204].  The combined 
effect of Ras/MAP kinase signaling can induce expression of TGF-B1, enhancing the 
signaling pathway, which could explain the increased levels of TGF-B1 in breast tumors 
and subsequent tumor invasion [205-206].   
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 The formation of a network of blood vessels (angiogenesis) is necessary to 
provide nutrients to the tumor cells.  High levels of TGF-β1 mRNA have been found to 
be associated with increased microvessel density in human breast tumors [207].  In this 
environment TGF-β1 has been found to induce the expression of an angiogenic growth 
factor: vascular endothelial growth factor (VEGF), which acts to stimulate proliferation in 
endothelial cells [100, 208].  Research suggests an indirect role for RUNX2 and breast 
metastasis through alteration of VEGF as well [120].  Conversely, RUNX3 is found to be 
down-regulated in most breast cancers, Chen and colleagues reported that when RUNX3 
is activated or overexpressed the invasive potential of breast cancer cells (MDA-MB-
231) is reduced in-vitro [209].   
 The role of ERα signaling and breast cancer promotion is not well understood.  A 
potential mechanism may involve the recruitment of co-factors by ERα that have a 
negative effect on cell motility and invasion, although these results have been 
inconsistent are dependent on complex interactions with other signaling pathways [210].  
Disruptions in the ERα-signaling pathway could lead to estrogen-dependent or estrogen-
independent mechanisms involving loss of hormone responsiveness, reduction of tumor 
suppressor functions, interaction with growth factors (i.e. VEGF), and nuclear proto-
oncogenes (normal genes mutated to be oncogenes, i.e. c-fos and c-myc), to name a few 
[200, 203, 211]. 
Stratification by Proportion Native American Ancestry 
Summary Results 
 Unlike previous studies evaluating TGF-β1 and TGF- βRI and breast cancer risk, 
this dissertation study was able to test for interaction effects with genetic admixture.  
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Unique associations were observed by genetic admixture.  Predominantly, TGF-β 
signaling genes and ERα did not differ by genetic admixture; there were however, three 
SNPs were more associated with increased breast cancer risk in women of moderate 
(RUNX3 (rs906296) and TGF-β1 (1800469)) and high (RUNX1 (rs7279383)) Native 
American ancestry after adjustment for multiple comparisons.  There was also a 
significant interaction found between RUNX1 (rs7279383) and genetic admixture 
(p=0.04). 
Previous Literature 
 Previously, Slattery and colleagues [8] reported that women with higher NA 
ancestry were at a reduced risk compared to women with a more European ancestry.  In 
the present study, the difference in risk between selected SNPs and admixture strata may 
support the hypothesis that genetic variation related to important factors such as cell 
growth and hormones can influence breast cancer differently in Hispanic and NHW 
women.   
 Published data from the 4-CBCS also indicate that there are ethnic differences for 
associations of select SNPs and breast cancer:  the interleukin-6 (IL6) SNPs had a greater 
association with risk among Hispanic than NHW women [212]; a higher risk among 
NHW was observed with serum Insulin-like growth factor 1 (IGF-1) compared to 
Hispanic women [213]; the beta-2-adrenergic receptor (ADRB2) haplotype was 
associated with a greater risk in NHW than Hispanic women having a BMI ≥25 kg/m2 
[214].  Other data from the BCHD study also indicate bone morphogenetic proteins 
(BMP1, BMP6, BMPR1B, BMPR2), which are members of the TGF-β signaling 
pathway, differ across genetic admixture groups [215].  One plausible explanation for 
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these differences in risk between ethnic groups could be that there is a region including 
unmeasured biologically functional variants that differs by ethnicity that contributes to 
breast cancer susceptibility.   
Stratification by Menopausal status 
Summary Results 
 In general, breast cancer risk did not differ by menopausal status in the present 
study.  There were no significant interactions with menopausal status.  Within 
menopausal strata the The CG/GG genotype of RUNX3 (rs906296) was significantly 
associated greater risk among pre-menopausal (OR=1.33), but not post-menopausal 
women.  Although ERα (rs1801132) was not associated with overall risk after adjustment 
for multiple comparisons, the risk for the GG-genotype was >2-fold among post-
menopausal women, while risk for pre-menopausal women was attenuated and not 
significant. 
Associations with Breast cancer Defined by ER/PR status 
Summary Results 
 Data from the present study supports the theory that these genes are associated 
with breast cancer phenotypes as defined by their hormone receptors.  SNPs in these 
genes were associated with specific breast cancer tumor phenotypes:  RUNX3 (2 SNPs) 
was associated with ER+/PR+ tumors (OR 1.18 and 1.90); RUNX1 (2 SNPs) and TGF-
βR1 (1 SNP) were associated with ER+/PR- tumors (OR between 0.44 and 3.55); RUNX3 
(3 SNPs) was associated with ER-/PR+ tumors (OR between 2.52 and 2.88); and RUNX1 
(1 SNP), RUNX2 ( 5 SNPs), RUNX3 (2 SNPs) were associated with ER-/PR- tumors 
(OR between 0.77 and 2.31).  After adjustment for multiple comparisons, four RUNX 
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SNPs remained significantly associated with an increased risk of ER-/PR- (n=3) and ER-
/PR+ (n=1) tumors.  Further evaluation of ER+/ER- tumors by menopausal status showed 
that risk for ER- tumors is significantly associated with >2-fold increase in post-
menopausal women (RUNX1, rs2268288 and RUNX2, rs12333172).  When determining 
whether risk of ER+/ER- breast differed by proportion Native American ancestry, there 
were a larger number of significant positive [ER+ (n=2), ER- (n=1)] and inverse 
associations [ER+ (n=1) ER- (n=1)] for those with moderate to high Native American 
ancestry, which were not observed in the low Native American ancestry group. 
 This study is the first to evaluate associations TGF-β and RUNX genes and risk of 
breast cancer defined by ER/PR tumor phenotypes.  Although the present analysis 
included 1,962 cases with available data on ER/PR status, there was a lack of tumor 
phenotype data for the MBCS, limiting power when evaluating some tumor phenotypes, 
specifically ER-/PR+ (n=45 cases).  However, these results strengthen the importance of 
these genes and estrogen-related associations with breast cancer. 
Biological Mechanism: Estrogen Links Signaling Pathways 
 Genes in the TGF- β signaling pathway have been associated with estrogen via 
expression of estrogen receptors (ERα) and estrogen signaling pathways [133, 136, 216].  
Although ERα and TGF- β have an opposing regulatory effect on normal cell 
proliferation (promotion and inhibition, respectively), a potential relationship in breast 
carcinogenesis has been elucidated.  Several studies have provided evidence that receptor 
regulated SMADs (R-SMAD2, R-SMAD3) and common mediator (Co-SMAD4) comes 
into direct physical contact with ERα [129-132].  Co-SMAD4 is found to be a mediator of 
crosstalk between TGF-β and ERα where it acts as a co-repressor of the transcription of 
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ERα, inhibiting tumor growth.  Interestingly, Co-SMAD4 has been found to induce 
apoptosis in ERα+ but not ERα– cells [133].  In the absence of Co-SMAD4, ERα-estrogen 
cell proliferation is enhanced [131].  Estrogen will act acting directly on the TGF-β 
signaling pathway to block the phosphorylation of R-SMAD 2/3 complex via ubiquitin-
proteasome pathway [130].  Bierie and colleagues compared breast cancer expression 
signatures to TGF-β response signatures and found two associations: first, the TGF-β 
response signature was associated with ERα-negative tumors and poor prognosis; second, 
the absence of TGF-β response signature was found to be higher in ERα-positive tumors 
and was associated with a poor prognosis [135].   
 The RUNX transcription factors were reported to interact with estrogen signaling.   
RUNX1 has been called an ‘accessibility factor’ for ERα binding sites, and may function 
as a regulator of ERα gene expression specifically in ERα-positive cells [216].  RUNX1 
has been found to suppress the oncogenic effects of estrogens mostly through this 
physical interaction with ERα, called ‘tethering’ [217].  RUNX2 has been observed to 
interact with ERα involving two mechanisms: first, RUNX2 decreases ERα mRNA and 
protein levels in breast cancer cells; and second, the interaction of RUNX2 and ERα-
binding domain results in decrease association of ERα with its target genes [218].  Using 
mouse models, Huang and colleagues showed that RUNX3 may target ERα to function as 
a tumor suppressor by destabilizing the gene and inhibiting its expression [136].  An 
inverse relationship was observed between expressions of the two genes; a higher RUNX3 
expression was associated with lower ERα in ERα-positive cells and vice versa, while 




Evaluation of Potential Crosstalk between Signaling Pathways 
Summary Results 
 Evaluation of SNP-SNP interactions provided support that the multiplicative 
effect of SNPs in the TGF-β signaling pathway alters breast cancer susceptibility.  
Specifically there were two significant interactions between RUNX3 and TGF-βRI.  Two 
GRS evaluated the cumulative effect of risk alleles for SNPs that were found to have an 
inverse association and positive association with breast cancer.  Findings for the GRS 
including four SNPs showed that the per-allele trend of risk alleles reduced risk 
(range=0-7 alleles) (OR=0.92 95% CI 0.88-0.96).  There was also a higher risk observed 
for the GRS including 6 SNPs (range=0-10 alleles) (OR=1.14 95% CI 1.04-1.25), and 
was also positively associated with ER+ tumors but not ER- tumors.  It is important to 
note that the p-values for these findings are biased due to the fact that the risk alleles for 
selected SNPs were based solely on this study population.  To further test this hypothesis, 
a refinement of statistical methods would be necessary, such as permutation testing, 
allowing for the correct distribution of a test statistic under a null hypothesis, resulting in 
a true p-value [219].  Nevertheless, this is the first population-based observational study 
evaluating the crosstalk between TGF-β and ERα signaling pathways reporting that it is 
suggestive of a positive association with breast cancer. 
Strengths and Limitations 
 Strengths of this study include the substantial sample size based on 4,700 
Hispanic women (cases=2,100; controls=2,600) who completed demographic and 
lifestyle questionnaires and had DNA available for analysis.  Data harmonization, based 
on variables derived from study-specific questions, was carried out and new variables 
 
124 
were created that used the same or the closest information possible from each original 
study variable to ensure consistency.  The distributions of the new variables were 
compared and found to be very similar across these three studies providing validity to the 
harmonization process [8].  This process helped to rule out differential misclassification 
bias between ethnic groups or case-control status at different study sites.   
 Selection bias could be possible across study populations and countries due to 
differences in recruiting processes.  The present study used several methods of 
identifying and recruiting eligible subjects including (but not limited to):  mailing lists, 
driver’s license lists, SEER registries, hospital-catchment areas, county or city-specific 
residence, and random-digit dialing.  Some of these methods may have resulted in lower 
response rates, especially among H women in the US study populations [139-140].  The 
present study does not have the ability to measure characteristics of non-respondents and 
it is possible they are different than the study participants.   
 Although ~30% of the subjects did not provide a blood/saliva sample, the blood 
draw rates (or mouthwash samples) were comparable between cases (72%) and controls 
(76%), but were slightly higher among Hispanic (73%) and NHW participants (66%) 
overall, which could result in a selection bias.  These issues could make this sample less 
representative of the general population. 
 Participants are being asked to remember lifestyle choices prior to diagnosis or 
selection which could result in recall bias.  This was reduced by setting the referent year 
to be the same for cases and controls.  Although, the present genetic association study did 
not show evidence of confounding by lifestyle factors.   
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 There is also potential for genotyping errors in the lab such as cross-
contamination or low concentration.  This could result in drop outs, or samples that are 
not read during the PCR process.  In order to reduce this error the concentrations of DNA 
samples were standardized prior to PCR and dropouts were genotyped again. 
 This is the first study to evaluate these particular genes in a genetically admixed 
population and their association with breast cancer, with the ability to compare Hispanic 
to NHW women, and did not have to rely on self-reported ethnicity.  The STRUCTURE 
program determined genetic admixture, although the two were highly correlated.  This 
program is unique in that it does not assume previous knowledge about the population; it 
lets the genotype define the population structure [145].  False positives may result in 
association studies when admixed populations with differences in incidence rates, 
genotype distribution, and LD between SNPs on the same locus are not adequately 
identified [220].  In relation to the present study, a genetic variant that is more common 
in NHW (high-incidence population) can appear to be associated with breast cancer in the 
admixed population, although no true causal association exists.  By using genetic 
admixture as a confounder, the potential bias was controlled for risk estimates.  The large 
sample size allowed sufficient power to test for genetic admixture as an effect modifier of 
the SNP and breast cancer.   
 Adjustment was made for multiple comparisons, reducing the potential of false 
positive findings, the step-down Bonferroni-Holm method is conservative, however, this 
does not completely remove the possibility of spurious associations [151].  The present 
study utilized spectral decomposition to determine the number of effective SNPs by gene 
before the multiple comparison adjustment.  This ensured that the joint Type I error (α) 
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remained at 0.05 for each SNP which were jointly adjusted for multiple comparisons by 
gene.  Another issue when adjusting for multiple comparisons is an increase in the Type 
II error rate, or number of false negatives that can be anticipated, which may obscure true 
associations [146].  Nonetheless, the present study recognizes the importance of reducing 
false positive results by adjusting for multiple comparisons.  Very few of the above 
mentioned studies adjusted for multiple comparisons, mostly because they only reviewed 
one SNP at a time.  In addition, other major findings reported were significant prior to 
adjusting for multiple comparisons, and should be interpreted with caution.   
 Because of sparse data in the literature, comparisons to previous literature were 
limited to only a few SNPs for TGF-β1 (rs1982073, rs1800469), TFG-βRI (*6A) and 
ERα (Pvull (rs2234693), XbaI (rs9340799), rs1800132, rs3798577, rs2046210, rs851984, 
rs6913578) and no comparisons were possible for RUNX SNPs.  The interpretation of 
findings from the present study is general and guided mostly by in-vivo and transgenic 
(genetically modified) mouse studies.  While some of the SNPs have been found to 
modify the protein production, a true causal variant is yet to be elucidated by genetic 
markers located on these genes.  To determine the causal variant, sequencing would have 
to be conducted, which was beyond the means of the present study.  Using a tag-SNP 
approach, the present study was able to cover a large part of each gene, allowing 
detection of unmeasured common genetic variants, as these tagSNPs are in LD with 
common variants not reported in this study.  Stram and colleagues explain that for the 
purpose of determining whether genetic variation is related to risk, it is not necessary to 
genotype the actual causal variant.  By genotyping SNPs that also fall on the original 
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ancestral chromosome (gene), near the causal variant, some part of the signal of the 
actual causal variant will be picked up [221].   
Future Direction 
 Replication of these findings is warranted among similarly diverse populations 
with larger sample sizes having available data on relevant confounders.  More convincing 
evidence could be derived from cohort studies with incident cases.  However, this may be 
difficult and prove to be costly.  In most cases, data and resources would need to be 
pooled as they were in this study.   
 To better understand the function of these genes, the measurement of gene 
expression of these tagSNPs within breast tumors could provide evidence of the influence 
genetic variation may have on the activity, structure, and communication within and 
across signaling pathways [222].  An understanding of how these genes switch roles from 
tumor suppressors to promoters in breast cancer, which can be thought of as the concept 
of reprogramming gene activity in relation to tumor growth, is important for future 
research. 
 Unique findings from the present study may provide implication for further breast 
cancer phenotype classification.  Specifically, genetic variation that attributes to ER+ and 
ER-tumors may be useful for examining the variance of breast cancer attributable by 
these specific genes and determining how they affect the tumor biology differently in 
Hispanic and NHW women.  Understanding the biological basis of breast cancer may 
assist in illuminating the health disparity pertaining to differences in tumor biology and 
the microenvironment between Hispanic and NHW women [223].  Using these genes for 
further phenotype classification may prove to be a good risk predicting tool that can 
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specifically target differences in diverse ethnic populations.  In addition, evaluating 
cumulative or additive effects of low-penetrance SNPs in complex genetic pathways may 
provide a feasible approach for prediction of risk based on common genetic variation.  
Using a genetic risk profile has implication for policy to make improvements in the 
effectiveness of population-based programs of interventions for breast cancer.  In turn, 
policies would need to target interventions for ethnically diverse populations of various 
socio-economic backgrounds to further counteract the unequal burden of breast cancer 
[224]. 
Conclusion 
 In conclusion, the results of the present analyses provide evidence that genetic 
variation in TGF-β and RUNX genes may influence breast cancer risk.  These 
associations may differ by tumor phenotype, menopausal status, and genetic admixture.  
These results suggest that genetic variation in these genes may explain the greater 
likelihood in Hispanic women for premenopausal, ER- breast cancer.  This is one of the 
first reports that may explain these associations in Hispanic women.  These associations 
were predominantly observed in RUNX genes; the present study is the first observational 
study to report the significant relationship between genetic variation among these genes 
and breast cancer risk.  There is a clear implication for further tumor phenotype 
classification which may be useful to discriminate high- and low- risk genotypes and 
provide biological targets to reduce health disparities between Hispanic and NHW 
women. 
 Biologic significance of the genes is strongly suggested, although specific alleles 
evaluated in the present study may or may not be functional (i.e. may serve as a proxy for 
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other alleles).  A better understanding of how TGF-β and RUNX genes can switch their 
role from tumor suppressor to initiator and how cross-regulatory effects of signaling 
pathways may contribute to breast cancer is needed.  Studies evaluating a larger 
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Table 7.  TGF-β signaling pathway: genotype distributions, BCHD population, stratified by self-reported race and case-control 
status 
  






























        
 rs11701453 GG 2395 (68.0) 2917 (69.3) 
0.37 
913 (63.9) 1033 (64.6) 
0.82 
1482 (70.8) 1884 (72.2) 
0.46 <.0001 
 
GC 1030 (29.2) 1169 (27.8) 459 (32.1) 498 (31.1) 571 (27.3) 671 (25.7) 
 
CC 97 (2.8) 124 (2.9) 58 (4.0) 69 (4.3) 39 (1.9) 55 (2.1) 
 rs1474479 GG 2014 (57.2) 2432 (57.8) 
0.80 
586 (40.9) 638 (39.9) 
0.31 
1428 (68.2) 1794 (68.7) 
0.71 <.0001 
 
GA 1237 (35.1) 1443 (34.3) 646 (45.2) 717 (44.8) 591 (28.4) 726 (27.8) 
 
AA 272 (7.7) 335 (7.9) 198 (13.9) 245 (15.3) 74 (3.5) 90 (3.5) 
 rs1883066 GG 2856 (81.0) 3471 (82.5) 
0.14 
1081 (75.5) 1229 (76.9) 
0.59 
1775 (84.8) 2242 (85.9) 
0.23 <.0001 
 
GC 633 (17.9) 696 (16.5) 330 (23.1) 341 (21.3) 303 (14.5) 355 (13.6) 
 
CC 35 (1.0) 42 (1.0) 20 (1.4) 29 (1.8) 15 (0.7) 13 (0.5) 
 rs2252585 TT 1456 (41.3) 1697 (40.3) 
0.18 
763 (53.3) 841 (52.6) 
0.52 
693 (33.1) 856 (32.8) 
0.57 <.0001 
 
TC 1584 (45.0) 1889 (44.9) 576 (40.3) 645 (40.3) 1008 (48.2) 1244 (47.7) 
 
CC 483 (13.7) 624 (14.8) 92 (6.4) 114 (7.1) 391 (18.7) 510 (19.5) 
 rs2268288 TT 2500 (70.9) 3027 (71.9) 
0.18 
890 (62.2) 1014 (63.4) 
0.32 
1610 (77.0) 2013 (77.1) 
0.71 <.0001 
 
TC 915 (26.0) 1081 (25.7) 469 (32.8) 520 (32.5) 446 (21.3) 561 (21.5) 
 
CC 108 (3.1) 102 (2.4) 72 (5.0) 66 (4.1) 36 (1.7) 36 (1.4) 
 rs7279123 CC 2236 (63.7) 2629 (62.7) 
0.31 
818 (57.5) 870 (54.7) 
0.15 
1418 (67.9) 1759 (67.6) 
0.63 <.0001 
 
CT 1109 (31.6) 1361 (32.4) 506 (35.6) 606 (38.1) 603 (28.9) 755 (28.9) 
 
TT 163 (4.7) 206 (4.9)  98 (6.9) 116 (7.3)  65 (3.1) 90 (3.5)   
 rs7279383 CC 2647 (75.1) 3099 (73.6) 
0.17 
977 (68.3) 1051 (65.7) 
0.07 
1670 (79.8) 2048 (78.5) 
0.54 <.0001 
 
CG 812 (23.1) 1033 (24.5) 424 (29.7) 501 (31.3) 388 (18.5) 532 (20.4) 
 GG 64 (1.8) 77 (1.8) 29 (2.0) 47 (2.9) 35 (1.7) 30 (1.2) 

































N (%) N (%)  N (%) N (%)  N (%) N (%)   
 
TC 1215 (34.5) 1383 (32.9) 355 (24.8) 364 (22.8) 860 (41.1) 1019 (39.1) 
 
CC 192 (5.4) 230 (5.5) 22 (1.5) 30 (1.9) 170 (8.1) 200 (7.7) 
RUNX2 (n=17)  
 
 
        
 rs10948238 CC 1245 (35.4) 1516 (36.0) 
0.11 
487 (34.1) 574 (35.9) 
0.04 
758 (36.2) 942 (36.1) 
0.74 0.23 
 
CT 1705 (48.4) 2086 (49.6) 692 (48.4) 800 (50.0) 1013 (48.4) 1286 (49.3) 
 
TT 571 (16.2) 605 (14.4) 250 (17.5) 225 (14.1) 321 (15.3) 380 (14.6) 
 rs1200428 CC 1932 (54.8) 2316 (55.0) 
0.89 
825 (57.7) 953 (59.6) 
0.14 
1107 (52.9) 1363 (52.2) 
0.47 <.0001 
 
CA 1370 (38.9) 1629 (38.7) 533 (37.2) 585 (36.6) 837 (40.0) 1044 (40.0) 
 
AA 222 (6.3) 265 (6.3) 73 (5.1) 62 (3.9) 149 (7.1) 203 (7.8) 
 rs12208240 GG 2800 (79.5) 3354 (79.7) 
0.88 
1231 (86.1) 1350 (84.4) 
0.32 
1569 (75.0) 2004 (76.8) 
0.26 <.0001 
 
GA 680 (19.3) 807 (19.2) 187 (13.1) 242 (15.1) 493 (23.6) 565 (21.7) 
 
AA 41 (1.2) 49 (1.2) 12 (0.8) 8 (0.5) 29 (1.4) 41 (1.5) 
 rs12209785 AA 1850 (52.5) 2211 (52.5) 
0.58 
771 (54.0) 888 (55.5) 
0.14 
1079 (51.6) 1323 (50.7) 
0.75 0.0001 
 
AG 1413 (40.1) 1720 (40.9) 563 (39.4) 633 (39.6) 850 (40.6) 1087 (41.7) 
 
GG 259 (7.4) 277 (6.6) 95 (6.6) 79 (4.9) 164 (7.8) 198 (7.6) 
 rs12333172 CC 2415 (68.6) 2839 (67.4) 
0.67 
932 (65.2) 1021 (63.8) 
0.69 
1483 (70.9) 1818 (69.7) 
0.66 <.0001 
 
CT 982 (27.9) 1245 (29.6) 432 (30.2) 514 (32.1) 550 (26.3) 731 (28.0) 
 
TT 126 (3.6) 126 (3.0) 66 (4.6) 65 (4.1) 60 (2.9) 61 (2.3) 
 rs1316330 GG 2259 (64.1) 2709 (64.4) 
0.64 
783 (54.7) 881 (55.1) 
0.55 
1476 (70.5) 1828 (70.1) 
0.64 <.0001 
 
GT 1130 (32.1) 1351 (32.1) 558 (39.0) 634 (39.6) 572 (27.3) 717 (27.5) 
 
TT 135 (3.8) 148 (3.5) 90 (6.3) 85 (5.3) 45 (2.2) 63 (2.4) 
 rs13201287 GG 1784 (50.6) 2137 (50.8) 
0.41 
768 (53.7) 874 (54.6) 
0.16 
1016 (48.5) 1263 (48.4) 
0.86 <.0001 
 
GA 1442 (40.9) 1762 (41.9) 557 (38.9) 642 (40.1) 885 (42.3) 1120 (42.9) 
 
AA 298 (8.5) 311 (7.3) 106 (7.4) 84 (5.3) 192 (9.2) 227 (8.7) 

































N (%) N (%)  N (%) N (%)  N (%) N (%)   
 
CA 1310 (37.2) 1591 (37.8) 369 (25.8) 421 (26.3) 941 (45.0) 1170 (44.8) 
 
AA 297 (8.4) 358 (8.5) 42 (2.9) 42 (2.6) 255 (12.2) 316 (12.1) 
 rs17209895 TT 2354 (66.8) 2805 (66.6) 
0.79 
769 (53.8) 852 (53.3) 
0.84 
1585 (75.7) 1953 (74.8) 
0.56 <.0001 
 
TC 1007 (28.6) 1234 (29.3) 553 (38.7) 643 (40.2) 454 (21.7) 591 (22.6) 
 
CC 162 (4.6) 171 (4.1) 108 (7.5) 105 (6.5) 54 (2.6) 66 (2.5) 
 rs2396441 CC 911 (25.9) 1034 (24.6) 
0.84 
397 (27.7) 387 (24.2) 
0.08 
514 (24.6) 647 (24.8) 
0.23 0.30 
 
CT 1762 (50.0) 2198 (52.2) 707 (49.4) 832 (52.0) 1055 (50.4) 1366 (52.4) 
 
TT 851 (24.2) 976 (23.2) 327 (22.9) 380 (23.8) 524 (25.0) 596 (22.8) 
 rs2677108 TT 973 (27.6) 1130 (26.9) 
0.26 
499 (34.9) 557 (34.8) 
0.94 
474 (22.6) 573 (22.0) 
0.36 <.0001 
 
TC 1727 (49.0) 2048 (48.7) 689 (48.2) 769 (48.1) 1038 (49.6) 1279 (49.0) 
 
CC 824 (23.4) 1030 (24.5) 243 (16.9) 274 (17.1) 581 (27.8) 756 (29.0) 
 rs2790093 AA 1609 (45.7) 1917 (45.5) 
0.80 
613 (42.8) 701 (43.8) 
0.39 
996 (47.6) 1216 (46.6) 
0.64 0.002 
 
AG 1552 (44.0) 1882 (44.7) 658 (46.0) 737 (46.1) 894 (42.7) 1145 (43.9) 
 
GG 362 (10.3) 411 (9.8) 160 (11.2) 162 (10.1) 202 (9.7) 249 (9.5) 
 rs2819854 TT 898 (25.5) 1113 (26.5) 
0.31 
348 (24.3) 372 (23.3) 
0.70 
550 (26.3) 741 (28.4) 
0.14 0.0006 
 
TC 1752 (49.7) 2081 (49.5) 716 (50.0) 818 (51.2) 1036 (49.5) 1263 (48.4) 
 
CC 873 (24.8) 1014 (24.1) 367 (25.7) 409 (25.5) 506 (24.2) 605 (23.2) 
 rs598953 TT 1266 (35.9) 1480 (35.2) 
0.50 
563 (39.3) 618 (38.6) 
0.80 
703 (33.6) 862 (33.0) 
0.66 <.0001 
 
TA 1683 (47.8) 2030 (48.2) 678 (47.4) 771 (48.2) 1005 (48.0) 1259 (48.2) 
 
AA 575 (16.3) 700 (16.6) 190 (13.3) 211 (13.2) 385 (18.4) 489 (18.7) 
 rs6930053 CC 1518 (43.1) 1821 (43.3) 
0.47 
525 (36.7) 541 (33.8) 
0.09 
993 (47.4) 1280 (49.0) 
0.05 <.0001 
 
CT 1562 (44.3) 1899 (45.1) 695 (48.6) 803 (50.2) 867 (41.4) 1096 (41.9) 
 
TT 443 (12.6) 490 (11.6) 210 (14.7) 256 (16.0) 233 (11.1) 234 (8.9) 
 rs7750470 TT 2252 (63.9) 2718 (64.6) 
0.53 
886 (61.9) 1040 (65.0) 
0.13 
1366 (65.3) 1678 (64.3) 
0.66 0.48 
 

































N (%) N (%)  N (%) N (%)  N (%) N (%)   
 
CC 148 (4.2) 170 (4.0) 57 (4.0) 63 (3.9) 91 (4.3) 107 (4.1) 
 rs9463090 GG 2281 (64.8) 2743 (65.2) 
0.44 
870 (60.8) 997 (62.4) 
0.28 
1411 (67.5) 1746 (66.9) 
0.91 <.0001 
 
GA 1075 (30.5) 1288 (30.6) 474 (33.2) 516 (32.3) 601 (28.7) 772 (29.6) 
 





        
 rs11249206 TT 1247 (36.0) 1472 (35.5) 
0.97 
372 (26.4) 378 (24.0) 
0.08 
875 (42.5) 1094 (42.7) 
0.37 <.0001 
 
TC 1607 (46.3) 1956 (47.2) 715 (50.6) 803 (50.9) 892 (43.4) 1153 (44.9) 
 
CC 615 (17.7) 715 (17.3) 325 (23.0) 397 (25.1) 290 (14.1) 318 (12.4) 
 rs2236850 TT 1189 (33.8) 1486 (35.4) 
0.13 
434 (30.4) 519 (32.5) 
0.31 
755 (36.1) 967 (37.1) 
0.33 <.0001 
 
TC 1686 (47.9) 1984 (47.2) 709 (49.6) 764 (47.9) 977 (46.7) 1220 (46.8) 
 
CC 645 (18.3) 733 (17.4) 286 (20.0) 312 (19.6) 359 (17.2) 421 (16.1) 
 rs4478762 GG 2719 (77.2) 3272 (77.8) 
0.31 
1112 (77.7) 1248 (78.0) 
0.43 
1607 (76.8) 2024 (77.6) 
0.48 0.43 
 
GA 751 (21.3) 891 (21.2) 295 (20.6) 341 (21.3) 456 (21.8) 550 (21.1) 
 
AA 54 (1.5) 45 (1.0) 24 (1.7) 11 (0.7) 30 (1.4) 34 (1.3) 
 rs6688058 GG 2604 (73.9) 3142 (74.6) 
0.37 
1068 (74.6) 1208 (75.5) 
0.36 
1536 (73.4) 1934 (74.1) 
0.64 0.14 
 
GA 842 (23.9) 986 (23.4) 331 (23.1) 368 (23.0) 511 (24.4) 618 (23.7) 
 
AA 78 (2.2) 82 (2.0) 32 (2.3) 24 (1.5) 46 (2.2) 58 (2.2) 
 rs7517302 TT 1260 (35.8) 1537 (36.5) 
0.17 
438 (30.6) 507 (31.7) 
0.24 
822 (39.3) 1030 (39.5) 
0.59 <.0001 
 
TC 1655 (47.0) 2006 (47.7) 698 (48.8) 795 (49.7) 957 (45.8) 1211 (46.5) 
 
CC 606 (17.2) 664 (15.8) 294 (20.6) 298 (18.6) 312 (14.9) 366 (14.0) 
 rs7551188 CC 886 (25.2) 1107 (26.3) 
0.59 
328 (22.9) 343 (21.4) 
0.19 
558 (26.7) 764 (29.3) 
0.13 <.0001 
 
CT 1756 (49.9) 2037 (48.5) 714 (49.9) 792 (49.5) 1042 (49.9) 1245 (47.8) 
 
TT 878 (24.9) 1061 (25.2) 389 (27.2) 465 (29.1) 489 (23.4) 596 (22.9) 
 rs906296 CC 2143 (60.9) 2701 (64.2) 
0.005 
820 (57.3) 952 (59.5) 
0.38 
1323 (63.2) 1749 (67.1) 
0.007 <.0001 
 

































N (%) N (%)  N (%) N (%)  N (%) N (%)   
 
GG 171 (4.9) 190 (4.5) 77 (5.4) 90 (5.6) 94 (4.5) 100 (3.8) 
 rs9438876 AA 1016 (28.9) 1265 (30.0) 
0.39 
308 (21.5) 366 (22.9) 
0.92 
708 (33.8) 899 (34.4) 
0.48 <.0001  
AG 1713 (48.6) 2005 (47.6) 713 (49.9) 751 (46.9) 1000 (47.8) 1254 (48.1) 
 





        
 rs1800469 CC 1253 (36.2) 1523 (36.6) 
0.57 
664 (47.6) 753 (47.9) 
0.87 
589 (28.5) 770 (29.7) 
0.15 <.0001 
 
CT 1590 (45.9) 1913 (46.0) 585 (41.9) 642 (40.8) 1005 (48.7) 1271 (49.2) 
 
TT 618 (17.9) 722 (17.4) 147 (10.5) 177 (11.3) 471 (22.8) 545 (21.1) 
 rs4803455 CC 1193 (37.0) 1401 (35.4) 
0.62 
368 (26.2) 409 (26.0) 
0.80 
825 (45.3) 992 (41.6) 
0.18 <.0001 
 
CA 1460 (45.3) 1890 (47.7) 698 (49.7) 780 (49.5) 762 (41.9) 1110 (46.5) 
 





        
 rs1013186 GG 2578 (73.2) 3109 (73.9) 
0.53 
912 (63.7) 1026 (64.1) 
0.86 
1666 (79.6) 2083 (79.8) 
0.62 <.0001 
 
GA 874 (24.8) 1016 (24.1) 475 (33.2) 513 (32.1) 399 (19.1) 503 (19.3) 
 
AA 72 (2.0) 85 (2.0) 44 (3.1) 61 (3.8) 28 (1.3) 24 (0.9) 
 rs10733710 GG 1834 (52.1) 2092 (49.7) 
0.01 
906 (63.4) 954 (59.7) 
0.03 
928 (44.3) 1138 (43.6) 
0.28 <.0001 
 
GA 1387 (39.4) 1694 (40.3) 467 (32.7) 565 (35.3) 920 (44.0) 1129 (43.3) 
 
AA 302 (8.5) 423 (10.0) 57 (3.9) 80 (5.0) 245 (11.7) 343 (13.1) 
 rs11568785 AA 3093 (87.8) 3730 (88.6) 
0.19 
1172 (81.9) 1343 (83.9) 
0.15 
1921 (91.8) 2387 (91.5) 
0.90 <.0001 
 
AG 410 (11.6) 463 (11.0) 245 (17.1) 243 (15.2) 165 (7.9) 220 (8.4) 
 
GG 21 (0.6) 17 (0.4) 14 (1.0) 14 (0.9) 7 (0.3) 3 (0.1) 
 rs1571590 AA 2580 (73.2) 3112 (73.9) 
0.48 
912 (63.7) 1026 (64.2) 
0.88 
1668 (79.7) 2086 (79.9) 
0.57 <.0001 
 
AG 872 (24.7) 1014 (24.1) 475 (33.2) 512 (32.0) 397 (19.0) 502 (19.2) 
 
GG 72 (2.0) 83 (1.9) 44 (3.1) 61 (3.8) 28 (1.3) 22 (0.8) 

































N (%) N (%)  N (%) N (%)  N (%) N (%)   
 
TA 1637 (46.5) 1958 (46.5) 690 (48.3) 768 (48.0) 947 (45.2) 1190 (45.6) 
 
AA 639 (18.1) 677 (16.1) 342 (23.9) 361 (22.6) 297 (14.2) 316 (12.1) 
Note: Percentages are rounded and may not total to 100%
 
a 
Case-control comparison for entire study population and within each ethnic group (p-values reported from Mantel-Haenszel chi-square tests)
 
b 
Ethnic group comparison, regardless of case-control status (p-values reported from Mantel-Haenszel chi-square tests) 
c 








Table 8.  ERα: genotype distribution, New Mexico subpopulation by self-reported race and case-control status 
  
Study Population Study Population Stratified by Self-Reported Race  
Gene/SNP Genotype
c 





























        
rs1801132 CC 383 (55.2) 415 (58.0) 
0.07 
252 (55.6) 286 (60.2) 
0.07 
131 (54.1) 129 (53.8) 
0.57 0.04 
 
CG 258 (37.2) 267 (37.3) 171 (37.8) 171 (36.0) 87 (36.0) 96 (40.0) 
 
GG 53 (7.6) 33 (4.6) 29 (6.4) 18 (3.8) 24 (9.9) 15 (6.2) 
rs3798577 TT 215 (31.0) 222 (31.1) 
0.19 
128 (28.3) 138 (29.1) 
0.17 
87 (36.0) 84 (35.0) 
0.68 0.004 
 
TC 318 (45.8) 362 (50.6) 210 (46.5) 244 (51.4) 108 (44.6) 118 (49.2) 
 
CC 161 (23.2) 131 (18.3) 114 (25.2) 93 (19.6) 47 (19.4) 38 (15.8) 
rs2046210 GG 288 (41.5) 328 (45.9) 
0.27 
169 (37.4) 198 (41.7) 
0.41 
119 (49.2) 130 (54.2) 
0.38 <.0001 
 
GA 322 (46.4) 298 (41.7) 223 (49.3) 211 (44.4) 99 (40.9) 87 (36.3) 
 
AA 84 (12.1) 89 (12.5) 60 (13.3) 66 (13.9) 24 (9.9) 23 (9.6) 
rs851984 GG 255 (36.7) 274 (38.3) 
0.41 
167 (36.9) 186 (39.2) 
0.40 
88 (36.4) 88 (36.7) 
0.82 0.53 
 
GA 327 (47.1) 336 (47.0) 213 (47.1) 221 (46.5) 114 (47.1) 115 (47.9) 
 
AA 112 (16.1) 105 (14.7) 72 (15.9) 68 (14.3) 40 (16.5) 37 (15.4) 
rs6913578 AA 315 (45.4) 352 (49.2) 
0.15 
190 (42.0) 215 (45.3) 
0.34 
125 (51.7) 137 (57.1) 
0.21 0.0003 
 
AC 302 (43.5) 293 (41.0) 208 (46.0) 208 (43.8) 94 (38.8) 85 (35.4) 
 
CC 77 (11.1) 70 (9.8) 54 (12.0) 52 (10.9) 23 (9.5) 18 (7.5) 
Note: Percentages are rounded and may not total to 100%
 
a 
Case-control comparison for entire study population and within each ethnic group (p-values reported from Mantel-Haenszel chi-square tests
 
b 
Ethnic group comparison, regardless of case-control status (p-values reported from Mantel-Haenszel chi-square tests) 
c 




Table 11b: TGF-β signaling and ERα genes: overall associations with breast cancer risk:  
The Breast Cancer Health Disparities Study (Full table) 
    Controls   Cases        





       
 
 
CC 3098 73.6 
 




CG/GG 1110 26.4 
 
876 24.9 0.89 (0.80, 0.99) 
RUNX1 (rs2268288) 
       
 
 
TT/TC 4107 97.6 
 
3415 96.9 1.00 
  0.14 (0.75) 
 
CC 102 2.4 
 
108 3.1 1.23 (0.93, 1.62) 
RUNX1 (rs2252585) 
       
 
 
TT/TC 3585 85.2 
 




CC 624 14.8 
 
483 13.7 0.95 (0.83, 1.08) 
RUNX1 (rs11701453) 
       
 
 
GG 2917 69.3 
 
2395 68.0 1.00 
  0.59 (1.00) 
 
GC 1168 27.8 
 
1030 29.2 1.06 (0.96, 1.17) 
 
CC 124 2.9 
 
97 2.8 0.91 (0.70, 1.20) 
RUNX1 (rs8127225) 
       
 
 
TT 2591 61.6 
 




TC/CC 1612 38.4 
 
1407 39.9 1.11 (1.01, 1.22) 
RUNX1 (rs1474479) 
       
 
 
GG/GA 3874 92.0 
 




AA 335 8.0 
 
272 7.7 0.92 (0.77, 1.09) 
RUNX1 (rs1883066) 
       
 
 
GG 3470 82.5 
 




GC/CC 738 17.5 
 
668 19.0 1.07 (0.95, 1.20) 
RUNX1 (rs7279123) 
       
 
 
CC 2628 62.6 
 
2236 63.7 1.00 
  0.13 (0.75) 
 
CT 1361 32.4 
 
1109 31.6 0.94 (0.85, 1.03) 
 
TT 206 4.9 
 
163 4.6 0.90 (0.72, 1.11) 
RUNX2 (rs1321075) 
       
 
 
CC 2260 53.7 
 
1916 54.4 1.00 
  0.56 (1.00) 
 
CA 1591 37.8 
 
1310 37.2 1.01 (0.92, 1.12) 
 
AA 358 8.5 
 
297 8.4 1.06 (0.89, 1.26) 
RUNX2 (rs17209895) 
       
 
 
TT 2804 66.6 
 
2354 66.8 1.00 
  0.51 (1.00) 
 
TC 1234 29.3 
 
1007 28.6 0.93 (0.84, 1.03) 
 
CC 171 4.1 
 
162 4.6 1.06 (0.84, 1.32) 
RUNX2 (rs2677108) 
       
 
 
TT 1129 26.8 
 
973 27.6 1.00 
  0.55 (1.00) 
 
TC 2048 48.7 
 
1727 49.0 0.99 (0.89, 1.11) 
 
CC 1030 24.5 
 
824 23.4 0.96 (0.85, 1.09) 
RUNX2 (rs2819854) 
       
 
 
TT 1113 26.5 
 
898 25.5 1.00 
  0.36 (1.00) 
 
TC 2080 49.4 
 
1752 49.7 1.04 (0.93, 1.16) 
 
CC 1014 24.1 
 
873 24.8 1.06 (0.94, 1.20) 
 
160 
    Controls   Cases        





       
 
 
AA 1917 45.5 
 
1609 45.7 1.00 
  0.80 (1.00) 
 
AG 1882 44.7 
 
1552 44.1 0.98 (0.89, 1.08) 
 
GG 410 9.7 
 
362 10.3 1.05 (0.90, 1.23) 
RUNX2 (rs9463090) 
       
 
 
GG 2742 65.2 
 
2281 64.8 1.00 
  0.60 (1.00) 
 
GA 1288 30.6 
 
1075 30.5 0.99 (0.90, 1.10) 
 
AA 175 4.2 
 
166 4.7 1.12 (0.89, 1.39) 
RUNX2 (rs2396441) 
       
 
 
CC 1034 24.6 
 
911 25.9 1.00 
  0.81 (1.00) 
 
CT 2198 52.2 
 
1762 50.0 0.91 (0.82, 1.02) 
 
TT 976 23.2 
 
851 24.1 0.99 (0.87, 1.12) 
RUNX2 (rs1316330) 
       
 
 
GG 2709 64.4 
 
2259 64.1 1.00 
  0.89 (1.00) 
 
GT 1350 32.1 
 
1130 32.1 0.98 (0.89, 1.08) 
 
TT 148 3.5 
 
135 3.8 1.04 (0.82, 1.33) 
RUNX2 (rs7750470) 
       
 
 
TT 2717 64.6 
 
2252 63.9 1.00 
  0.56 (1.00) 
 
TC 1322 31.4 
 
1124 31.9 1.02 (0.93, 1.13) 
 
CC 170 4.0 
 
148 4.2 1.05 (0.84, 1.32) 
RUNX2 (rs6930053) 
       
 
 
CC 1820 43.2 
 
1518 43.1 1.00 
  0.94 (1.00) 
 
CT 1899 45.1 
 
1562 44.3 0.96 (0.87, 1.06) 
 
TT 490 11.6 
 
443 12.6 1.04 (0.90, 1.21) 
RUNX2 (rs12208240) 
       
 
 
GG 3353 79.7 
 
2800 79.5 1.00 
  0.58 (1.00) 
 
GA 807 19.2 
 
680 19.3 1.03 (0.92, 1.16) 
 
AA 49 1.2 
 
41 1.2 1.04 (0.69, 1.59) 
RUNX2 (rs12209785) 
       
 
 
AA/AG 3931 93.4 
 




GG 276 6.6 
 
259 7.4 1.15 (0.96, 1.37) 
RUNX2 (rs10948238) 
       
 
 
CC/CT 3602 85.6 
 




TT 604 14.4 
 
571 16.2 1.15 (1.01, 1.30) 
RUNX2 (rs13201287) 
       
 
 
GG/GA 3899 92.6 
 




AA 310 7.4 
 
298 8.5 1.18 (1.00, 1.39) 
RUNX2 (rs12333172) 
       
 
 
CC/CT 4083 97.0 
 




TT 126 3.0 
 
126 3.6 1.16 (0.90, 1.49) 




    Controls   Cases        





       
 
 
CC 2316 55.0 
 
1932 54.8 1.00 
  0.61 (1.00) 
 
CA 1628 38.7 
 
1370 38.9 1.02 (0.93, 1.13) 
 
AA 265 6.3 
 
222 6.3 1.03 (0.85, 1.24) 
RUNX2 (rs598953) 
       
 
 
TT 1480 35.2 
 
1266 35.9 1.00 
  0.76 (1.00) 
 
TA 2029 48.2 
 
1683 47.8 0.98 (0.89, 1.09) 
 
AA 700 16.6 
 
575 16.3 0.98 (0.86, 1.12) 
RUNX3 (rs2236850) 
       
 
 
TT 1486 35.4 
 
1189 33.8 1.00 
  0.18 (0.75) 
 
TC 1983 47.2 
 
1686 47.9 1.05 (0.95, 1.16) 
 
CC 733 17.4 
 
645 18.3 1.09 (0.95, 1.24) 
RUNX3 (rs9438876) 
       
 
 
AA 1265 30.1 
 
1016 28.8 1.00 
  0.75 (1.00) 
 
AG 2004 47.6 
 
1713 48.6 1.04 (0.94, 1.16) 
 
GG 940 22.3 
 
793 22.5 1.02 (0.89, 1.16) 
RUNX3 (rs7517302) 
       
 
 
TT/TC 3542 84.2 
 




CC 664 15.8 
 
606 17.2 1.10 (0.98, 1.24) 
RUNX3 (rs906296) 
       
 
 
CC 2701 64.2 
 




CG/GG 1505 35.8 
 
1379 39.2 1.15 (1.04, 1.26) 
RUNX3 (rs7551188) 
       
 
 
CC 1106 26.3 
 
886 25.2 1.00 
  0.90 (1.00) 
 
CT 2037 48.5 
 
1756 49.9 1.06 (0.95, 1.18) 
 
TT 1061 25.2 
 
878 24.9 1.01 (0.89, 1.14) 
RUNX3 (rs6688058) 
       
 
 
GG/GA 4127 98.1 
 




AA 82 1.9 
 
78 2.2 1.16 (0.85, 1.58) 
RUNX3 (rs11249206) 
       
 
 
TT 1471 35.5 
 
1247 35.9 1.00 
  0.38 (1.00) 
 
TC 1956 47.2 
 
1607 46.3 0.94 (0.84, 1.04) 
 
CC 715 17.3 
 
615 17.7 0.96 (0.83, 1.10) 
RUNX3 (rs4478762) 
       
 
 
GG/GA 4162 98.9 
 




AA 45 1.1 
 
54 1.5 1.45 (0.97, 2.17) 
TGF-β1 (rs1800469) 
       
 
 
CC/CT 3435 82.6 
 




TT 722 17.4 
 
618 17.9 1.08 (0.96, 1.22) 
TGF-β1 (rs4803455) 
       
 
 
CC 1400 35.3 
 




CA/AA 2561 64.7 
 
2032 63.0 0.89 (0.81, 0.98) 




    Controls   Cases        




TGF- βR1 (rs6478974) 
      
 
 
TT/TA 3531 83.9 
 




AA 677 16.1 
 
639 18.1 1.13 (1.00, 1.28) 
TGF- βR1 (rs1571590) 
      
 
 
AA 3111 73.9 
 
2580 73.2 1.00 
  0.89 (1.00) 
 
AG 1014 24.1 
 
872 24.7 0.99 (0.89, 1.11) 
 
GG 83 2.0 
 
72 2.0 0.98 (0.71, 1.35) 
TGF- βR1 (rs1013186) 
      
 
 
GG 3108 73.8 
 
2578 73.2 1.00 
  0.85 (1.00) 
 
GA 1016 24.1 
 
874 24.8 1.00 (0.89, 1.11) 
 
AA 85 2.0 
 
72 2.0 0.96 (0.70, 1.32) 
TGF- βR1 (rs11568785) 
      
 
 
AA/AG 4192 99.6 
 




GG 17 0.4 
 
21 0.6 1.41 (0.74, 2.69) 
TGF- βR1 (rs10733710) 
      
 
 
GG/GA 3785 89.9 
 




AA 423 10.1 
 
302 8.6 0.88 (0.75, 1.03) 
ERα (rs1801132) 
       
 
 
CC/CG 672 95.3 
 




GG 33  4.7 
 
53  7.8 1.72 (1.10, 2.69) 
ERα (rs3798577)  









CC 128 18.2  157 23.0 1.36 (1.04, 1.76) 
ERα (rs2046210) 
       
 
 
GG 322 45.7 
 




GA/AA 383 54.3 
 
402 58.9 1.22 (0.98,  1.51) 
ERα (rs851984) 
       
 
 
GG 272 38.6 
 
251 36.8 1.00 
  0.37 (0.37) 
 
GA 330 46.8 
 
322 47.1 1.06 (0.84,  1.33) 
 
AA 103 14.6 
 
110 16.1 1.16 (0.84,  1.59) 
ERα (rs6913578) 
       
 
 
AA 346 49.1 
 
308 45.1 1.00 
  0.11 (0.19) 
 
AC 289 41.0 
 
298 43.6 1.17 (0.93, 1.46) 
 
CC 70 9.9 
 
77 11.3 1.26 (0.88,  1.81) 
a 
 TGF-β signaling SNPs (n=7733)  adjusted for age, study site, and genetic admixture;  ERα SNPs adjusted for age and 
genetic admixture (n=1388) 
b 







Table 12b. The association of TGF-β signaling and ERα genes and breast cancer stratified by menopausal status (Full table) 










    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
RUNX1 (rs7279383) 
                
 
CC 1131 74.4 
 
980 75.0 1.00 
   
1884 73.2 
 




CG/GG 390 25.6 
 




522 24.8 0.88 (0.77, 1.01) 
 Wald-p 
c 
   
1.00 
        
0.39 
   RUNX1 (rs2268288) 
                
 
TT/TC 1480 97.3 
 
1273 97.5 1.00 
   
2515 97.7 
 
2033 96.6 1.00 
  
0.10 (0.77)  
 
CC 41 2.7 
 








   
1.00 
        
0.26 
   RUNX1 (rs2252585) 
                
 
TT/TC 1268 83.4 
 
1098 84.1 1.00 
   
2214 86.0 
 




CC 253 16.6 
 








   
1.00 
        
0.68 
   RUNX1 (rs11701453) 
                
 
GG 1084 71.3 
 
911 69.8 1.00 
   
1755 68.2 
 




GC 398 26.2 
 




638 30.3 1.07 (0.94, 1.21) 
 
 
CC 39 2.6 
 




52 2.5 0.78 (0.54, 1.11) 
 p-trend 
c 
   
1.00 
        
1.00 
   RUNX1 (rs8127225) 
                
 
TT 919 60.6 
 
747 57.2 1.00 
   
1602 62.3 
 




TC/CC 598 39.4 
 








   
0.06 
        
1.00 
   RUNX1 (rs1474479) 
                
 
GG/GA 1422 93.5 
 
1207 92.5 1.00 
   
2344 91.1 
 




AA 99 6.5 
 








   
1.00 
        
0.39 

















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
RUNX1 (rs1883066) 
                
 
GG 1279 84.1 
 
1071 82.0 1.00 
   
2092 81.3 
 




GC/CC 242 15.9 
 








   
1.00 
        
1.00 
   RUNX1 (rs7279123) 
                
 
CC 972 64.1 
 
835 64.2 1.00 
   
1583 61.7 
 




CT 486 32.0 
 




671 32.0 0.93 (0.82, 1.06) 
 
 
TT 59 3.9 
 








   
1.00 
        
0.48 
   RUNX2 (rs1321075) 
                
 
CC 770 50.6 
 
706 54.1 1.00 
   
1427 55.4 
 




CA 604 39.7 
 




794 37.7 1.08 (0.95, 1.23) 
 
 
AA 147 9.7 
 








   
1.00 
        
1.00 
   RUNX2 (rs17209895) 
                
 
TT 1043 68.6 
 
885 67.8 1.00 
   
1685 65.5 
 




TC 422 27.7 
 




610 29.0 0.92 (0.81, 1.05) 
 
 
CC 56 3.7 
 








   
1.00 
        
1.00 
   RUNX2 (rs2677108) 
                
 
TT 411 27.0 
 
369 28.3 1.00 
   
686 26.7 
 




TC 709 46.6 
 




1044 49.6 0.99 (0.86, 1.14) 
 
 
CC 400 26.3 
 








   
1.00 
        
1.00 
   RUNX2 (rs2819854) 
                
 
TT 392 25.8 
 
319 24.4 1.00 
   
689 26.8 
 



















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
 
TC 747 49.1 
 




1058 50.3 1.04 (0.91, 1.20) 
 
 
CC 382 25.1 
 








   
1.00 
        
1.00 
   RUNX2 (rs2790093) 
                
 
AA 693 45.6 
 
626 48.0 1.00 
   
1177 45.7 
 




AG 677 44.5 
 




945 44.9 1.03 (0.92, 1.17) 
 
 
GG 151 9.9 
 








   
1.00 
        
1.00 
   RUNX2 (rs9463090) 
                
 
GG 991 65.2 
 
850 65.1 1.00 
   
1676 65.2 
 




GA 475 31.3 
 




649 30.8 1.03 (0.90, 1.17) 
 
 
AA 54 3.6 
 








   
1.00 
        
1.00 
   RUNX2 (rs2396441) 
                
 
CC 369 24.3 
 
330 25.3 1.00 
   
635 24.7 
 




CT 808 53.1 
 




1081 51.4 0.96 (0.84, 1.11) 
 
 
TT 344 22.6 
 








   
1.00 
        
1.00 
   RUNX2 (rs1316330) 
                
 
GG 984 64.7 
 
853 65.3 1.00 
   
1657 64.4 
 




GT 483 31.8 
 




685 32.5 1.01 (0.89, 1.15) 
 
 
TT 53 3.5 
 








   
1.00 
        
1.00 
   RUNX2 (rs7750470) 
                
 
TT 986 64.8 
 
824 63.1 1.00 
   
1662 64.6 
 




TC 472 31.0 
 






















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
 
CC 63 4.1 
 








   
1.00 
        
1.00 
   RUNX2 (rs6930053) 
                
 
CC 686 45.1 
 
570 43.7 1.00 
   
1086 42.2 
 




CT 678 44.6 
 




958 45.5 0.98 (0.87, 1.11) 
 
 
TT 157 10.3 
 








   
1.00 
        
1.00 
   RUNX2 (rs12208240) 
                
 
GG 1198 78.8 
 
1008 77.2 1.00 
   
2070 80.4 
 




GA 301 19.8 
 




381 18.1 0.99 (0.85, 1.15) 
 
 
AA 22 1.4 
 








   
1.00 
        
1.00 
   RUNX2 (rs12209785) 
                
 
AA/AG 1416 93.2 
 
1217 93.2 1.00 
   
2408 93.6 
 




GG 104 6.8 
 








   
1.00 
        
1.00 
   RUNX2 (rs10948238) 
                
 
CC/CT 1306 86.0 
 
1095 83.8 1.00 
   
2197 85.4 
 




TT 213 14.0 
 








   
1.00 
        
1.00 
   RUNX2 (rs13201287) 
                
 
GG/GA 1406 92.4 
 
1201 92.0 1.00 
   
2386 92.7 
 




AA 115 7.6 
 








   
1.00 
        
0.93 
   RUNX2 (rs12333172) 
                
 
CC/CT 1479 97.2 
 
1261 96.6 1.00 
   
2492 96.8 
 



















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
 
TT 42 2.8 
 




79 3.8 1.14 (0.83, 1.57) 
 Wald-p 
c 
   
1.00 
        
1.00 
   RUNX2 (rs1200428) 
                
 
CC 829 54.5 
 
726 55.6 1.00 
   
1422 55.2 
 




CA 591 38.9 
 




819 38.9 1.04 (0.92, 1.17) 
 
 
AA 101 6.6 
 








   
1.00 
        
1.00 
   RUNX2 (rs598953) 
                 
 
TT 531 34.9 
 
476 36.4 1.00 
   
903 35.1 
 




TA 734 48.3 
 




995 47.3 0.97 (0.85, 1.11) 
 
 
AA 256 16.8 
 








   
1.00 
        
1.00 
   RUNX3 (rs2236850) 
                
 
TT 579 38.1 
 
451 34.5 1.00 
   
875 34.1 
 




TC 698 45.9 
 




993 47.3 0.98 (0.86, 1.12) 
 
 
CC 243 16.0 
 








   
0.41 
        
1.00 
   RUNX3 (rs9438876) 
                
 
AA 484 31.8 
 
385 29.5 1.00 
   
756 29.4 
 




AG 726 47.7 
 




1016 48.3 1.03 (0.90, 1.19) 
 
 
GG 311 20.4 
 








   
0.47 
        
1.00 
   RUNX3 (rs7517302) 
                
 
TT/TC 1299 85.5 
 
1091 83.5 1.00 
   
2146 83.4 
 




CC 221 14.5 
 








   
0.44 
        
1.00 

















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 
(95% CI) p-int 
b 
RUNX3 (rs906296) 
                 
 
CC 1009 66.3 
 
774 59.3 1.00 
   
1619 63.0 
 




CG/GG 512 33.7 
 








   
0.002 
        
1.00 
   RUNX3 (rs7551188) 
                
 
CC 392 25.8 
 
351 26.9 1.00 
   
683 26.6 
 




CT 753 49.6 
 




1047 49.8 1.11 (0.96, 1.28) 
 
 
TT 374 24.6 
 








   
0.41 
        
1.00 
   RUNX3 (rs6688058) 
                
 
GG/GA 1492 98.1 
 
1284 98.3 1.00 
   
2526 98.1 
 




AA 29 1.9 
 








   
0.80 
        
0.82 
   RUNX3 (rs11249206) 
                
 
TT 550 36.8 
 
499 38.7 1.00 
   
888 35.0 
 




TC 695 46.5 
 




969 46.8 0.98 (0.85, 1.11) 
 
 
CC 251 16.8 
 








   
0.23 
        
1.00 
   RUNX3 (rs4478762) 
                
 
GG/GA 1504 98.9 
 
1293 99.0 1.00 
   
2546 99.0 
 




AA 16 1.1 
 








   
0.95 
        
0.21 
   TGF-β1 (rs1800469) 
                
 
CC 522 34.9 
 
458 35.6 1.00 
   
963 37.8 
 




CT 716 47.8 
 




947 45.9 1.08 (0.95, 1.23) 
 
 
TT 259 17.3 
 






















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 





   
0.34 
        
0.28 
   TGF-β1 (rs4803455) 
                
 
CC 510 36.3 
 
462 38.9 1.00 
   
861 35.0 
 




CA/AA 896 63.7 
 








   
0.07 
        
0.28 
   TGF- βRI (rs6478974) 
                
 
TT/TA 1273 83.8 
 
1077 82.5 1.00 
   
2156 83.8 
 




AA 247 16.3 
 








   
0.77 
        
0.23 
   TGF- βRI (rs1571590) 
                
 
AA 1155 75.9 
 
962 73.7 1.00 
   
1872 72.8 
 




AG 342 22.5 
 




526 25.0 0.96 (0.83, 1.10) 
 
 
GG 24 1.6 
 








   
0.77 
        
1.00 
   TGF- βRI (rs1013186) 
                
 
GG 1156 76.0 
 
960 73.5 1.00 
   
1869 72.6 
 




GA 339 22.3 
 




526 25.0 0.95 (0.83, 1.09) 
 
 
AA 26 1.7 
 








   
0.77 
        
1.00 
   TGF- βRI (rs11568785) 
                
 
AA/AG 1517 99.7 
 
1298 99.4 1.00 
   
2562 99.5 
 




GG 4 0.3 
 








   
0.77 
        
1.00 
   TGF- βRI (rs10733710) 
                
 
GG/GA 1356 89.2 
 
1202 92.0 1.00 
   
2326 90.4 
 




AA 164 10.8 
 






















    N (%)   N (%) OR 
a 
(95% CI)  N (%)   N (%) OR 
a 





   
0.21 
        
1.00 
   ERα (rs1801132) 
                 
 
CC/CG 220 94.0 
 









GG 14 6.0 
 











        
0.04 
   ERα (rs3798577)  
                
 
TT/TC 188 80.3 
 









CC 46 19.7 
 








   
0.57 
        
0.22 
   ERα (rs2046210)  
                
 
GG 107 45.7 
 










GA/AA 127 54.3 
 








   
0.51 
        
0.78 
   ERα (rs851984)  
                
 
GG 90 38.5 
 









GA 110 47.0 
 




204 45.8 1.10 (0.75, 1.33) 
 
 
AA 34 14.5 
 








   
0.65 
        
0.78 
   ERα (rs6913578)  
                
 
AA 113 48.3 
 









AC 103 44.0 
 




187 42.0 1.14 (0.86, 1.51) 
 
 
CC 18 7.7 
 








   
0.54 
        
0.78 
   a Odds Ratios adjusted for age, study, and genetic admixture 
b 
Interaction p-value (SNP*menopause); Bonferroni p-value for adjustment for multiple comparisons shown in parentheses  







Table 13b. The association of TGF-β signaling genes and breast cancer stratified by proportion Native American ancestry (Full table) 
Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a






             
 














   
0.14 
   
0.05 
   RUNX1 (rs2268288) 
             
 














   
1.00 
   
1.00 
   RUNX1 (rs2252585) 
             
 














   
1.00 
   
1.00 
   RUNX1 (rs11701453) 
             
 








GC 548/583 1.06 (0.92, 1.22) 374/451 1.05 (0.89, 1.23) 108/134 1.26 (0.94, 1.69) 
 
 






   
1.00 
   
1.00 
   RUNX1 (rs8127225) 
             
 














   
0.12 
   
1.00 
   RUNX1 (rs1474479) 
             
 














   
1.00 
   
1.00 







Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a






             
 














   
1.00 
   
1.00 
   RUNX1 (rs7279123) 
             
 








CT 601/704 0.91 (0.79, 1.04) 412/508 0.99 (0.85, 1.16) 96/149 0.91 (0.68, 1.23) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs1321075) 
             
 








CA 470/513 1.00 (0.86, 1.16) 612/764 1.01 (0.87, 1.17) 228/314 1.05 (0.79, 1.40) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs17209895) 
             
 








TC 659/731 1.01 (0.88, 1.16) 300/427 0.84 (0.71, 0.99) 48/76 0.89 (0.61, 1.32) 
 
 






   
0.57 
   
1.00 
   RUNX2 (rs2677108) 
             
 








TC 833/906 1.02 (0.88, 1.18) 681/840 0.94 (0.79, 1.13) 213/302 0.99 (0.70, 1.40) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs2819854) 
             
 













Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a






TC 865/948 1.01 (0.86, 1.19) 668/829 1.05 (0.88, 1.24) 219/303 1.13 (0.85, 1.51) 
 
 






   
1.00 
   
1.00 
   
              RUNX2 (rs2790093) 
             
 








AG 763/851 1.01 (0.88, 1.16) 590/743 0.95 (0.82, 1.11) 199/288 1.06 (0.82, 1.38) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs9463090) 
             
 








GA 559/602 1.04 (0.90, 1.20) 392/528 0.89 (0.76, 1.04) 124/158 1.12 (0.85, 1.48) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs2396441) 
             
 








CT 839/983 0.82 (0.70, 0.96) 699/880 1.04 (0.87, 1.24) 224/335 0.89 (0.67, 1.20) 
 
 






   
0.91 
   
1.00 
   RUNX2 (rs1316330) 
             
 








GT 654/721 1.01 (0.88, 1.16) 385/484 0.96 (0.82, 1.13) 91/145 0.89 (0.66, 1.20) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs7750470) 
             
 













Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a






TC 578/589 1.15 (1.00, 1.32) 437/554 0.96 (0.82, 1.12) 109/179 0.84 (0.63, 1.12) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs6930053) 
             
 








CT 808/944 0.87 (0.75, 1.00) 596/731 1.06 (0.91, 1.23) 158/224 0.98 (0.75, 1.27) 
 
 






   
0.57 
   
1.00 
   RUNX2 (rs12208240) 
             
 








GA 239/288 0.90 (0.74, 1.08) 328/366 1.15 (0.97, 1.37) 113/153 1.05 (0.79, 1.39) 
 
 






   
0.50 
   
1.00 
   RUNX2 (rs12209785) 
             
 














   
1.00 
   
1.00 
   RUNX2 (rs10948238) 
             
 














   
1.00 
   
1.00 
   RUNX2 (rs13201287) 
             
 














   
1.00 
   
1.00 
   RUNX2 (rs12333172) 







Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a




















   
1.00 
   
1.00 
   RUNX2 (rs1200428) 
             
 








CA 617/684 1.02 (0.89, 1.17) 546/653 1.03 (0.89, 1.20) 207/291 1.11 (0.85, 1.44) 
 
 






   
1.00 
   
1.00 
   RUNX2 (rs598953) 
             
 








TA 791/909 0.93 (0.80, 1.07) 668/797 1.02 (0.87, 1.20) 224/323 1.13 (0.84, 1.53) 
 
 






   
1.00 
   
0.92 
   RUNX3 (rs2236850) 
             
 








TC 844/890 1.10 (0.95, 1.28) 653/810 1.04 (0.89, 1.22) 189/283 0.93 (0.71, 1.20) 
 
 






   
0.86 
   
1.00 
   RUNX3 (rs9438876) 
             
 








AG 846/888 1.09 (0.92, 1.29) 681/825 1.06 (0.90, 1.24) 186/291 0.89 (0.68, 1.15) 
 
 






   
1.00 
   
1.00 
   RUNX3 (rs7517302) 
             
 
















Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a










   
1.00 
   
1.00 
   RUNX3 (rs906296) 
             
 














   
0.04 
   
0.61 
   RUNX3 (rs7551188) 
             
 








CT 848/934 0.96 (0.81, 1.14) 699/821 1.16 (0.98, 1.38) 209/282 1.03 (0.79, 1.36) 
 
 






   
1.00 
   
1.00 
   RUNX3 (rs6688058) 
             
 














   
1.00 
   
1.00 
   RUNX3 (rs11249206) 
             
 








TC 834/953 0.89 (0.75, 1.04) 633/781 1.01 (0.87, 1.19) 140/222 0.77 (0.59, 1.01) 
 
 






   
1.00 
   
0.71 
   RUNX3 (rs4478762) 
             
 














   
1.00 
   
1.00 
   TGF-β1 (rs1800469) 
             
 
















Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a












   
0.04 
   
0.94 
   TGF-β1 (rs4803455) 
             
 














   
0.05 
   
0.94 
   TGF-βRI  (rs6478974) 
             
 














   
0.20 
   
1.00 
   TGF-βRI  (rs1571590) 
             
 








AG 561/589 1.07 (0.93, 1.24) 267/362 0.89 (0.74, 1.06) 44/63 0.98 (0.65, 1.48) 
 
 






   
0.74 
   
1.00 
   TGF-βRI  (rs1013186) 
             
 








GA 561/592 1.06 (0.92, 1.23) 268/360 0.90 (0.75, 1.07) 45/64 0.98 (0.65, 1.47) 
 
 






   
0.74 
   
1.00 
   TGF-βRI  (rs11568785) 
             
 






0.19  (0.44) 
 






   
0.23 
   
1.00 
   TGF-βRI  (rs10733710) 
             
 













Gene (SNP) Genotype Low (0-28%) Moderate (29-70%) High (71-100%) 
 
  
Case/Control OR (95% CI) 
a 
Case/Control OR (95% CI) 
a












   
0.74 
   
1.00 
   
a  Odds Ratios adjusted for age and study 
b  Interaction p-value (SNP*admixture); Bonferroni-Holm p-value for multiple comparisons shown in parenthesis; bold text indicates significance after MC adjustment 
c
 Wald (or trend) p-value within strata adjusted for multiple comparisons (MC) by admixture strata (Bonferroni-Holm step-down method), bold text indicates significance (p≤0.05) or 









Table 15b.  The Association of TGF-β signaling genes and breast cancer defined by ER/PR status* (Full table) 
  




Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
RUNX1 (rs7279383) 
                  
 


















   
1.00 
   
1.00 
   
0.26 
   RUNX1 (rs2268288) 
                  
 


















   
1.00 
   
0.98 
   
1.00 
   RUNX1 (rs2252585) 
                  
 


















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs11701453) 
                 
 










GC 931 382 1.03 (0.89, 1.19) 60 0.83 (0.61, 1.13) 14 1.09 (0.58, 2.07) 130 1.16 (0.92, 1.45) 
 
 








   
0.77 
   
1.00 
   
1.00 
   RUNX1 (rs8127225) 
                  
 


















   
0.12 
   
1.00 
   
1.00 
   RUNX1 (rs1474479) 
                  
 


















   
0.77 
   
1.00 
   
1.00 












Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
RUNX1 (rs1883066) 
                  
 


















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs7279123) 
                  
 










CT 1083 466 1.12 (0.97, 1.29) 65 0.72 (0.53, 0.97) 14 0.83 (0.44, 1.57) 135 0.98 (0.78, 1.22) 
 
 








   
0.03 
   
1.00 
   
1.00 
   RUNX2 (rs1321075) 
                  
 










CA 1102 456 1.11 (0.97, 1.28) 80 1.00 (0.75, 1.34) 19 1.33 (0.71, 2.51) 127 0.90 (0.72, 1.14) 
 
 








   
1.00 
   
1.00 
   
0.34 
   RUNX2 (rs17209895) 
                 
 










TC 1054 408 0.92 (0.80, 1.06) 67 0.82 (0.60, 1.11) 21 1.92 (1.04, 3.54) 139 1.12 (0.89, 1.41) 
 
 








   
1.00 
   
1.00 
   
0.61 
   RUNX2 (rs2677108) 
                  
 










TC 1559 646 1.06 (0.91, 1.24) 115 0.95 (0.70, 1.29) 29 2.48 (1.08, 5.71) 186 0.96 (0.75, 1.23) 
 
 








   
1.00 
   
1.00 
   
0.61 
   RUNX2 (rs2819854) 
                  
 




















Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
 
TC 1599 643 1.03 (0.88, 1.21) 120 1.19 (0.85, 1.67) 27 1.16 (0.58, 2.31) 188 0.84 (0.65, 1.07) 
 
 








   
1.00 
   
1.00 
   
0.61 
   RUNX2 (rs2790093) 
                  
 










AG 1458 574 0.98 (0.86, 1.12) 109 1.02 (0.77, 1.35) 13 0.49 (0.25, 0.96) 180 0.97 (0.78, 1.21) 
 
 








   
1.00 
   
1.00 
   
0.96 
   RUNX2 (rs9463090) 
                  
 










GA 1016 410 1.02 (0.88, 1.17) 70 0.93 (0.70, 1.25) 17 1.34 (0.72, 2.50) 130 1.10 (0.87, 1.38) 
 
 








   
1.00 
   
1.00 
   
0.009 
   RUNX2 (rs2396441) 
                  
 










CT 1684 625 0.92 (0.78, 1.08) 113 0.82 (0.60, 1.13) 16 0.68 (0.31, 1.46) 207 0.88 (0.69, 1.13) 
 
 








   
1.00 
   
1.00 
   
0.61 
   RUNX2 (rs1316330) 
                  
 










GT 1109 459 1.03 (0.90, 1.19) 78 0.95 (0.71, 1.26) 14 0.94 (0.49, 1.79) 128 0.90 (0.72, 1.13) 
 
 








   
1.00 
   
1.00 
   
0.61 
   RUNX2 (rs7750470) 
                  
 























Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
 








   
1.00 
   
1.00 
   
0.34 
   RUNX2 (rs6930053) 
                  
 










CT 1516 598 1.01 (0.88, 1.16) 118 1.16 (0.87, 1.54) 20 0.99 (0.52, 1.89) 181 0.85 (0.68, 1.06) 
 
 








   
1.00 
   
1.00 
   
0.27 
   RUNX2 (rs12208240) 
                 
 










GA 583 241 1.07 (0.91, 1.27) 42 1.00 (0.70, 1.41) 6 0.64 (0.27, 1.52) 74 0.99 (0.75, 1.30) 
 
 








   
1.00 
   
1.00 
   
0.94 
   RUNX2 (rs12209785) 
                 
 


















   
1.00 
   
1.00 
   
0.27 
   RUNX2 (rs10948238) 
                 
 


















   
1.00 
   
1.00 
   
0.12 
   RUNX2 (rs13201287) 
                 
 


















   
1.00 
   
1.00 
   
0.34 
   RUNX2 (rs12333172) 
                 
 




















Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
 








   
1.00 
   
1.00 
   
0.007 
   RUNX2 (rs1200428) 
                  
 










CA 1220 491 1.02 (0.89, 1.17) 96 1.10 (0.83, 1.44) 14 0.71 (0.37, 1.36) 146 0.93 (0.75, 1.16) 
 
 








   
1.00 
   
1.00 
   
0.93 
   RUNX2 (rs598953) 
                  
 










TA 1539 607 0.96 (0.83, 1.11) 112 0.92 (0.69, 1.23) 24 1.23 (0.64, 2.36) 204 1.07 (0.85, 1.34) 
 
 








   
1.00 
   
1.00 
   
0.63 
   RUNX3 (rs2236850) 
                  
 










TC 1526 620 1.08 (0.93, 1.26) 112 1.02 (0.76, 1.38) 15 0.96 (0.44, 2.10) 216 1.44 (1.13, 1.85) 
 
 








   
1.00 
   
0.03 
   
0.09 
   RUNX3 (rs9438876) 
                  
 










AG 1527 634 1.10 (0.94, 1.28) 120 1.08 (0.79, 1.49) 19 1.37 (0.60, 3.15) 192 1.09 (0.84, 1.41) 
 
 








   
1.00 
   
0.09 
   
0.75 
   RUNX3 (rs7517302) 
                  
 


















   
1.00 
   
0.08 
   
0.03 












Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) p 
b 
RUNX3 (rs906296) 
                  
 


















   
0.86 
   
0.63 
   
1.00 
   RUNX3 (rs7551188) 
                  
 










CT 1569 650 1.08 (0.92, 1.27) 129 1.27 (0.91, 1.79) 24 1.48 (0.66, 3.31) 198 0.95 (0.73, 1.22) 
 
 








   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs6688058) 
                  
 


















   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs11249206) 
                 
 










TC 1560 611 0.92 (0.79, 1.07) 120 1.15 (0.84, 1.59) 22 1.16 (0.57, 2.38) 185 0.85 (0.67, 1.08) 
 
 








   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs4478762) 
                  
 
















   
1.00 
   
1.00 
   
1.00 
   TGF-β1 (rs1800469) 
                  
 










CT 1425 544 0.96 (0.83, 1.11) 106 1.19 (0.88, 1.60) 21 1.22 (0.61, 2.43) 191 1.13 (0.90, 1.43) 
 
 













Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a








   
0.15 
   
0.58 
   
0.57 
   TGF-β1 (rs4803455) 
                  
 


















   
0.58 
   
0.99 
   
0.57 
   TGF-βR1 (rs6478974) 
                 
 


















   
1.00 
   
0.85 
   
0.43 
   TGF-βR1 (rs1571590) 
                 
 










AG 859 360 1.04 (0.90, 1.21) 67 1.10 (0.82, 1.48) 9 0.70 (0.33, 1.47) 106 1.00 (0.79, 1.27) 
 
 








   
1.00 
   
0.57 
   
1.00 
   TGF-βR1 (rs1013186) 
                 
 










GA 862 360 1.04 (0.90, 1.20) 68 1.12 (0.83, 1.51) 9 0.70 (0.33, 1.46) 106 0.99 (0.78, 1.26) 
 
 








   
1.00 
   
0.57 
   
1.00 
   TGF-βR1 (rs11568785) 
                 
 


















   
0.10 
   
0.39 
   
1.00 
   TGF-βR1 (rs10733710) 
                 
 























Genotype N N OR 
a 
(95% CI) N OR 
a
 (95% CI) N OR 
a
 (95% CI) N OR 
a








   
0.14 
   
0.87 
   
0.27 
   * ER/PR data were compared with 3,214 controls from sites where cases have ER/PR data Mexico data is excluded because they do not have data for ER/PR status (n=1,810) 
a Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture. 
b Wald-p for overall model,  Bonferroni-Holm p-value adjustment for MC shown  








Table 17b.  TGF-β signaling and ERα SNPs and breast cancer defined by ER status, stratified by menopausal status (Full table) 






a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX1 (rs7279383) 
                 
 










CG 864 130 0.88 (0.69, 1.13) 51 0.86 (0.61, 1.23) 242 0.87 (0.72, 1.03) 45 0.65 (0.46, 0.92) 
 
 







   
1.00 
   
1.00 
   
0.16 
   RUNX1 (rs2268288) 
                 
 
















   
1.00 
   
1.00 
   
0.04 
   RUNX1 (rs2252585) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs11701453) 
                 
 










GC 900 134 0.97 (0.76, 1.24) 64 1.25 (0.90, 1.73) 286 0.99 (0.84, 1.18) 71 1.07 (0.79, 1.45) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs8127225) 
                 
 










TC 914 167 1.32 (1.04, 1.68) 69 1.29 (0.92, 1.79) 312 1.15 (0.97, 1.36) 64 0.88 (0.65, 1.21) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs1474479) 













a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 
















   
1.00 
   
1.00 
   
0.99 
   RUNX1 (rs1883066) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs7279123) 
                 
 










CT 1049 170 1.03 (0.81, 1.29) 70 1.04 (0.75, 1.43) 337 1.05 (0.89, 1.24) 72 0.93 (0.69, 1.26) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs1321075) 
                 
 










CA 1059 178 1.03 (0.81, 1.30) 63 0.82 (0.58, 1.15) 338 1.14 (0.96, 1.35) 75 1.08 (0.79, 1.47) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs17209895) 
                 
 










TC 1017 160 1.00 (0.79, 1.27) 75 1.42 (1.02, 1.98) 298 0.86 (0.72, 1.02) 80 1.12 (0.83, 1.51) 
 
 






   
0.37 
   
1.00 
   
1.00 
   RUNX2 (rs2677108) 
                 
 
























a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs2819854) 
                 
 










TC 1543 253 1.11 (0.85, 1.46) 95 0.88 (0.61, 1.28) 482 1.05 (0.87, 1.27) 106 0.85 (0.62, 1.18) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs2790093) 
                 
 










AG 1402 224 0.95 (0.76, 1.19) 79 0.77 (0.56, 1.06) 435 1.02 (0.87, 1.20) 101 1.01 (0.76, 1.36) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs9463090) 
                 
 










GA 978 152 0.89 (0.71, 1.12) 66 1.05 (0.76, 1.47) 309 1.08 (0.91, 1.28) 73 1.19 (0.88, 1.62) 
 
 






   
0.34 
   
1.00 
   
0.13 
   RUNX2 (rs2396441) 
                 
 










CT 1620 230 0.82 (0.63, 1.07) 95 0.84 (0.58, 1.22) 487 0.99 (0.82, 1.20) 116 0.97 (0.69, 1.36) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs1316330) 
                 
 
























a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs7750470) 
                 
 










TC 989 169 1.16 (0.92, 1.46) 69 1.16 (0.84, 1.60) 296 0.94 (0.79, 1.11) 75 1.11 (0.82, 1.49) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs6930053) 
                 
 










CT 1462 230 1.05 (0.83, 1.33) 87 0.86 (0.62, 1.19) 467 1.06 (0.89, 1.25) 103 0.90 (0.67, 1.20) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs12208240) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs12209785) 
                 
 














      
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs10948238) 
                 
 
















   
0.34 
       
1.00 
   RUNX2 (rs13201287) 













a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 
















   
0.89 
   
1.00 
   
1.00 
   
                    RUNX2 (rs12333172) 
                 
 
















   
0.90 
   
1.00 
   
0.04 
   RUNX2 (rs1200428) 
                 
 










CA 1178 178 0.89 (0.71, 1.11) 75 1.01 (0.73, 1.38) 383 1.10 (0.94, 1.30) 75 0.80 (0.59, 1.07) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX2 (rs598953) 
                 
 










TA 1489 233 0.85 (0.68, 1.07) 97 1.02 (0.73, 1.42) 456 0.99 (0.84, 1.18) 118 1.09 (0.81, 1.47) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs2236850) 
                 
 










TC 1463 233 1.06 (0.83, 1.35) 105 1.45 (1.01, 2.07) 461 1.05 (0.88, 1.26) 110 1.26 (0.91, 1.76) 
 
 






   
0.44 
   
1.00 
   
0.42 
   RUNX3 (rs9438876) 
                 
 





















a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 
AG 1463 249 1.03 (0.79, 1.33) 92 1.01 (0.70, 1.48) 476 1.18 (0.98, 1.42) 103 1.14 (0.81, 1.61) 
 
 






   
1.00 
   
1.00 
   
0.78 
   RUNX3 (rs7517302) 
                 
 
















   
1.00 
   
0.83 
   
0.42 
   RUNX3 (rs906296) 
                 
 
















   
1.00 
   
0.76 
   
0.78 
   RUNX3 (rs7551188) 
                 
 










CT 1521 260 1.03 (0.79, 1.34) 101 0.94 (0.65, 1.36) 490 1.12 (0.92, 1.36) 111 1.03 (0.73, 1.46) 
 
 






   
1.00 
   
1.00 
   
0.87 
   RUNX3 (rs6688058) 
                 
 
















   
1.00 
   
0.68 
   
0.78 
   RUNX3 (rs11249206) 
                 
 










TC 1505 234 0.85 (0.67, 1.09) 93 0.81 (0.58, 1.14) 466 0.99 (0.82, 1.19) 105 1.03 (0.74, 1.44) 
 
 






   
0.66 
   
1.00 
   
0.78 













a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX3 (rs4478762) 
                 
 
















   
1.00 
   
0.13 
   
0.78 
   TGF-β1 (rs1800469) 
                 
 










CT 1368 226 1.02 (0.81, 1.30) 84 0.92 (0.65, 1.30) 394 0.98 (0.82, 1.16) 115 1.43 (1.05, 1.95) 
 
 






   
0.92 
   
0.37 
   
0.27 
   TGF-β1 (rs4803455) 
                 
 










CA 1414 200 0.98 (0.75, 1.27) 74 0.85 (0.58, 1.23) 406 0.83 (0.69, 1.00) 92 0.86 (0.62, 1.21) 
 
 






   
0.92 
   
0.13 
   
0.27 
   TGF-βRI  (rs6478974) 
                 
 
















   
1.00 
   
1.00 
   
0.16 
   TGF-βRI  (rs1571590) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   TGF-βRI  (rs1013186) 
                 
 
























a ER+ ER- ER+ ER- 
     N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b






   
1.00 
   
1.00 
   
1.00 
   TGF-βRI  (rs11568785) 
                 
 
















   
1.00 
   
0.43 
   
1.00 
   TGF-βRI  (rs10733710) 
                 
 
















   
0.10 
   
0.61 
   
1.00 
   
a ER  data were compared with 3,214 controls from sites where cases have ER data Mexico data is excluded because they do not have data for ER status (n=1,810) 
b Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture; OR in bold text indicates significance (p≤0.05) or suggestive of an association 
(p≤0.15) for p-trend (per-allele) or Wald-p after adjustment for multiple comparisons 








Table 18b. TGF-β signaling and ERα SNPs and breast cancer defined by ER status, stratified by Native American ancestry (Full table) 
   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX1 (rs7279383) 
                 
 
















   
0.74 
   
0.97 
   
1.00 
   RUNX1 (rs2268288) 
                 
 
















   
1.00 
   
1.00 
   
0.43 
   RUNX1 (rs2252585) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs11701453) 
                 
 










GC 931 296 1.03 (0.87, 1.22) 80 1.06 (0.79, 1.41) 146 0.96 (0.76, 1.20) 64 1.30 (0.94, 1.80) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs8127225) 
                 
 
















   
1.00 
   
0.008 
   
1.00 
   RUNX1 (rs1474479) 
                 
 


















   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b






   
1.00 
   
0.97 
   
1.00 
   RUNX1 (rs1883066) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX1 (rs7279123) 
                 
 










CT 1083 341 0.96 (0.81, 1.13) 88 0.93 (0.70, 1.24) 190 1.23 (1.00, 1.52) 61 1.02 (0.74, 1.41) 
 
 






   
1.00 
   
0.75 
   
1.00 
   RUNX2 (rs1321075) 
                 
 










CA 1102 269 1.07 (0.90, 1.28) 59 0.88 (0.64, 1.20) 267 1.13 (0.92, 1.39) 87 1.02 (0.74, 1.40) 
 
 






   
0.88 
   
0.77 
   
1.00 
   RUNX2 (rs17209895) 
                 
 










TC 1054 347 0.92 (0.78, 1.08) 108 1.29 (0.98, 1.71) 128 0.89 (0.71, 1.13) 52 1.06 (0.76, 1.50) 
 
 






   
0.38 
   
0.77 
   
1.00 
   RUNX2 (rs2677108) 
                 
 










TC 1559 468 1.03 (0.87, 1.23) 120 1.12 (0.83, 1.53) 293 1.06 (0.83, 1.36) 95 0.92 (0.64, 1.34) 
 
 






   
0.73 
   
0.88 
   
1.00 







   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX2 (rs2819854) 
                 
 










TC 1599 469 0.99 (0.82, 1.21) 132 1.04 (0.75, 1.44) 294 1.16 (0.91, 1.47) 83 0.71 (0.50, 1.01) 
 
 






   
0.73 
   
0.77 
   
1.00 
   RUNX2 (rs2790093) 
                 
 










AG 1458 441 1.10 (0.93, 1.30) 109 1.00 (0.75, 1.33) 242 0.85 (0.69, 1.04) 84 0.82 (0.60, 1.12) 
 
 






   
0.83 
   
0.77 
   
1.00 
   RUNX2 (rs9463090) 
                 
 










GA 1016 304 1.01 (0.85, 1.19) 89 1.29 (0.97, 1.72) 176 1.00 (0.81, 1.24) 58 0.94 (0.68, 1.32) 
 
 






   
0.03 
   
0.77 
   
0.73 
   RUNX2 (rs2396441) 
                 
 










CT 1684 460 0.83 (0.69, 1.01) 115 0.72 (0.52, 0.98) 278 1.02 (0.80, 1.31) 108 1.11 (0.77, 1.60) 
 
 






   
0.48 
   
0.08 
   
1.00 
   RUNX2 (rs1316330) 
                 
 










GT 1109 381 1.10 (0.94, 1.30) 87 0.92 (0.69, 1.22) 156 0.89 (0.71, 1.11) 55 0.90 (0.64, 1.25) 
 
 






   
0.95 
   
0.77 
   
1.00 







   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
RUNX2 (rs7750470) 
                 
 










TC 1024 315 1.12 (0.94, 1.32) 81 1.12 (0.84, 1.50) 168 0.85 (0.69, 1.06) 74 1.16 (0.85, 1.59) 
 
 






   
0.43 
   
0.77 
   
1.00 
   RUNX2 (rs6930053) 
                 
 










CT 1516 447 0.90 (0.76, 1.08) 108 0.69 (0.52, 0.93) 269 1.22 (0.99, 1.50) 93 1.10 (0.81, 1.49) 
 
 






   
0.09 
   
0.37 
   
1.00 
   RUNX2 (rs12208240) 
                 
 










GA 583 136 0.94 (0.75, 1.17) 37 0.97 (0.66, 1.40) 147 1.22 (0.97, 1.53) 43 0.94 (0.65, 1.35) 
 
 






   
0.83 
   
0.53 
   
1.00 
   RUNX2 (rs12209785) 
                 
 
















   
0.33 
   
0.77 
   
1.00 
   RUNX2 (rs10948238) 
                 
 
















   
0.03 
   
0.77 
   
1.00 
   RUNX2 (rs13201287) 
                 
 















   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 






   
0.43 
   
0.77 
   
1.00 
   RUNX2 (rs12333172) 
                 
 
















   
0.33 
   
0.77 
   
0.07 
   RUNX2 (rs1200428) 
                 
 










CA 1220 359 1.10 (0.93, 1.30) 76 0.84 (0.62, 1.12) 228 0.95 (0.77, 1.16) 84 0.99 (0.73, 1.35) 
 
 






   
0.73 
   
0.77 
   
1.00 
   RUNX2 (rs598953) 
                 
 










TA 1539 421 0.89 (0.75, 1.06) 123 1.06 (0.80, 1.41) 298 1.06 (0.86, 1.32) 105 1.12 (0.81, 1.56) 
 
 






   
0.84 
   
0.67 
   
1.00 
   RUNX3 (rs2236850) 
                 
 










TC 1526 451 1.03 (0.86, 1.24) 126 1.31 (0.95, 1.81) 281 1.13 (0.90, 1.41) 105 1.47 (1.03, 2.09) 
 
 






   
0.55 
   
0.49 
   
0.03 
   RUNX3 (rs9438876) 
                 
 










AG 1527 464 1.04 (0.86, 1.28) 108 0.88 (0.62, 1.24) 290 1.14 (0.91, 1.43) 103 1.38 (0.97, 1.98) 
 
 








   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b






   
1.00 
   
1.00 
   
0.06 
   RUNX3 (rs7517302) 
                 
 
















   
0.16 
   
1.00 
   
1.00 
   RUNX3 (rs906296) 
                 
 
















   
1.00 
   
0.04 
   
1.00 
   RUNX3 (rs7551188) 
                 
 










CT 1569 479 1.03 (0.84, 1.26) 120 0.83 (0.59, 1.15) 300 1.21 (0.96, 1.54) 102 1.23 (0.85, 1.77) 
 
 






   
0.45 
   
1.00 
   
1.00 
   RUNX3 (rs6688058) 
                 
 
















   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs11249206) 
                 
 










TC 1560 452 0.83 (0.69, 1.01) 116 0.83 (0.60, 1.15) 279 1.12 (0.91, 1.39) 91 0.95 (0.69, 1.32) 
 
 






   
1.00 
   
1.00 
   
1.00 
   RUNX3 (rs4478762) 
                 
 















   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
 






   
1.00 
   
1.00 
   
1.00 
   TGF-β1 (rs1800469) 
                 
 










CT 1425 372 0.97 (0.82, 1.15) 108 1.18 (0.89, 1.58) 278 1.06 (0.84, 1.34) 104 1.08 (0.76, 1.53) 
 
 






   
0.55 
   
0.07 
   
0.81 
   TGF-β1 (rs4803455) 
                 
 
















   
0.55 
   
0.07 
   
0.92 
   TGF-βR1 (rs6478974) 
                 
 
















   
1.00 
   
1.00 
   
0.74 
   TGF-βR1 (rs1571590) 
                 
 










AG 859 306 1.05 (0.89, 1.25) 75 0.97 (0.72, 1.30) 121 1.04 (0.82, 1.32) 40 0.96 (0.66, 1.39) 
 
 






   
1.00 
   
1.00 
   
1.00 
   TGF-βR1 (rs1013186) 
                 
 










GA 862 306 1.05 (0.88, 1.24) 75 0.96 (0.72, 1.29) 122 1.05 (0.83, 1.34) 40 0.96 (0.66, 1.39) 
 
 






   
1.00 
   
1.00 
   
1.00 







   




a ER+ ER- ER+ ER-   
    N N OR
b 
(95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) N OR
b
 (95% CI) p-int
c 
TGF-βR1 (rs11568785) 
                
 
















   
1.00 
   
1.00 
   
0.24 
   TGF-βR1 (rs10733710) 
                
 
















   
1.00 
   
0.04 
   
0.05 
   
a ER data were compared with 3,214 controls from sites where cases have ER data Mexico data is excluded because they do not have data for ER status (n=1,810) 
b Odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, study, and genetic admixture; OR in bold text indicates significance (p≤0.05) or suggestive of an association 
(p≤0.15) for p-trend (per-allele) or Wald-p after adjustment for multiple comparisons 





Table 22b.  SNP-SNP interactions between ERα and TGF-β signaling genes (Full table) 

































CA/AA 31/26 1.19 (0.68-2.08) 





















CA/AA 106/88 1.17 (0.81-1.67) 





















AA 11/3 4.01 (1.11-14.47) 





















AA 31/29 1.22 (0.72-2.07) 





















CG/GG 21/9 2.42 (1.10-5.36) 





















CC 2/0 -- 





















TC/CC 16/12 1.44 (0.67-3.09) 





















CT/TT 20/13 1.56 (0.77-3.19) 
  
        
 
204 

































CG/GG 51/41 1.34 (0.87-2.08) 





















CC 7/6 1.31 (0.44-3.94) 





















TC/CC 44/31 1.58 (0.97-2.56) 
















CC 98/77 1.33 (0.95-1.86) 
    CC   CT/TT 57/51 1.17 (0.78-1.77)     





















GG 4/3 1.51 (0.34-6.81) 





















TT 9/8 1.22 (0.47-3.19) 





















AA 3/3 1.11 (0.22-5.51) 





















GG 13/7 2.13 (0.84-5.40) 



































TT 24/22 1.21 (0.67-2.20) 
















GG/GA 144/119 1.36 (1.04-1.79) 
    CC   AA 13/9 1.65 (0.70-3.91)     





















CC 12/4 3.37 (1.08-10.53) 





















CG/GG 25/16 1.80 (0.95-3.43) 





















AA 0/0 -- 





















CC 35/24 1.65 (0.96-2.83) 





















CG/GG 64/49 1.58 (1.05-2.37) 
















GG/GA 155/126 1.36 (1.04-1.77) 
    CC   AA 2/2 1.09 (0.15-7.76)     
aMinor alleles are denoted in bold text 
bOR and 95% CI adjusted for age and genetic admixture 
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Graduation date: May, 2008. 
 
SPALDING UNIVERSITY, Louisville, Kentucky  
Bachelor of Science, Major: Biology, Minor: Chemistry; cum laude 
Graduation date: May, 2006 
 
AWARDED GRANTS, SCHOLARSHIPS, AND HONORS___________________________ 
 2013  Dean’s Citation Award, University of Louisville 
 2013  Dissertation Completion Award, University of Louisville 
 2012  Sponsored Research Tuition Award, University of Louisville 
 2011  1st place, Public Health Student, Research! Louisville, University of 
Louisville Health Sciences Center for poster presentation, “Patterns of 
All-Cause Mortality Over 10 years by Breast Cancer Tumor Phenotype 
and Hispanic versus non-Hispanic White Ethnicity” 
 2010-present Susan B. Komen, Dissertation Training Grant, University of Louisville 
 2009-present Graduate Research Assistantship, University of Louisville 
 2003-2006  Caritas Award, Spalding University 
 2004-2006  Larry Hamfeldt Scholarship, Spalding University 
   Carlton Froess Award, Spalding University 
 2002-2006  Honors List (Minimum 3.5 GPA), Spalding University 




UNIVERSITY OF LOUISVILLE, SCHOOL OF PUBLIC HEALTH AND INFORMATION 
SCIENCES 




Assisting in conducting the research study: New Mexico Women’s Health Study: Long Term 
Quality of Life Phase.  Responsibilities include: interviewing participants, data entry and tracking, 
and assistance with design and development of materials useful to study, as well as preparation of 
final documents and manuscripts for submission to National Institute of Health. 
 
UNIVERSITY OF LOUISVILLE, SCHOOL OF PUBLIC HEALTH AND INFORMATION 
SCIENCES 
Program Coordinator, Sr., May 2008 – August 2009 
Responsibilities included overseeing all aspects, and coordinating the research study The New 
Mexico Women’s Health Study: Long Term Quality of Life Phase funded by the National Institute 
of Health including; staff and data management.  There was thorough involvement with the design 
and development of materials useful to study through the use of databases such as Oracle, Access, 
SAS, and graphics software.  Develop, implement, and coordinate data collection efforts with 
staff, as well as collaborate with outside agencies such as a tumor registry and the National Death 
Index. Identify resources, collect data, develop protocols and data dictionaries, enter and analyze 
data, and assist in preparing summaries and reports of findings. Work with program faculty and 
staff to monitor progress on the established project goals and objectives.  Coordinate submissions 
to Institutional Review Board. 
 
UNIVERSITY OF LOUISVILLE, SCHOOL OF PUBLIC HEALTH AND INFORMATION 
SCIENCES 
Research Assistant, September 2007-May 2008, New Mexico Women’s Health Study: Long Term 
Quality of Life Phase.  Responsibilities included: interviewing participants, data entry and 
tracking, and assistance with design and development of materials useful to study. 
 
RELATED EXPERIENCE          
 December 2009-February 2011  Assist Dr. Katherine B. Baumgartner, University of 
Louisville, by preparing evidence tables, summarizing information, assist with rechecking 
table entries, as well as, the STATA data for the analyses and references for the sections on 
active and passive smoking and breast cancer for the 2011 Surgeon General's Report (2004-
2006 Update) (The Health Consequences of Smoking and Involuntary Exposure to Tobacco 
Smoke: An Update) 
 
SERVICE ACTIVITIES          
 August 2008-August 2009  Member, Master in Public Health Advisory Committee University 
of Louisville, School of Public and Information Sciences.  
 May 2007-May 2008 Treasurer, Student Government Association, University of Louisville, 
School of Public and Information Sciences.  
 March 2009-November 2010 Volunteer, Health Career Expo Presenter 
o Description: provide interactive “hands-on” presentations promoting health 
professions to middle and high school youth 
 
PRESENTATIONS____________________________________________________________ 
 Stephanie Boone, MPH. Oral Presentation: TGF-B Signaling Pathway, ERα and the 
Heterogeneity of Breast Cancer Risk among Hispanic and non-Hispanic White Women.  
o Susan G. Komen for the Cure Post-Baccalaureate Training in Disparities 2nd Annual 
Meeting October 26-30, 2012  
 Stephanie Denkhoff, MPH, Richard N. Baumgartner, PhD, Kathy B. Baumgartner, PhD.   
Ethnicity As a Predictor of Long-Term Quality of Life In Breast Cancer Survivors  
Abstract/Poster presented at:  
 
211 
o Cancer Survivorship Conference: Cancer Survivorship Research: Translating Science 
to Care June 14-16, 2012. Arlington, VA. 
o Research! Louisville, University of Louisville, September 18, 2012 
 Stephanie Denkhoff, MPH, Kathy B. Baumgartner, PhD, Christina Pinkston, MS, Dongyan 
Yang, MS, M.D. , Richard N. Baumgartner, PhD. Patterns of All-Cause Mortality Over 10 
years by Breast Cancer Tumor Phenotype and Hispanic versus non-Hispanic White 
Ethnicity. Abstract/Poster presented at:  
o Research! Louisville, University of Louisville, October 13, 2011 
o James Graham Brown Cancer Retreat, University of Louisville, November 4, 2011 
o American Association of Cancer Research Conference: The Science of Cancer 
Health Disparities 
in Racial/Ethnic Minorities and the Medically Underserved. September 18-21, 
2011.  Washington D.C. 
 Stephanie Denkhoff, MPH, Kathy B. Baumgartner, PhD, Christina Pinkston, MS, Dongyan 
Yang, MS, M.D. , Richard N. Baumgartner, PhD.  Hormone Receptor Status and Breast 
Cancer Survival among Hispanic and non-Hispanic White Women over 10 Years of 
Follow-Up. Abstract/Poster presented at: San Antonio Breast Cancer Symposium. December 
6-9, 2011.  San-Antonio, TX 
 Stephanie Denkhoff, MPH, Dongyan Yang, MS, MD, Christina Pinkston, MS, Richard 
Baumgartner, PhD, Kathy Baumgartner, MA, MS, PhD.  Predictors of Quality of Life 
among Hispanic and Non-Hispanic White Women: A 15 Year Follow-up Study of Long-
Term Breast Cancer Survivors. Abstract/Poster presented at: 
o Research! Louisville, University of Louisville, October 12, 2010 
o James Graham Brown Cancer Retreat, University of Louisville, November 5, 2010 
o American Association of Cancer Research 102nd Annual Meeting 2011, April 2-6, 
2011.  Orlando, Florida 
 Stephanie Denkhoff, MPH and Carlton Hornung, PhD. A Review: The Gene-Environment 
Interaction: Cigarette Smoking, Apolipoprotein E Genotype, and the Risk of 




 Society for Epidemiology Research (SER) 
o  Student Member 2009-present 
 American Association of Cancer Research (AACR) 
o  Associate Member 2010-present 
o Women in Cancer Research (sub-group, AACR) 2011-present  
 
PUBLICATIONS_______________________________________________________________ 
1. Boone, SD, Baumgartner, KB, Joste, NE, Pinkston, CM, Yang, D, Baumgartner RN. (2013) 
The joint contribution of tumor phenotype and education to breast cancer survival disparity 
between Hispanic and non-Hispanic white women [Submitted, Journal of Clinical Oncology] 
 
2. Boone, SD, Baumgartner RN, Brock, G, Groves, F, Kerber, R, Pinkston, CM, Connor, AE, A, 
Hines, L, John, EM, Slattery, ML, Torres-Mejia,G, Wolff, R, 
 
Baumgartner, KB (2013) TGF-B 
Signaling Pathway, ERα and the Heterogeneity of Breast Cancer Risk among Hispanic and 
non-Hispanic White Women. [in preparation] 
 
3. Boone, SD, Baumgartner, RN, Pinkston, CM, Yang, D, Baumgartner, KB (2013) Predictors of 
Quality of Life among Hispanic and Non-Hispanic White Women: A 15 Year Follow-up 
Study of Long-Term Breast Cancer Survivors [in preparation] 
